



ctos®

2020 Virtual Annual Meeting

November 18 - 21, 2020

ALL TIMES ARE EASTERN STANDARD TIME (EST)

Wednesday, 18 November, 2020

8:00 am - 11:00 am	TARPSWG Meeting (email: tarpswg@gmail.com) – Chair: Alessandro Gronchi
11:00 am - 1:00 pm	Ultra Rare Sarcoma Meeting – Chair: Silvia Stacchiotti
1:00 pm - 3:00 pm	SARC Meeting
3:00 pm - 5:00 pm	SELNET Meeting: State of Art of Management for Localized STS in Limbs and Retroperitoneum – Chair: Javier Martin-Broto

Thursday, 19 November, 2020

8:00 am - 9:00 am

– Session 1 –

OPENING CEREMONY INTRODUCTION TO CTOS 2020

President: **Kirsten Sundby Hall**

Program Chairs: **Silvia Stacchiotti, Margaret von Mehren, Inga-Marie Schaefer**

25 YEAR RETROSPECTIVE

Presenter: **Shreyas Patel**

9:00 am - 10:00 am

– Session 2 –

IMMUNOTHERAPY IN SARCOMA: ALVEOLAR SOFT PART SARCOMA, CLEAR CELL SARCOMA, SYNOVIAL SARCOMA

Chair: **Seth Pollack**

Discussant: **Breelyn Wilky**

Panelists: **Armelle Dufresne, Bob Maki, Enrico Grignani**

Presenters: **Akira Kawai, Nadia Hindi, Sandra d'Angelo, Brian van Tine**

Paper #01 3421748

EFFICACY AND SAFETY OF NIVOLUMAB MONOTHERAPY IN PATIENTS WITH UNRESECTABLE CLEAR CELL SARCOMA AND ALVEOLAR SOFT PART SARCOMA (OSCAR TRIAL, NCCH1510): A MULTICENTER, PHASE 2 CLINICAL TRIAL

Akira Kawai², Tadaaki Nishikawa¹, Mamiko Kawasaki³, Sawako Tomatsuri³, Nobuko Okamura³, Gakuto Ogawa³, Akihiro Hirakawa⁴, Taro Shibata³, Kenichi Nakamura³, Shigeki Kakunaga⁵, Kenji Tamura¹, Masashi Ando⁶, Toshifumi Ozaki⁷, Takafumi Ueda⁵, Kan Yonemori¹

¹Breast and Medical Oncology, National Cancer Center Hospital, Tokyo, JAPAN; ²Oncology and Rehabilitation Medicine, National Cancer Center Hospital, Tokyo, JAPAN; ³National Cancer Center, Tokyo, JAPAN; ⁴Tokyo Medical and Dental University, Tokyo, JAPAN; ⁵Orthopaedic Surgery, National Hospital Organization Osaka National Hospital, Osaka, JAPAN; ⁶Aichi Cancer Center, Aichi, JAPAN; ⁷Orthopaedic Surgery, Okayama University, Okayama, JAPAN

Thursday, 19 November, 2020

Paper #02 3464044

EFFICACY OF IMMUNE CHECKPOINT INHIBITORS IN ALVEOLAR SOFT PART SARCOMA: RESULTS FROM A RETROSPECTIVE WORLD-WIDE REGISTRY

Nadia Hindi¹, Evan Rosenbaum², Piotr Rutkowski³, Hans Gelderblom⁴, Kjetil Boye⁵, Clemence Henon⁶, Bruno Vincenzi⁷, Andres Redondo⁸, Javier Martinez-Trufero⁹, Claudia Valverde¹⁰, Jose Antonio Lopez-Martin¹¹, Paulina Jagodzinska³, Elizabeth Connolly¹², William D. Tap², Javier Martin-Broto¹

¹Medical Oncology, Hospital Universitario Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS), Seville, SPAIN; ²Memorial Sloan Kettering Cancer Center, New York, New York, UNITED STATES; ³Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, POLAND; ⁴Leiden University Medical Center, Leiden, NETHERLANDS; ⁵Institute for Cancer Research, Oslo University Hospital, Department of Oncology, Oslo University Hospital, Oslo, NORWAY; ⁶C. Henon, Medical Oncology, Institut de Cancérologie Gustave Roussy, Villejuif, FRANCE; ⁷Medical Oncology, University Campus Bio-Medico, Rome, ITALY; ⁸Medical Oncology, Hospital Universitario La Paz - IdiPAZ, Madrid, SPAIN; ⁹Medical Oncology, Hospital Universitario Miguel Servet, Zaragoza, SPAIN; ¹⁰Medical Oncology, Hospital Universitario Vall d'Hebron, Barcelona, SPAIN; ¹¹Medical Oncology, Hospital Universitario 12 de Octubre, Translational Oncology Instituto de Investigación Hospital 12 de Octubre (i+12), Madrid, SPAIN; ¹²Chris O'Brien Lifehouse, Sydney, New South Wales, AUSTRALIA

Paper #03 3462142

FINAL ANALYSIS OF THE PHASE 1 TRIAL OF NY-ESO-1-SPECIFIC T-CELL RECEPTOR (TCR) T-CELL THERAPY (LETETRESGENE AUTOLEUCEL; GSK3377794) IN PATIENTS (PTS) WITH ADVANCED SYNOVIAL SARCOMA (SS)

Sandra D'Angelo¹, George Demetri², Brian A. Van Tine³, Mihaela Druta⁴, John Glod⁵, Warren Chow⁶, Naimish Pandya⁷, Aisha Hasan⁷, Victoria L. Chiou⁷, Jenna Tress⁷, Julie Edwards⁸, Tim Young⁷, Mary Woessner⁷, Alexandra Gyurdieva⁷, Stefan Zajic⁷, Sophia Goodison⁷, Dejka Araujo⁹

¹Memorial Sloan Kettering Cancer Center, New York, New York, UNITED STATES; ²Dana Farber Cancer Institute and Ludwig Center at Harvard, Boston, Massachusetts, UNITED STATES; ³Washington University, St. Louis, Missouri, UNITED STATES; ⁴H. Lee Moffitt Cancer Center, Tampa, Florida, UNITED STATES; ⁵National Cancer Institute, Bethesda, Maryland, UNITED STATES; ⁶City of Hope Comprehensive Cancer Center, Duarte, California, UNITED STATES; ⁷GlaxoSmithKline, Collegeville, Pennsylvania, UNITED STATES; ⁸GlaxoSmithKline, Stockley Park, Middlesex, UNITED KINGDOM; ⁹University of Texas/MD Anderson Cancer Center, Houston, Texas, UNITED STATES

Paper #04 3463188

DURABLE RESPONSES IN PATIENTS WITH SYNOVIAL SARCOMA IN THE PHASE I TRIAL OF ADP-A2M4 (MAGE-A4)

Brian A. Van Tine¹, David S. Hong², Melissa L. Johnson⁶, David A. Liebner³, Kunle Odunsi⁴, Trupti Trivedi⁸, Quan Lin⁸, Swethajit Biswas⁷, Erica Elefant⁸, Jean-Marc Navenot⁸, Joana Senra⁷, Zohar Wolchinsky⁷, Robyn Broad⁷, Gareth Betts⁷, Natalie Bath⁷, Will Spinner⁷, Alex Tipping⁷, Svetlana Fayngerts⁸, Karen Miller⁷, Amy Sun⁸, Dennis Williams⁸, Paula M. Fracasso⁸, Elliott Norry⁸, Marcus O. Butler⁵

¹Washington University, St. Louis, St. Louis, Missouri, UNITED STATES; ²The University of Texas, MD Anderson Cancer Center, Houston, Texas, UNITED STATES; ³Ohio State University Medical Center, Columbus, Ohio, UNITED STATES; ⁴Roswell Park Comprehensive Cancer Center, Buffalo, New York, UNITED STATES; ⁵Princess Margaret Cancer Centre, Toronto, Ontario, CANADA; ⁶Sarah Cannon Research Institute, Nashville, Tennessee, UNITED STATES; ⁷Adaptimmune Ltd, Abingdon, Oxfordshire, UNITED KINGDOM; ⁸Adaptimmune LLC, Philadelphia, Pennsylvania, UNITED STATES

10:00 am - 10:30 am

Morning Break

10:30 am - 11:30 am

– Special Awards Session –

YOUNG INVESTIGATOR AWARD WINNERS

Brittany Glassberg, BS

Shiv Verma, MD

Introduction by Program Chairs: **Stacchiotti, von Mehren, Schaefer**

Young Investigator Award 3464426

INCIDENCE OF MALIGNANT PERIPHERAL NERVE SHEATH TUMOR (MPNST) DEVELOPMENT IN PATIENTS WITH NF1 RECEIVING AND NOT RECEIVING MEDICAL THERAPIES DIRECTED AT PLEXIFORM NEUROFIBROMAS (PN)

Brittany Glassberg¹, Andrea Gross¹, Eva Dombi¹, Andrea Baldwin¹, Trish Whitcomb¹, Ana Best¹, Amanda Carbonell¹, Kara Heisey¹, Janet Therrien¹, Oxana Kapustina¹, Brigitte C. Widemann¹, Hari Sankaran¹

¹Pediatric Oncology Branch, National Institutes of Health, Woodbury, New York, UNITED STATES

Young Investigator Award 3465542

THE ASPSCR1-TFE3 TRANSCRIPTIONAL COMPLEX IN ALVEOLAR SOFT PART SARCOMAGENESIS

Shiv Verma¹; Amir Pozner¹; Li Li¹; Shuxin Wang²; Jared J. Barrott¹; Sarmishta Kannan¹; Jamie Yu³; Sydney L. Lambert¹; Alexander Lazar⁴; Martin Hirst⁵; Torsten O. Nielsen³; Peter S. Shen²; Kevin B. Jones¹

¹Orthopaedics and Oncological Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, UNITED STATES; ²Department of Biochemistry, University of Utah, Salt Lake City, Utah, UNITED STATES; ³Department of Pathology, University of British Columbia, Vancouver, British Columbia, CANADA; ⁴Department of Pathology, MD Anderson Cancer Center, Houston, Texas, UNITED STATES; ⁵Genome Sciences Center, University of British Columbia, Vancouver, British Columbia, CANADA

LIDDY SHRIVER EARLY RESEARCH AWARD WINNER

Professor Nicolo Riggi

Introduction by Chair: **David Thomas**

BASIC SCIENCE SARCOMA RESEARCH AWARD WINNERS

David Kirsch

Benjamin Nacev

Isidro Cortes-Ciriano

Introduction by Chair: **Lee Helman**

NATIONAL LEIOMYOSARCOMA FOUNDATION RESEARCH GRANT

Chair: **Seth Pollack**

11:30 am - 12:30 pm

– Session 3 –

LEIOMYOSARCOMA AND UNDIFFERENTIATED PLEOMORPHIC SARCOMA

Chair: **Suzanne George**

Discussant: **Dirk Strauss**

Panelists: **Matt van de Rijn, Paolo A. Dei Tos, Robin Jones**

Presenters: **Sant P. Chawla, Nathaniel Anderson, Nicolas A. Devaud, Nathan D. Seligson**

Paper #05 3465673

UPDATED PHASE I STUDY TO EVALUATE THE SAFETY AND EFFICACY OF RIVOCERANIB (APATINIB) AND NIVOLUMAB IN PATIENTS WITH UNRESECTABLE OR METASTATIC CANCER

Sant P. Chawla¹, Victoria Chua-Alcala¹, Steven M. Wong¹, Doris Quon¹, Ania M. Moradkhani¹, Kelly Wang¹, Ish Bhuiyan¹, Olivia Pelenghian¹, Sandon Scott¹, Natalie Krkyan¹, Kitty Zheng¹, Steven Norton², Kehua Wu², Ted M. Kim¹, Erlinda M. Gordon¹

¹Sarcoma Oncology Center, Santa Monica, California, UNITED STATES; ²Elevartherapeutics, Inc., Salt Lake City, Utah, UNITED STATES

Paper #06 3463196

LINEAGE-DEFINED LEIOMYOSARCOMA SUBTYPES EMERGE YEARS BEFORE DIAGNOSIS, DETERMINING PATIENT SURVIVAL

Nathaniel Anderson¹, Yael Babichev², Fabio Fuligni¹, Federico Comitani¹, Mehdi Layeghifard¹, Rosemarie Venier², Anant Maheshwari¹, Sheena Guram², Claire Wunker², J. Drew Thompson¹, Marcus Bernadini³, Jay Wunder², Irene Andrulis², Peter Ferguson⁴, Albiruni Abdul Razak³, Carol J. Swallow², Rima Al-Awar⁵, Richard Marcellus⁵, Marjan Rouzbahman³, Daniel Durocher², Ludmil Alexandrov⁶, Brendan Dickson², Rebecca Gladdy², Adam Shlien¹

¹Genetics and Genome Biology, The Hospital for Sick Children, Toronto, Ontario, CANADA; ²Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, CANADA; ³University Health Network, Toronto, Ontario, CANADA; ⁴University Musculoskeletal Oncology Unit, Mount Sinai Hospital, Toronto, Ontario, CANADA; ⁵Ontario Institute for Cancer Research, Toronto, Ontario, CANADA; ⁶University of California San Diego, San Diego, California, UNITED STATES

Paper #07 3464097

IS SITE OF ORIGIN (IVC VS. NON-IVC) PROGNOSTIC FOLLOWING RESECTION OF PRIMARY RETROPERITONEAL LEIOMYOSARCOMA (RP LMS)? COMBINED EXPERIENCE OF TWO SARCOMA REFERRAL CENTRES

Nicolas A. Devaud¹, Deanna Ng¹, Harini Suraweera¹, Abha A. Gupta², Albiruni Razak², Peter Chung³, Savtaj Brar¹, Thomas Lindsay¹, Rebecca Gladdy¹, Ian McGilvray¹, Claudia Sangalli⁵, Roberta Sanfilippo⁴, Silvia Stacchiotti⁴, Dario Callegaro⁶, Marco Fiore⁶, Alessandro Gronchi⁶, Carol J. Swallow¹

¹Surgery, University of Toronto, Toronto, Ontario, CANADA; ²Medical Oncology, University of Toronto, Toronto, Ontario, CANADA; ³Radiation Oncology, University of Toronto, Toronto, Ontario, CANADA; ⁴Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Lombardia, ITALY; ⁵Radiation Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Lombardia, ITALY; ⁶Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Lombardia, ITALY

Paper #08 3457194

HOMOLOGOUS RECOMBINATION DNA REPAIR AND LOSS OF HETEROZYGOSITY IN LEIOMYOSARCOMA

Nathan D. Seligson¹, Sherri Z. Millis³, Dexter Jin³, Nicholas Grosenbacher², Monica P. Bennett¹, Alexander M. Litvintchouk¹, Colin M. Stets², Julia A. Elvin³, John L. Hays², James Chen²

¹University of Florida, Jacksonville, Florida, UNITED STATES; ²Ohio State University, Columbus, Ohio, UNITED STATES; ³Foundation Medicine Inc, Cambridge, Massachusetts, UNITED STATES

12:30 pm - 1:30 pm

– Session 4 –

OSTEOSARCOMA AND PEDIATRIC BONE SARCOMAS

Chair: **Maureen O'Sullivan**

Discussant: **Lor Randall**

Panelists: **Emanuela Palmerini, Petur Nielsen, Kurt Weiss**

Presenters: **Jong Min Lee, Kelly Bailey, Reid Davison, Jovana Pavisic**

Paper #09 3437417

A COMPARISON OF ONCOLOGICAL AND SURGICAL OUTCOMES IN ENDOPROSTHETIC RECONSTRUCTION VERSUS ROTATIONPLASTY FOR PAEDIATRIC LOWER EXTREMITY BONE SARCOMA

Jong Min Lee², Jonathan R. Perera¹, Eliane R. Trottier², Sevan Hopyan², Kim Tsoi¹

¹Orthopaedic Oncology, Mount Sinai Hospital, Amersham, Buckinghamshire, UNITED KINGDOM;

²Paediatric Orthopaedics, SickKids, Toronto, Ontario, CANADA

Paper #10 3464085

EXPRESSION PROFILING AND SPATIAL LOCALIZATION OF CD45+ LEUKOCYTES INFILTRATING PRIMARY AND RELAPSED BONE SARCOMAS

Anthony Cillo², Elina Mukherjee³, Sayali Onkar², Kurt R. Weiss⁴, Melissa A. Burgess⁵, Tanya Heim⁴, Dario Vignali², Tullia Bruno², **Kelly Bailey**¹

¹Pediatrics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, UNITED STATES; ²Immunology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, UNITED STATES; ³Pediatrics, University of Pittsburgh, Pittsburgh, Pennsylvania, UNITED STATES; ⁴Orthopaedic Surgery, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, UNITED STATES; ⁵Medicine, University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, Pennsylvania, UNITED STATES

Thursday, 19 November, 2020

Paper #11 3446540

PULMONARY MICRONODULES LESS THAN 5 MM DETECTED ON CT AT PRESENTATION IN PATIENTS WITH OSTEOSARCOMA DO NOT EFFECT 5 YEAR OVERALL SURVIVAL

Reid Davison¹, Fadi Hamati¹, Paul Kent¹

¹Rush Medical Hospital, Chicago, Illinois, UNITED STATES

Paper #12 3461610

TARGETING MASTER REGULATOR DEPENDENCIES IN PEDIATRIC OSTEOSARCOMA

Jovana Pavisic¹, Katherine Janeway², Andrew Kung³, Filemon Dela Cruz³, Alejandro Sweet-Cordero⁵, Inge Behroozfard⁵, Stanley Leung⁵, Alex Lee⁵, Darrell Yamashiro¹, Julia Glade Bender³, Andrea Califano⁴

¹Pediatrics, Columbia University Irving Medical Center, New York, New York, UNITED STATES; ²Pediatrics, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, Massachusetts, UNITED STATES; ³Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York, UNITED STATES; ⁴Systems Biology, Columbia University Irving Medical Center, New York, New York, UNITED STATES; ⁵Pediatrics, University of California San Francisco, San Francisco, California, UNITED STATES

1:30 pm - 2:30 pm

MEET THE EXPERTS

Multidisciplinary Discussion of Clinical Cases

Room 1:	Room 2:	Room 3:
GIST	Bone Sarcomas	Soft Tissue Sarcomas
Moderator: William Tap	Moderator & Presenter: Anna Maria Frezza	Moderator: Rick Haas
Presenter: Maria Abbondanza Pantaleo	Panelists: Josh Sommer Abha Gupta Hans Gelderblom Sandra Strauss Jay Wunder Thomas DeLaney Paolo A. Dei Tos Kannan Rajesparan	Presenter: Armelle Dufresne
Panelists: Sara Rothschild George Demetri Tom Wei-Wu Chen Paolo Casali Piotr Rutkowski Aisha Miah Eva Wardelmann		Panelists: Roger Wilson Jean Yves Blay Andrew Wagner Claudia Valverde Morales Alessandro Gronchi Elizabeth Baldini Christopher Fletcher

2:30 pm - 3:30 pm

CTOS Executive Committee Meeting

3:00 pm - 4:30 pm

– Symposium –

THE CASE FOR CHALLENGING CONVENTIONAL CARE IN TENOSYNOVIAL GIANT CELL TUMOR: INSIGHTS ON INTEGRATING TARGETED THERAPY INTO MULTIMODAL MANAGEMENT

Friday, 20 November, 2020

8:00 am - 9:00 am

– Session 5 –

“WHAT IS NEW IN SARCOMA PATHOLOGY AND MOLECULAR DIAGNOSTICS”

Cristina Antonescu

9:00 am - 10:00 am

– Session 6 –

CHONDROSARCOMA, CHORDOMA, AND OTHER BONE TUMORS

Chair: **Judith Bovée**

Discussant: **David Kirsch**

Panelists: **Elizabeth Baldini, Javier Martin-Broto, Rick Haas**

Presenters: **Sanne Venneker, Ivar Hompland, Thomas F. DeLaney, Sant P. Chawla**

Paper #13 3465391

BEYOND THE INFLUENCE OF IDH MUTATIONS: EXPLORING EPIGENETIC VULNERABILITIES IN CHONDROSARCOMA

Sanne Venneker¹, Alwine B. Kruisselbrink¹, Zuzanna Baranski², Ieva Palubeckaite¹, Inge H. Briaire-de Bruijn¹, Jan Oosting¹, Pim J. French³, Erik Danen², Judith V. Bovee¹

¹Department of Pathology, Leiden University Medical Center, Leiden, NETHERLANDS; ²Division of Drug Discovery and Safety, Leiden Academic Centre for Drug Research, Leiden, NETHERLANDS; ³Department of Neurology, Erasmus University Medical Center, Rotterdam, NETHERLANDS

Paper #14 3442269

OUTCOME IN DEDIFFERENTIATED CHONDROSAROMA FOR PATIENTS TREATED WITH MULTIMODAL THERAPY: RESULTS FROM THE EURO-B.O.S.S STUDY

Ivar Hompland¹, Stefano Ferrari², Stefan Bielack³, Emanuela Palmerini², Kirsten S. Hall¹, Davide M. Donati², Elisabetta Setola², Virginia Ferraresi⁴, Rossella Bertulli⁹, Alessandro Comandone⁵, Pierro Picci¹, Stefanie Hecker-Nolting³, Claudia Blattmann³, Leo Kager⁷, Thomas Kühne⁶, Peter Reichardt⁸, Sigbjørn Smeland¹

¹Department of Oncology, Oslo University Hospital, Norwegian Radium Hospital, Oslo, NORWAY; ²Oncology Department, Istituto Ortopedico Rizzoli, Bologna, ITALY; ³Stuttgart Cancer Center, Pediatrics 5 (Oncology, Hematology, Immunology), Klinikum Stuttgart Olgahospital, Stuttgart, GERMANY; ⁴Oncology Department, Istituto Regina Elena, Rome, ITALY; ⁵Oncology Department, Ospedale Humanitas-Gradenigo, Turin, ITALY; ⁶Division of Oncology and Hematology, University Children's Hospital, Basel, SWITZERLAND; ⁷Department of Pediatrics, St Anna Children's Hospital, Medical University Vienna, Vienna, AUSTRIA; ⁸Department of Oncology, Helios Klinikum Berlin-Buch, Berlin, GERMANY; ⁹Oncology Department, Istituto Nazionale Tumori, Milan, ITALY

Paper #15 3461741

DEFINITIVE HIGH-DOSE, PROTON-BASED RADIATION FOR UNRESECTED MOBILE SPINE AND SACRAL CHORDOMAS

Thomas F. DeLaney¹, Norbert J. Liebsch¹, Saveli Goldberg¹, Walter H. Banfield², Myrsini Ioakeim-Ioannidou¹, Soha Ahmed³, Joseph H. Schwab⁴, Francis J. Hornicek⁷, Gregory M. Cote⁵, John H. Shin⁶, Edwin Choy⁵, Yen-Lin E. Chen¹

¹Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts, UNITED STATES; ²University of Virginia School of Medicine, Charlottesville, Virginia, UNITED STATES; ³Clinical Oncology, Aswan University Medical Center, New Aswan City, Aswan, EGYPT; ⁴Orthopaedic Oncology, Massachusetts General Hospital, Boston, Massachusetts, UNITED STATES; ⁵Hematology/Oncology Section, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, UNITED STATES; ⁶Neurosurgery, Massachusetts General Hospital, Boston, Massachusetts, UNITED STATES; ⁷Orthopaedic Surgery, UCLA Medical Center, Los Angeles, California, UNITED STATES

Friday, 20 November, 2020

Paper #16 3463234

RESULTS FROM THE CHONDROSARCOMA PHASE 1 STUDY EXPANSION COHORT OF THE TETRAVALENT DEATH RECEPTOR 5 AGONIST INBRX-109

Sant P. Chawla¹, Nehal Lakhani⁴, Anthony Tolcher⁵, Christopher Lieu³, Breelyn A. Wilky³, Klaus W. Wagner², Analeah Heidt², Brendan Eckelman², Quinn Deveraux², James Kalabus², Anthony P. Conley⁶, Vivek Subbiah⁶

¹Sarcoma Oncology Center, Santa Monica, California, UNITED STATES; ²Inhibrx, Inc, La Jolla, California, UNITED STATES;

³University of Colorado, Aurora, Colorado, UNITED STATES; ⁴START Midwest, Grand Rapids, Michigan, UNITED STATES;

⁵NEXT Oncology, San Antonio, Texas, UNITED STATES; ⁶MD Anderson Cancer Center, Houston, Texas, UNITED STATES

10:00 am - 10:30 am

Morning Break

10:30 am - 11:30 am

– Session 7 –

LIPOSARCOMA

Chair: **Mark Dickson**

Discussant: **Carol Swallow**

Panelists: **Neeta Somaiah, Alessandro Gronchi**

Presenters: **Dario Callegaro, Jonathan R. Perera, Jules Lansu, Mrinal Gounder, Marco Fiore**

Paper #17 3464763

PREOPERATIVE RADIOTHERAPY IN PATIENTS WITH PRIMARY RETROPERITONEAL SARCOMA (RPS): TRIAL (STRASS) VS OFF-TRIAL (STREXIT) RESULTS

Dario Callegaro¹, Chandrajit Raut¹², Ajayi Taiwo², Dirk Strauss³, Sylvie Bonvalot⁴, Deanna Ng⁵, Eberhard Stoeckle⁶, Mark Fairweather¹², Piotr Rutkowski⁷, Winan J. van Houdt⁸, Hans Gelderblom⁹, Claudia Sangalli¹³, Andrew Hayes³, Charles Honoré¹⁰, Rebecca Gladly⁵, Magali Fau⁶, Rick L. Haas¹¹, Dmitri Tzanis⁴, Aisha B. Miah¹⁴, Peter Chung¹⁵, Elizabeth H. Baldini¹⁶, Sandrine Marreaud², Saskia Litière², Carol J. Swallow⁵, Alessandro Gronchi¹

¹Surgery, Fondazione IRCCS Istituto Nazionale Tumori, Milan, ITALY; ²EORTC Headquarters, Brussels, BELGIUM;

³General Surgery, Sarcoma Unit, Royal Marsden NHS Foundation Trust, London, UNITED KINGDOM; ⁴Surgery, Institut Curie, Paris, FRANCE; ⁵Surgical Oncology, Princess Margaret Cancer Centre/Mount Sinai Hospital, University of Toronto,

Toronto, Ontario, CANADA; ⁶Surgery, Institut Bergonié, Bordeaux, FRANCE; ⁷Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, POLAND; ⁸Surgery, The Netherlands Cancer

Institute, Amsterdam, NETHERLANDS; ⁹Medical Oncology, Leiden University Medical Center, Leiden, NETHERLANDS;

¹⁰Surgery, Institute Gustave Roussy, Villejuif, FRANCE; ¹¹Radiation Oncology, The Netherlands Cancer Institute,

Amsterdam, NETHERLANDS; ¹²Surgery, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical

School, Boston, Massachusetts, UNITED STATES; ¹³Radiation Oncology, Fondazione IRCCS Istituto Nazionale Tumori,

Milan, ITALY; ¹⁴Radiation Oncology, Royal Marsden NHS Foundation Trust, London, UK, London, UNITED KINGDOM;

¹⁵Radiation Oncology, Princess Margaret Cancer Centre/Mount Sinai Hospital, Toronto, Ontario, CANADA; ¹⁶Radiation

Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston,

Massachusetts, UNITED STATES

Paper #18 3437448

INTERMUSCULAR MYXOID LIPOSARCOMA CAN BE MANAGED BY MARGINAL SURGICAL RESECTION FOLLOWING NEOADJUVANT RADIOTHERAPY

Jonathan R. Perera¹, Ahmed Aoude¹, Izuchuwu Ibe¹, Anthony Griffin¹, Peter Ferguson¹, Jay Wunder¹, Kim Tsoi¹

¹Orthopaedic Oncology, Mount Sinai Hospital, Amersham, Buckinghamshire, UNITED KINGDOM

Friday, 20 November, 2020

Paper #19 3437081

**DOSE REDUCTION OF PREOPERATIVE RADIOTHERAPY FOR MYXOID LIPOSARCOMA (DOREMY):
A PROSPECTIVE, MULTICENTER, SINGLE-ARM, PHASE 2 TRIAL**

Jules Lansu¹, Judith V. Bovee², Pètra Braam³, Hester van Boven⁴, Uta Flucke³, Han Bonenkamp³, Aisha B. Miah⁵, Shane H. Zaidi⁵, Khin Thway⁵, Øyvind S. Bruland⁶, Elizabeth H. Baldini⁷, Nina L. Jebesen⁸, Astrid N. Scholten¹, Piet L. van den Ende⁹, Augustinus D. Krol², Fred Ubbels¹⁰, Jos A. van der Hage², Erik van Werkhoven⁴, Houke M. Klomp⁴, Winette T. van der Graaf⁴, Frits van Coevorden⁴, Yvonne Schrage⁴, Winan J. van Houdt⁴, Rick L. Haas¹

¹Radiotherapy, Netherlands Cancer Institute, Amsterdam, NETHERLANDS; ²Leiden University Medical Center, Leiden, NETHERLANDS; ³Nijmegen University Medical Center, Nijmegen, NETHERLANDS; ⁴Netherlands Cancer Institute, Amsterdam, NETHERLANDS; ⁵The Royal Marsden Hospital and The Institute of Cancer Research, London, UNITED KINGDOM; ⁶The Norwegian Radium Hospital, Oslo University Hospital, and Institute of Clinical Medicine, Oslo, NORWAY; ⁷Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts, UNITED STATES; ⁸Center for Bone- and Soft Tissue Tumors, Dep. of Oncology/Dep. of Orthopedic Surgery, Haukeland University Hospital, Bergen, NORWAY; ⁹MAASTRO, Maastricht, NETHERLANDS; ¹⁰Groningen University Medical Center, Groningen, NETHERLANDS

Paper #20 3461475

**A PHASE 2/3, RANDOMIZED, DOUBLE BLIND, CROSS-OVER, STUDY OF SELINEXOR VERSUS PLACEBO IN
ADVANCED UNRESECTABLE DEDIFFERENTIATED LIPOSARCOMA (DDL5)**

Mrinal Gounder¹, Albiruni Abdul Razak², Neeta Somaiah³, Javier Martin-Broto⁴, Scott Schuetze⁵, Giovanni Grignani⁶, Sant P. Chawla⁷, Bartosz Chmielowski⁸, Bruno Vincenzi⁹, Silvia Stacchiotti¹⁰, Andrew J. Wagner¹¹, Axel Le Cesne¹², Richard F. Riedel¹³, Robin L. Jones¹⁴, Kristen Ganjoo¹⁵, Xavier Garcia del Muro¹⁶, Melissa A. Burgess¹⁷, Dayana Michel¹⁸, Hongwei Wang¹⁸, Jatin J. Shah¹⁸, Steven Attia¹⁹

¹Memorial Sloan Kettering Cancer Center, New York, New York, UNITED STATES; ²Princess Margaret Cancer Centre, Toronto, Ontario, CANADA; ³Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, UNITED STATES; ⁴Virgen del Rocio University Hospital, Institute of Biomedicine Research (IBIS)/CSIC/Universidad de Sevilla, Seville, SPAIN; ⁵University of Michigan, Ann Arbor, Michigan, UNITED STATES; ⁶Division of Medical Oncology, Candiolo Cancer Institute, FPO-IRCCS, Candiolo (TO), Candiolo (TO), ITALY; ⁷Sarcoma Oncology Center, Santa Monica, California, UNITED STATES; ⁸Division of Hematology-Oncology, David Geffen School of Medicine, University of California, Los-Angeles, Los Angeles, California, UNITED STATES; ⁹Policlinico Universitario Campus, Bio-Medico, Rome, ITALY; ¹⁰Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, ITALY; ¹¹Dana-Farber Cancer Institute, Boston, Massachusetts, UNITED STATES; ¹²Institut Gustave Roussy, Villejuif, FRANCE; ¹³Duke Cancer Institute, Duke University Medical Center, Durham, North Carolina, UNITED STATES; ¹⁴The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London, UNITED KINGDOM; ¹⁵Stanford Cancer Institute, Stanford, California, UNITED STATES; ¹⁶Catalan Institute of Oncology, IDIBELL, University of Barcelona, Barcelona, SPAIN; ¹⁷University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, Pennsylvania, UNITED STATES; ¹⁸Karyopharm Therapeutics Inc., Newton, Massachusetts, UNITED STATES; ¹⁹Mayo Clinic, Jacksonville, Florida, UNITED STATES

Paper #21 3447775

**NEUTROPHIL-TO-LYMPHOCYTE RATIO IS A PROGNOSTIC FACTOR REGARDLESS PREOPERATIVE TREATMENTS
IN PRIMARY RETROPERITONEAL SARCOMA**

Marco Fiore¹, Sandro Pasquali¹, Daniele Morelli², Giuseppe Cuomo², Marta Barisella³, Claudia Sangalli⁴, Alessandro Gronchi¹

¹Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, ITALY; ²Department of Laboratory and Transfusion Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, ITALY; ³Department of Pathology and Experimental Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, ITALY; ⁴Department of Radiation Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, ITALY

Friday, 20 November, 2020

11:30 am - 12:30 pm – Session 8 –

GIST

Chair: **Cesar Serrano**

Discussant: **Ron deMatteo**

Panelists: **Chandrajit Raut, Piotr Rutkowski**

Presenters: **Jason Sicklick, Lorenzo D'Ambrosio, Jonathan Trent, Suzanne George, Sebastian Bauer**

Paper #22 3462544

HUMAN SUCCINATE DEHYDROGENASE-DEFICIENT GASTROINTESTINAL STROMAL TUMORS ARE SENSITIVE TO TEMOZOLOMIDE VIA INDUCTION OF ER STRESS AND DNA DAMAGE

Mayra Yebra¹, Avi Kumar², Adam Burgoyne³, Chih-Min Tang¹, Hyunho Yoon¹, Sudeep Banerjee⁴, Joseph Aguilera¹, Thekla Cordes¹, Vipul Sheth⁵, Sangkyu Noh¹, Rowan Ustoy¹, Sunil Advani¹, Christopher Corless⁷, Michael Heinrich⁶, Razelle Kurzrock¹, Scott M. Lippman¹, Paul T. Fanta¹, Olivier Harismendy¹, Christian Metallo¹, **Jason K. Sicklick**¹
¹University of California, San Diego, La Jolla, California, UNITED STATES; ²University of California San Diego, La Jolla, California, UNITED STATES; ³University of California San Diego, La Jolla, California, UNITED STATES; ⁴University of California Los Angeles, Los Angeles, California, UNITED STATES; ⁵Stanford University, Palo Alto, California, UNITED STATES; ⁶Portland VA Health Care System, Portland, Oregon, UNITED STATES; ⁷OHSU Knight Cancer Institute, Portland, Oregon, UNITED STATES

Friday, 20 November, 2020

Paper #23 3465722

ASSESSMENT OF A GUIDELINE-BASED FOLLOW-UP STRATEGY AFTER COMPLETE SURGERY IN PATIENTS AFFECTED BY GASTROINTESTINAL STROMAL TUMOR (GIST) WITH LOW-RISK OF RECURRENCE

Lorenzo D'Ambrosio¹, Elena Fumagalli², Margherita Nannini³, Tommaso Martino De Pas⁴, Bruno Vincenzi⁵, Francesca Ligorio², Elisabetta Pennacchioli⁶, Andrea Mogavero¹, Antonella Brunello⁷, Fabio Conforti⁴, Danila Comandini⁸, Giulia Manessi¹, Silvia Gasperoni⁹, Virginia Ferraresi¹⁰, Giuseppe Badalamenti¹¹, Sandra Aliberti¹, Marco Fiore¹², Maria Pantaleo³, Giovanni Grignani¹

¹Medical Oncology, Candiolo Cancer Institute, Candiolo, ITALY; ²Medical Oncology, IRCCS Istituto Nazionale dei Tumori di Milano, Milan, ITALY; ³Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, ITALY; ⁴Unit of Sarcomas and Thymomas, European Institute of Oncology, Milan, ITALY; ⁵Medical Oncology, Università Campus Bio-Medico, Rome, ITALY; ⁶Surgical Department Melanoma, European Institute of Oncology, Milan, ITALY; ⁷Medical Oncology, Istituto Oncologico Veneto - IRCCS, Padua, ITALY; ⁸Medical Oncology, Ospedale Policlinico San Martino, Genoa, ITALY; ⁹Medical Oncology, AOU Careggi, Florence, ITALY; ¹⁰Medical Oncology, Regina Elena National Cancer Institute, Rome, ITALY; ¹¹Department of Surgical, Oncological and Oral Sciences, University of Palermo, Palermo, ITALY; ¹²Department of Surgery, IRCCS Istituto Nazionale dei Tumori di Milano, Milan, ITALY

Paper #24 3458521

THE POTENT AND SELECTIVE KIT INHIBITOR PLX9486 DOSED IN COMBINATION WITH SUNITINIB DEMONSTRATES PROMISING PROGRESSION FREE SURVIVAL (PFS) IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMOR (GIST): FINAL RESULTS OF A PHASE 1/2 STUDY

Jonathan Trent¹, William D. Tap², Rashmi Chugh³, Gabriel Tinoco⁴, Athanasios Tsiatis⁵, Paul Sevenson⁵, Kerry Inokuchi⁵, Chao Zhang⁵, Glenn Michelson⁷, Andrew J. Wagner⁶

¹University of Miami, Miami, Florida, UNITED STATES; ²Memorial Sloan Kettering Cancer Center, New York, New York, UNITED STATES; ³University of Michigan, Ann Arbor, Michigan, UNITED STATES; ⁴The Ohio State University, Columbus, Ohio, UNITED STATES; ⁵Plexikon, Inc., Berkeley, California, UNITED STATES; ⁶Dana-Farber Cancer Institute, Boston, Massachusetts, UNITED STATES; ⁷KIQ Bio, San Francisco, California, UNITED STATES

Paper #25 3463167

RIPRETINIB INTRA-PATIENT DOSE ESCALATION FOLLOWING DISEASE PROGRESSION PROVIDES CLINICALLY MEANINGFUL PROGRESSION-FREE SURVIVAL IN GASTROINTESTINAL STROMAL TUMOR IN PHASE 1 STUDY

Suzanne George¹, Ping Chi², Michael Heinrich³, Margaret von Mehren⁴, Robin L. Jones⁵, Kristen Ganjoo⁶, Jonathan Trent⁷, Hans Gelderblom⁸, Albiruni Abdul Razak⁹, Michael Gordon¹⁰, Neeta Somaiah¹¹, Julia Jennings¹², Kelvin Shi¹², Rodrigo Ruiz-Soto¹², Filip Janku¹³

¹Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, UNITED STATES; ²Human Oncology and Pathogenesis Program & Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, UNITED STATES; ³Hematology/Medical Oncology, OHSU Knight Cancer Institute, Portland, Oregon, UNITED STATES; ⁴Hematology Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, UNITED STATES; ⁵Royal Marsden and Institute of Cancer Research, London, UNITED KINGDOM; ⁶Medical Oncology, Stanford University, Stanford, California, UNITED STATES; ⁷Medical Oncology, Sylvester Comprehensive Cancer Center/University of Miami, Miami, Florida, UNITED STATES; ⁸Medical Oncology, Leiden University Medical Center, Leiden, NETHERLANDS; ⁹Toronto Sarcoma Program, Princess Margaret Cancer Centre, Toronto, Ontario, CANADA; ¹⁰HonorHealth Research Institute, Scottsdale, Arizona, UNITED STATES; ¹¹Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, UNITED STATES; ¹²Deciphera Pharmaceuticals, LLC, Waltham, Massachusetts, UNITED STATES; ¹³Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, UNITED STATES


Friday, 20 November, 2020

Paper #26 3443599

CHARACTERIZATION OF THE EXTENSIVE HETEROGENEITY OF KIT/PDGFRA MUTATIONS IN PATIENTS WITH FOURTH-LINE ADVANCED GASTROINTESTINAL STROMAL TUMOR: GENOMIC ANALYSIS OF THE PHASE 3 INVICTUS STUDY

Sebastian Bauer¹, Patrick Schöffski², Michael Heinrich³, Suzanne George⁴, John Zalberg⁵, Hans Gelderblom⁶, César Serrano⁷, Robin L. Jones⁸, Steven Attia⁹, Gina D'amato¹⁰, Ping Chi¹¹, Peter Reichardt¹², Julie Meade¹³, Vienna L. Reichert¹³, Ying Su¹³, Rodrigo Ruiz-Soto¹³, Jean-Yves Blay¹⁴, Margaret von Mehren¹⁵

¹Sarcoma Center, West German Cancer Center, Essen, GERMANY; ²General Medical Oncology, University Hospitals Leuven, Leuven, BELGIUM; ³Hematology/Medical Oncology, OHSU Knight Cancer Institute, Portland, Oregon, UNITED STATES; ⁴Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, UNITED STATES; ⁵School of Public Health, Faculty of Medicine, Monash University, Melbourne, Victoria, AUSTRALIA; ⁶Medical Oncology, Leiden University Medical Center, Leiden, NETHERLANDS; ⁷Medical Oncology, Vall d'Hebron Institute of Oncology, Barcelona, SPAIN; ⁸Sarcoma Unit, Royal Marsden and Institute of Cancer Research, London, UNITED KINGDOM; ⁹Oncology, Mayo Clinic, Jacksonville, Florida, UNITED STATES; ¹⁰Medical Oncology, Sylvester Comprehensive Cancer Center/University of Miami, Miami, Florida, UNITED STATES; ¹¹Human Oncology and Pathogenesis Program & Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, UNITED STATES; ¹²Oncology and Palliative Care, Sarcoma Center, Helios Klinikum Berlin-Buch, Berlin, GERMANY; ¹³Deciphera Pharmaceuticals, LLC, Waltham, Massachusetts, UNITED STATES; ¹⁴Medicine, Centre Leon Berard, Lyon, FRANCE; ¹⁵Hematology Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, UNITED STATES

12:30 pm - 1:30 pm	HERMAN SUIT LECTURE – GENETICS, GENOMICS AND SARCOMAS David Thomas
1:30 pm - 2:30 pm	VIRTUAL GET-TOGETHER 
2:30 pm - 3:30 pm	CTOS Board of Directors Meeting
3:00 pm - 4:00 pm	– Symposium – PERSONALIZING AND PROLONGING CARE IN GIST: EXPERT GUIDANCE ON INTEGRATING NEW TKI STRATEGIES

8:00 am - 9:00 am

– Session 9 –

EPIGENETICALLY DRIVEN SARCOMAS

Presenter: **Cigall Kadoch**

9:00 am - 10:00 am

– Session 10 –

**ADVANCES IN ANGIOSARCOMA, PECOMA,
AND CLEAR CELL SARCOMA**

Chair: **Vinod Ravi**

Discussant: **William Tap**

Panelists: **Winette van der Graaf, Cristina Antonescu, Jayesh Desai**

Presenters: **Andrea Espejo-Freire, Jessica Burns, Andrew J. Wagner,
Ben Ozenberger**

Paper #27 3460221

GENOMIC LANDSCAPE OF ANGIOSARCOMA: A TARGETED AND IMMUNOTHERAPY BIOMARKER ANALYSIS OF 143 PATIENTS

Andrea Espejo-Freire¹, Andrew Elliott², Yamac Akgun¹, Philippos A. Costa¹, Maryam Alasfour¹, Andrew Rosenberg¹, Julio Diaz-Perez¹, Gina D'amato¹, Ty K. Subhawong¹, Junaid Arshad¹, W. Michael Korn², Don Dizon³, Margaret von Mehren⁴, Moh'd Khushman⁵, Atif Hussein⁶, Kirsten Leu⁷, Jonathan Trent¹

¹University of Miami Sylvester Comprehensive Cancer Center, Jackson Memorial Hospital, Miami, Florida, UNITED STATES; ²Caris Life Sciences, Irving, Texas, UNITED STATES; ³Brown University Lifespan Cancer Institute, Providence, Rhode Island, UNITED STATES; ⁴Fox Chase Cancer Center, Philadelphia, Pennsylvania, UNITED STATES; ⁵University of South Alabama Mitchell Cancer Institute, Mobile, Alabama, UNITED STATES; ⁶Memorial Cancer Institute, Hollywood, Florida, UNITED STATES; ⁷Nebraska Cancer Specialists, Omaha, Nebraska, UNITED STATES

Paper #28 3464567

THE PROTEOME LANDSCAPE OF SOFT TISSUE SARCOMAS DEFINES TWO FUNCTIONAL SUBGROUPS OF ANGIOSARCOMAS WITH DISTINCT SURVIVAL OUTCOMES

Jessica Burns¹, Lukas Krasny¹, Christopher Wilding¹, Maggie Cheang¹, Robin L. Jones², Paul Huang¹

¹Institute of Cancer Research, London, UNITED KINGDOM; ²The Royal Marsden NHS Foundation Trust, London, UNITED KINGDOM

Paper #29 3463014

LONG-TERM FOLLOW-UP FROM AMPECT, AN OPEN-LABEL PHASE 2 REGISTRATION TRIAL OF NAB-SIROLIMUS FOR PATIENTS WITH ADVANCED MALIGNANT PERIVASCULAR EPITHELIOID CELL TUMORS (PECOMA)

Andrew J. Wagner¹, Vinod Ravi², Richard F. Riedel³, Kristen Ganjoo⁵, Brian A. Van Tine⁶, Rashmi Chugh⁷, Lee D. Cranmer⁸, Erlinda M. Gordon⁹, Jason L. Hornick¹⁰, Heng Du¹⁰, Berta Grigorian⁴, Anita N. Schmid⁴, Shihe Hou⁴, Katherine Harris⁴, David Kwiatkowski¹⁰, Neil Desai⁴, Mark Dickson¹¹

¹Dana-Farber Cancer Institute, Boston, Massachusetts, UNITED STATES; ²Anderson Cancer Center, Houston, Texas, UNITED STATES; ³Duke Cancer Institute, Durham, North Carolina, UNITED STATES; ⁴Aadi Bioscience, Pacific Palisades, California, UNITED STATES; ⁵Stanford University, Stanford, California, UNITED STATES; ⁶Washington University in Saint Louis, St. Louis, Missouri, UNITED STATES; ⁷University of Michigan, Ann Arbor, Michigan, UNITED STATES; ⁸Univ Washington/Fred Hutchinson Cancer Res Ctr, Seattle, Washington, UNITED STATES; ⁹Sarcoma Oncology Center, Santa Monica, California, UNITED STATES; ¹⁰Brigham and Women's Hospital, Boston, Massachusetts, UNITED STATES; ¹¹Memorial Sloan Kettering Cancer Center, New York, New York, UNITED STATES

Saturday, 21 November, 2020

Paper #30 3465453

BEYOND THE FUSION: THE CLEAR CELL SARCOMA FUNCTIONAL GENOME

Emanuele Panza², **Ben Ozenberger**¹, Krystal Straessler³, Jared J. Barrott⁴, Anne M. Boulet⁵, Clint Mason⁶, Alexander Lazar⁷, Mario R. Capecchi⁵, Kevin B. Jones¹

¹Orthopaedics and Oncological Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, UNITED STATES; ²Department of Medical and Surgical Sciences - DIMEC, University of Bologna, Bologna, ITALY; ³School of Medicine, University of Utah, Salt Lake City, Utah, UNITED STATES; ⁴College of Pharmacy, Idaho State University, Pocatello, Idaho, UNITED STATES; ⁵Department of Human Genetics, University of Utah, Salt Lake City, Utah, UNITED STATES; ⁶Department of Pediatrics, University of Utah, Salt Lake City, Utah, UNITED STATES; ⁷Department of Pathology, MD Anderson Cancer Center, Houston, Texas, UNITED STATES

10:00 am - 10:30 am

Morning Break

10:30 am - 11:30 am

**NINA AXELRAD LECTURE –
EVOLUTION OF DOGMAS IN SARCOMA SURGERY**

Sylvie Bonvalot

11:30 am - 12:30 pm

– Session 11 –

RHABDOMYOSARCOMA AND EWING SARCOMA

Chair: **Abha Gupta**

Discussant: **Katherine Janeway**

Panelists: **Richard Womer, Kevin Jones**

Presenters: **Christine M. Heske, Wendy Allen-Rhoades, Margaret B. Nagel, Megann Boone, Joseph A. Ludwig**

Paper #31 3443006

SURVIVAL OUTCOMES OF PATIENTS WITH LOCALIZED FOXO1 FUSION POSITIVE RHABDOMYOSARCOMA TREATED ON RECENT CHILDREN'S ONCOLOGY GROUP CLINICAL TRIALS

Christine M. Heske¹, Yueh-Yun Chi², Rajkumar Venkatramani³, Minjie Li², Michael Arnold⁴, Roshni Dasgupta⁵, Susan M. Hiniker⁶, Douglas S. Hawkins⁷, Leo Mascarenhas⁸

¹Pediatric Oncology Branch, National Cancer Institute, Bethesda, Maryland, UNITED STATES; ²Department of Biostatistics, University of Florida, Gainesville, Florida, UNITED STATES; ³Division of Hematology/Oncology, Texas Children's Hospital, Houston, Texas, UNITED STATES; ⁴Department of Pathology and Laboratory Medicine, Children's Hospital Colorado, Aurora, Colorado, UNITED STATES; ⁵Division of Pediatric General and Thoracic Surgery, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, UNITED STATES; ⁶Stanford University School of Medicine, Department of Radiation Oncology, Stanford, California, UNITED STATES; ⁷Department of Pediatrics, Seattle Children's Hospital, Seattle, Washington, UNITED STATES; ⁸Division of Hematology/Oncology, Children's Hospital Los Angeles, Los Angeles, California, UNITED STATES

Paper #32 3461602

ALVEOLAR RHABDOMYOSARCOMA HAS SUPERIOR CLINICAL RESPONSE RATES TO VINORELBINE COMPARED TO EMBRYONAL RHABDOMYOSARCOMA IN PATIENTS WITH REFRACTORY OR RELAPSED DISEASE

Wendy Allen-Rhoades¹, Philip Lupo¹, Michael Scheurer¹, Yueh-Yun Chi², John Kuttesch³, William H. Meyer⁴, Rajkumar Venkatramani¹, Leo Mascarenhas²

¹Pediatrics, Baylor College of Medicine, Houston, Texas, UNITED STATES; ²Pediatrics, Children's Hospital of Los Angeles, University of Southern California, Los Angeles, California, UNITED STATES; ³Pediatrics, University of New Mexico Health Sciences Center, Albuquerque, New Mexico, UNITED STATES; ⁴Pediatrics, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, UNITED STATES

Paper #33 3457806

THE ROLE OF DLK1 IN FUSION-NEGATIVE RHABDOMYOSARCOMA

Margaret B. Nagel¹, Matthew R. Garcia¹, Mark E. Hatley¹

¹St Jude Children's Research Hospital, Memphis, Tennessee, UNITED STATES

Paper #34 3435189

STRUCTURE-FUNCTION MAPPING REVEALS NOVEL REGION OF FLI1 CRITICAL FOR EWS/FLI1 ACTIVITY IN EWING SARCOMA

Megann Boone¹, Cenny Taslim¹, Julia Selich-Anderson¹, Jesse Crow¹, Emily R. Theisen¹, Iftekhar Showpnil¹, Stephen Lessnick¹

¹Center for Childhood Cancer, Nationwide Children's Hospital, Columbus, Ohio, UNITED STATES

Saturday, 21 November, 2020

Paper #35 3464969

TK216 PHASE 1 STUDY IN METASTATIC, RELAPSED/REFRACTORY EWING SARCOMA

Joseph A. Ludwig², Noah Federman⁴, Peter Anderson¹⁰, Margaret Macy³, Lara E. Davis⁷, Richard F. Riedel¹⁵, Najat C. Daw², Jodi Muscal⁸, Ravin Ratan², Jeffrey Toretsky⁶, Xen Ianopoulos¹, Frank Hsu¹, James Breitmeyer¹, Paul Meyers⁹
¹Oncternal Therapeutics, San Diego, California, UNITED STATES; ²MD Anderson Cancer Center, Houston, Texas, UNITED STATES; ³Children's Hospital Colorado, Aurora, Colorado, UNITED STATES; ⁴UCLA David Geffen School of Medicine, Los Angeles, California, UNITED STATES; ⁵Duke University School of Medicine, Durham, North Carolina, UNITED STATES; ⁶Georgetown University, Washington, District of Columbia, UNITED STATES; ⁷Oregon Health & Science University, Portland, Oregon, UNITED STATES; ⁸Baylor College of Medicine, Houston, Texas, UNITED STATES; ⁹Memorial Sloan Kettering Cancer Center, New York, New York, UNITED STATES; ¹⁰Cleveland Clinic Foundation, Cleveland, Ohio, UNITED STATES

12:30 pm - 1:30 pm

– Session 12 –

**LOCALLY AGGRESSIVE MESENCHYMAL TUMORS:
DESMOID TUMOR, DIFFUSE-TYPE GIANT CELL TUMOR**

Chair: **Palma Dileo**

Discussant: **Winan Van Houdt**

Panelists: **Alexander Lazar, Bernd Kasper, Jay Wunder**

Presenters: **Javier Martin-Broto, Michael J. Nathenson, Albiruni Abdul Razak**

Lecture:

**RECENT UPDATES IN LOCALLY AGGRESSIVE MESENCHYMAL TUMORS:
DESMOID TUMOR, DIFFUSE-TYPE GIANT CELL TUMOR**

Mrinal Gounder

Paper #36

3465367

WEEKLY NAB-PACLITAXEL FOR PROGRESSIVE OR SYMPTOMATIC DESMOID TUMORS:

A MULTICENTER SINGLE ARM PHASE II TRIAL FROM THE SPANISH GROUP FOR RESEARCH ON SARCOMA (GEIS)

Javier Martin-Broto¹, Nadia Hindi¹, Andres Redondo², Jose Manuel Morales³, David Marcilla⁴, Claudia Valverde⁵, Pablo Luna⁶, Robert D. Beveridge⁷, Javier Martinez-Trufero⁸, Jose Antonio Lopez-Martin⁹, Virginia Martinez², Antonio Gutierrez¹⁰, Antonio Lopez-Pousa¹¹

¹Medical Oncology, Hospital Universitario Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS), Seville, SPAIN;

²Medical Oncology, Hospital Universitario La Paz - IdiPAZ, Madrid, Spain, Madrid, SPAIN; ³Radiology Department, Hospital Universitario Virgen del Rocío, Seville, SPAIN;

⁴Pathology Department, Hospital Universitario Virgen del Rocío, Seville, SPAIN; ⁵Medical Oncology, Hospital Universitario Vall d'Hebron, Barcelona, SPAIN; ⁶Medical Oncology, Hospital Universitario Son Espases, Palma de Mallorca, SPAIN;

⁷Medical Oncology, Hospital Universitario La Fe, Valencia, SPAIN; ⁸Medical Oncology, Hospital Universitario Miguel Servet, Zaragoza, SPAIN; ⁹Medical Oncology, Hospital Universitario 12 de Octubre, Translational Oncology Instituto de Investigación Hospital 12 de Octubre (i+12), Madrid, SPAIN;

¹⁰Hospital Universitario Son Espases, Mallorca, SPAIN; ¹¹Medical Oncology, Hospital Sant Pau, Barcelona, SPAIN

Saturday, 21 November, 2020

Paper #37 3459474

ASSOCIATION OF CTNNB1 MUTATION SUBTYPES WITH RESPONSE TO SYSTEMIC THERAPY IN PATIENTS WITH DESMOID TUMORS: A MULTI-INSTITUTIONAL RETROSPECTIVE STUDY

Michael J. Nathenson¹, Neeta Somaiah², Robert Hsu³, Peter DeMaria³, Heath Catoe³, Karan Malik¹, Christy Harris¹, Ty K. Subhawong⁴, Behrang Amini⁵, Jyothi P. Jagannathan⁶, Marta Braschi-Amirfarzan⁶, Kevin Sweet⁴, Katharina Feister⁴, Junxiao Hu⁷, Jamie Sheren⁸, Andrew Rosenberg⁹, Alexander Lazar¹⁰, Ravin Ratan², Vinod Ravi², Shreyaskumar Patel², Robert Maki¹², Pasquale Benedetto³, Jonathan Cohen³, Jonathan Trent³, Breelyn A. Wilky¹¹

¹Medicine, Dana Farber Cancer Institute, Boston, Massachusetts, UNITED STATES; ²Medicine, MD Anderson Cancer Center, Houston, Texas, UNITED STATES; ³Medicine, Sylvester Comprehensive Cancer Center University of Miami, Miami, Florida, UNITED STATES; ⁴Radiology, University of Miami School of Medicine, Miami, Florida, UNITED STATES; ⁵Radiology, MD Anderson Cancer Center, Houston, Texas, UNITED STATES; ⁶Radiology, Dana Farber Cancer Institute, Boston, Massachusetts, UNITED STATES; ⁷Biostatistics, University of Colorado School of Medicine, Aurora, Colorado, UNITED STATES; ⁸Pathology, University of Colorado School of Medicine, Aurora, Colorado, UNITED STATES; ⁹Pathology, University of Miami School of Medicine, Miami, Florida, UNITED STATES; ¹⁰Pathology, MD Anderson Cancer Center, Houston, Texas, UNITED STATES; ¹¹Medicine, University of Colorado School of Medicine, Aurora, Colorado, UNITED STATES; ¹²Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, UNITED STATES

Paper #38 3461713

PHASE 1 DOSE-ESCALATION STUDY OF THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF DCC-3014 IN ADVANCED SOLID TUMORS AND TENOSYNOVIAL GIANT CELL TUMOR (TGCT)

Albiruni Abdul Razak¹, Breelyn A. Wilky², Jacqueline Vuky³, Lara E. Davis³, Todd Bauer⁴, Hans Gelderblom⁵, Mary Michenzie⁶, Maitreyi Sharma⁶, Rodrigo Ruiz-Soto⁶, Matthew L. Sherman⁶, William D. Tap⁷

¹Toronto Sarcoma Program, Princess Margaret Cancer Center, Toronto, Ontario, CANADA; ²Medicine, University of Colorado Cancer Center, Aurora, Colorado, UNITED STATES; ³OHSU Knight Cancer Institute, Portland, Oregon, UNITED STATES; ⁴Sarah Cannon Research Institute and Tennessee Oncology, Nashville, Tennessee, UNITED STATES; ⁵Medical Oncology, Leiden University Medical Center, Leiden, NETHERLANDS; ⁶Deciphera Pharmaceuticals, LLC, Waltham, Massachusetts, UNITED STATES; ⁷Medical Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, UNITED STATES

1:30 pm - 2:00 pm

CLOSING REMARKS

President: **Kirsten Sundby Hall**

Program Chairs: **Silvia Stacchiotti, Margaret von Mehren, Inga-Marie Schaefer**

2:00 pm - 3:00 pm

CTOS Members' Business Meeting

Poster #001 3412554

DIFFICULTY OF DISTINGUISHING ARTERIAL INTIMAL SARCOMA FROM CHRONIC PULMONARY EMBOLISM THROUGH DIFFERENTIAL DIAGNOSIS

Hirotaka Suto¹, Yumiko Inui², Atsuo Okamura²

¹Kobe University, Kobe, JAPAN; ²Kakogawa Central City Hospital, Kakogawa, JAPAN

Poster #002 3412790

APATINIB FOR TREATMENT OF INOPERABLE METASTATIC OR LOCALLY ADVANCED CHONDROSARCOMA: WHAT CAN WE LEARN ABOUT THE BIOLOGICAL BEHAVIOR OF CHONDROSARCOMA FROM A MULTICENTER STUDY

Lu Xie¹, Jie Xu¹, Jin Gu², Zhe Lv³, Xiaodong Tang¹, Wei Guo¹

¹Musculoskeletal Tumor Center, Peking University People's Hospital, Beijing, Beijing, CHINA; ²Surgical Oncology, Peking University Shougang Hospital, Beijing, CHINA; ³Radiology Department, Peking University Shougang Hospital, Beijing, CHINA

Poster #003 3412794

DYNAMIC CHANGES IN QUALITY OF LIFE AND Q-TWIST ANALYSIS FOR EWING SARCOMA PATIENTS FOLLOWING ANLOTINIB AND IRINOTECAN, A COMBINATION OF PHASE 1B AND 2 TRIAL

Lu Xie¹, Jie Xu¹, Wei Guo¹, Xin Sun¹, Xiaodong Tang¹

¹Musculoskeletal Tumor Center, Peking University People's Hospital, Beijing, Beijing, CHINA

Poster #004 3412832

THE CLINICAL IMPLICATIONS OF TUMOR MUTATIONAL BURDEN IN OSTEOSARCOMA

Lu Xie¹, Yu-Fei Yang², Wei Guo¹, Dongxue Che², Jie Xu¹, Xin Sun¹, Kuisheng Liu¹, Xiaodong Tang¹

¹Musculoskeletal Tumor Center, Peking University People's Hospital, Beijing, Beijing, CHINA; ²Genetronhealth. Co. Ltd., Beijing, CHINA

Poster #005 3413225

EXTRASKELETAL MYXOID CHONDROSARCOMA: A HIGH INCIDENCE OF METASTATIC DISEASE TO LYMPH NODES

Matthew R. Claxton², Peter S. Rose¹, Doris Wenger³, **Matthew T. Houdek**¹

¹Orthopedic Surgery, Mayo Clinic, Rochester, Minnesota, UNITED STATES; ²School of Medicine, Mayo Clinic, Rochester, Minnesota, UNITED STATES; ³Radiology, Mayo Clinic, Rochester, Minnesota, UNITED STATES

Poster #006 3420516

CLINICAL EXPERIENCE OF 6 CASES OF MYXOID PLEOMORPHIC LIPOSARCOMA

Chiaki Sato¹, Eisuke Kobayashi¹, Akira Kawai¹

¹National Cancer Center Japan, Chu-ou-ku, Tokyo, JAPAN

Poster #007 3425027

VERSICAN AND EXTRACELLULAR MATRIX REMODELING PROMOTE CIRCULATING OSTEOSARCOMA CELL EXTRAVASATION AND METASTATIC SEEDING

Mark M. Cullen¹, Tyler A. Allen², Lan Nguyen³, Hiroyuki Mochizuk⁶, Paige Neme⁶, Etienne M. Flamant¹, Sarah Hoskinson⁴, Beatrice Thomas², Suzanne B. DeWitt⁴, Kathryn E. Ware², Luke Borst⁶, Ke Cheng⁶, William C. Eward⁵, Jason A. Somarelli²

¹School of Medicine, Duke University, Durham, North Carolina, UNITED STATES; ²Duke University Cancer Institute, Durham, North Carolina, UNITED STATES; ³Nazareth College, Rochester, New York, UNITED STATES; ⁴Orthopaedics, Duke University, Durham, North Carolina, UNITED STATES; ⁵Department of Orthopaedic Surgery, Duke Cancer Institute, Durham, North Carolina, UNITED STATES; ⁶College of Veterinary Medicine, North Carolina State University, Raleigh, North Carolina, UNITED STATES

Poster #008 3427115

THE ANATOMIC DISTRIBUTION OF OSTEOSARCOMA

Jeffrey Brown¹, David Matichak¹, John Groundland²

¹Orthopedics, University of Miami Miller School of Medicine, Miami, Florida, UNITED STATES; ²Orthopedics, Huntsman Cancer Institute, Salt Lake City, Utah, UNITED STATES

Poster #009 3428769

PROGNOSIS OF PATIENTS WITH METASTATIC SOFT TISSUE SARCOMA: ADVANCES IN RECENT YEARS

Jakob Lochner¹, Franka Menge¹, Nikolaos Vassos¹, Peter Hohenberger¹, **Bernd Kasper**¹

¹Interdisciplinary Tumor Center, Mannheim University Medical Center, Mannheim, GERMANY

Poster #010 3434418

RECURRENT MULTIFOCAL PLEOMORPHIC SARCOMA OF THE SCALP RESPONDING TO PEMBROLIZUMAB

Benjamin Powers¹, Elizabeth Friedman²

¹Medical Oncology, U of Kansas Cancer Center, Overland Park, Kansas, UNITED STATES; ²Pathology and Laboratory Medicine, U of Kansas Health System, Kansas City, Kansas, UNITED STATES

Poster #011 3434659

PROGNOSTIC FACTORS OF HIGH-GRADE OSTEOSARCOMA: ANALYSIS OF 20 YEARS DATA AT A SINGLE CENTER IN JAPAN

Akane Ariga¹, Yoshiaki Ando¹, Chigusa Sawamura¹, Jun Manabe¹, Tabu Gokita¹

¹Department of Orthopaedic Surgery, Saitama Cancer Center, Saitama, JAPAN

Poster #012 3436390

CHARACTERISTICS AND OUTCOMES OF LOCALLY RECURRENT RETROPERITONEAL SARCOMA AFTER FIRST RELAPSE IN A SINGLE TERTIARY ASIAN CENTRE AND APPLICABILITY OF THE SARCOLATOR

Hui Jun Lim², Ru Xin Wong¹, Yen Sin Koh¹, Zhirui Shaun Ho¹, Chin-Ann Johnny Ong², Farid Bin Harunal Rashid Mohamad³, Ching Ching Melissa Teo²

¹Department of Radiation Oncology, National Cancer Centre Singapore, Singapore, SINGAPORE; ²Department of Sarcoma, Peritoneal and Rare Tumours (SPRinT), Division of Surgery and Surgical Oncology, National Cancer Centre Singapore, Singapore, SINGAPORE; ³Department of Medical Oncology, National Cancer Centre Singapore, Singapore, SINGAPORE

Poster #013 3436645

CURRICULUM-BASED ONLINE CME IMPROVES PHYSICIAN KNOWLEDGE OF EPITHELIOID SARCOMA

Michelle A. Worst¹, Mindy Tanzola¹, Emily Van Laar¹, Mrinal Gounder², Mark Agulnik³

¹Medscape Oncology, New York, New York, UNITED STATES; ²Memorial Sloan Kettering Cancer Center, New York, New York, UNITED STATES; ³Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, UNITED STATES

Poster #014 3436999

ASSOCIATION BETWEEN OCCUPATIONAL EXPOSURES AND SARCOMA INCIDENCE AND MORTALITY: SYSTEMATIC REVIEW AND META-ANALYSIS

Dali Edwards¹, Angelina Voronina², Kristopher Attwood³, Anne Grand'Maison⁴

¹Department of Medicine, University at Buffalo, Buffalo, New York, UNITED STATES; ²Department of Medicine, New York–Presbyterian Queens, New York, New York, UNITED STATES; ³Department of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, New York, UNITED STATES; ⁴Department of Sarcoma Medical Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, New York, UNITED STATES

Poster #015 3437318

PELVIC SOFT TISSUE SARCOMAS: AN INTERNATIONAL RETROSPECTIVE STUDY FROM THE TRANS-ATLANTIC AUSTRALASIAN RETROPERITONEAL SARCOMA WORKING GROUP (TARPSWG)

Marco Fiore¹, Catherine Sarre-Lazcano¹, Sinziana Dumitra², Charles Honoré³, Paul Sargos⁴, Giovanni Grignani⁵, Shintaro Iwata⁶, Carolyn Nessim⁷, Marko Novak⁸, Dmitri Tzanis⁹, David E. Gyorki¹⁰, Piotr Rutkowski¹¹, Antoine Bouchard-Fortier¹², Kenneth Cardona¹³, Sergio D. Quildrian¹⁴, Dorian Y. Garcia-Ortega¹⁷, Winan J. van Houdt¹⁵, Sergio Valeri¹⁶, Carlo Abatini¹, Mario Terlizzi⁴, Francesco Tolomeo⁵, Michelle J. Wilkinson¹⁰, Jecek Skoczylas¹¹, Sandro Pasquali¹, Alessandro Gronchi¹

¹Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, ITALY; ²McGill University, Montreal, Ontario, CANADA; ³Gustave Roussy, Villejuif, FRANCE; ⁴Institut Bergonié, Bordeaux, FRANCE; ⁵Candiolo Cancer Institute, FPO IRCCS, Candiolo, ITALY; ⁶National Cancer Center Hospital, Tokyo, JAPAN; ⁷The Ottawa Hospital, Ottawa, Ontario, CANADA; ⁸Institute of Oncology Ljubljana, Ljubljana, SLOVENIA; ⁹Institut Curie, PSL University, Paris, FRANCE; ¹⁰Peter McCallum Cancer Center, Melbourne, Victoria, AUSTRALIA; ¹¹Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, POLAND; ¹²Alberta Health Services - University of Calgary, Calgary, Alberta, CANADA; ¹³Winship Cancer Institute, Emory University, Atlanta, Georgia, UNITED STATES; ¹⁴Angel H. Roffo Institute of Oncology, British Hospital, Buenos Aires, ARGENTINA; ¹⁵Antoni van Leeuwenhoek / The Nederland Cancer Institute, Amsterdam, NETHERLANDS; ¹⁶Campus Biomedico, Rome, ITALY; ¹⁷National Cancer Institute, Mexico City, MEXICO

Poster #016 3437396

OSTEOSARCOMA ORGANOIDS DEMONSTRATE FUNCTIONAL AND THERAPEUTIC HETEROGENEITY DEPENDING UPON GEOGRAPHIC SITE OF ORIGIN WITHIN THE TUMOR

Etienne M. Flamant¹, Mark M. Cullen¹, Sarah Hoskinson², Beatrice Thomas³, Sehwa Oh³, Gabrielle Rupprecht³, Joanne Tuohy⁴, David S. Hsu³, William C. Eward², Jason A. Somarelli³

¹Duke University School of Medicine, Durham, North Carolina, UNITED STATES; ²Department of Orthopaedic Surgery, Duke University Medical Center, Durham, North Carolina, UNITED STATES; ³Department of Medicine, Duke University Medical Center, Durham, North Carolina, UNITED STATES; ⁴Department of Small Animal Clinical Sciences, Virginia-Maryland College of Veterinary Medicine, Blacksburg, Virginia, UNITED STATES

Poster #017 3437413

RADIOLOGICAL ANALYSIS OF TUMOR RESPONSE TO AN EFFECTIVE TYROSINE KINASE INHIBITOR (TKI), PEXIDARTINIB, IN TENOSYNOVIAL GIANT CELL TUMORS (TGCT) FROM THE PHASE 3 ENLIVEN STUDY

Charles Peterfy¹, William D. Tap², John H. Healey², Andrew J. Wagner³, Souhil Zaim⁴, Hans Bloem⁵, Qiang Wang⁶, Dale Shuster⁶, Yan Chen¹, Michiel van de Sande⁵

¹Spire Sciences, Boca Raton, Florida, UNITED STATES; ²Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York, UNITED STATES; ³Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, UNITED STATES; ⁴Bioclinica, Newark, California, UNITED STATES; ⁵Leiden University Medical Center, Leiden, NETHERLANDS; ⁶Daiichi Sankyo, Inc., Basking Ridge, New Jersey, UNITED STATES

Poster #018

3437421

A NOVEL PRE-OPERATIVE RISK SCORE TO GUIDE PATIENT SELECTION FOR RESECTION OF SOFT TISSUE SARCOMA LUNG METASTASES: AN ANALYSIS FROM THE UNITED STATES SARCOMA COLLABORATIVE

Rachel Lee¹, Cecilia Ethun¹, Adriana Gamboa¹, Michael Turgeon¹, Thuy Tran², George Poultsides², Valerie Grignol³, J. H. Howard³, Meena Bedi⁴, Harveshp Mogal⁵, Callisia Clarke⁵, Jennifer Tseng⁶, Kevin Roggin⁶, Konstantinos Chouliaras⁷, Konstantinos Votanopoulos⁷, Bradley Krasnick⁸, Ryan Fields⁸, Shervin Oskouei¹, David Monson¹, Nickolas Reimer¹, Shishir Maithel¹, Allan Pickens⁹, Kenneth Cardona¹

¹Division of Surgical Oncology, Department of Surgery, Winship Cancer Institute, Emory University, Atlanta, Georgia, UNITED STATES; ²Department of Surgery, Stanford University Medical Center, Palo Alto, California, UNITED STATES;

³Division of Surgical Oncology, Department of Surgery, The Ohio State University, Columbus, Ohio, UNITED STATES;

⁴Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin, UNITED STATES;

⁵Division of Surgical Oncology, Department of Surgery, Medical College of Wisconsin, Milwaukee, Wisconsin, UNITED STATES;

⁶Department of Surgery, University of Chicago Medicine, Chicago, Illinois, UNITED STATES; ⁷Department of Surgery, Wake Forest University, Winston-Salem, North Carolina, UNITED STATES; ⁸Department of Surgery, Washington

University School of Medicine, St Louis, Missouri, UNITED STATES; ⁹Division of Cardiothoracic Surgery, Department of Surgery, Emory University, Atlanta, Georgia, UNITED STATES

Poster #019

3437427

THE ACCURACY OF A NOVEL SONOGRAPHIC SCANNING AND REPORTING PROTOCOL TO SURVEY FOR SOFT TISSUE SARCOMA LOCAL RECURRENCE: RESULTS OF A PROSPECTIVE PILOT STUDY

Adam D. Singer², Philip K. Wong², Monica B. Umpierrez², Nickolas Reimer³, Felix M. Gonzalez², David A. Reiter², Shervin Oskouei³, **Kenneth Cardona**¹

¹Surgery, Winship Cancer Institute, Emory University, Atlanta, Georgia, UNITED STATES; ²Radiology, Emory University, Atlanta, Georgia, UNITED STATES; ³Orthopedics, Emory University, Atlanta, Georgia, UNITED STATES

Poster #020

3437455

HISTOLOGICAL VARIATION AFTER PRE-OPERATIVE HYPOFRACTIONATED VERSUS STANDARD FRACTION RADIOTHERAPY IN SOFT TISSUE SARCOMAS

Casey Hollawell¹, Yulan Gong², Lori Rink², Elizabeth Handorf², Michael Shu¹, Margaret von Mehren², Jeffrey Farma², Stephanie Greco², John Abraham³, Josh Meyer², Krisha J. Howell²

¹Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania, UNITED STATES; ²Fox Chase Cancer Center, Philadelphia, Pennsylvania, UNITED STATES; ³Rothman Institute, Philadelphia, Pennsylvania, UNITED STATES

Poster #021

3437674

STRIVE-01: PHASE I STUDY OF EGFR806 CAR T CELL IMMUNOTHERAPY FOR RECURRENT/REFRACTORY SOLID TUMORS IN CHILDREN AND YOUNG ADULTS

Catherine M. Albert¹, Navin R. Pinto¹, Adam J. Johnson¹, Ashley L. Wilson¹, Stephanie Mgebroff¹, Christopher Brown¹, Catherine Lindgren¹, Erin Rudzinski², Bonnie L. Cole², Nicholas A. Vitanza¹, Juliane Gust³, Michael C. Jensen¹, Julie Park¹

¹Seattle Children's Research Institute, Seattle, Washington, UNITED STATES; ²Pathology, Seattle Children's Hospital and University of Washington, Seattle, Washington, UNITED STATES; ³Neurology, University of Washington, Seattle, Washington, UNITED STATES

Poster #022

3437802

NICLOSAMIDE STEARATE PRODRUG THERAPEUTIC (NSPT) ENHANCES MITOCHONDRIAL PROTON LEAK AND INDUCES POTENT CYTOTOXICITY IN OSTEOSARCOMAS

Mark M. Cullen¹, Etienne M. Flamant¹, Philip H. Khoury², Hailey E. Brighton⁶, David L. Kerr⁷, Gireesh B. Reddy⁸, Sarah Hoskinson⁶, Harrison R. Ferlauto¹, Suzanne B. DeWitt⁶, Kathryn E. Ware⁶, Beatrice Thomas⁶, Julia D. Visgauss⁴, Brian E. Brigman⁴, Jason A. Somarelli³, David Needham⁵, William C. Eward⁴

¹School of Medicine, Duke University, Durham, North Carolina, UNITED STATES; ²Duke University, Durham, North Carolina, UNITED STATES; ³Duke Cancer Institute, Durham, North Carolina, UNITED STATES; ⁴Department of Orthopaedic Surgery, Duke Cancer Institute, Durham, North Carolina, UNITED STATES; ⁵Department of Mechanical Engineering and Materials Science, Duke University, Durham, North Carolina, UNITED STATES; ⁶Comparative Oncology, Duke Cancer Institute, Durham, North Carolina, UNITED STATES; ⁷Department of Orthopaedic Surgery, Duke University Hospital, Durham, North Carolina, UNITED STATES; ⁸Department of Orthopaedic Surgery, University of Miami Health System, Miami, Florida, UNITED STATES

Poster #023 3438818

MAGNETIC RESONANCE GUIDED HIGH INTENSITY FOCUSED ULTRASOUND IN COMBINATION WITH THERMOSENSITIVE LIPOSOMAL DOXORUBICIN AS A NOVEL TREATMENT FOR RHABDOMYOSARCOMA

Claire Wunker¹, Ben Keunen³, Karolina Piorkowska³, Warren Foltz⁴, Maximilian Regenold⁵, Yael Babichev¹, Michael Dunne⁵, Maryam Siddiqui⁶, Samuel Pichardo⁶, Christine Allen⁵, Adam Waspe³, Rebecca Gladdy¹, Justin T. Gerstle²

¹Lunenfeld Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, CANADA; ²Pediatric Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, UNITED STATES; ³Center for Image Guided Innovation and Therapeutic Intervention, The Hospital for Sick Children, Toronto, Ontario, CANADA; ⁴Radiation Oncology, University of Toronto, Toronto, Ontario, CANADA; ⁵Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, CANADA; ⁶University of Calgary, Calgary, Alberta, CANADA

Poster #024 3439734

SOFT TISSUE SARCOMA: IS THERE A SURVIVAL GAP BETWEEN MIDDLE-AGED AND ELDERLY PATIENTS?

Freek Gillissen¹, Robbert Maatman¹, Frits Aarts¹, Paul Nijhuis¹

¹Surgery, VieCuri Medical Centre, Venlo, NETHERLANDS

Poster #025 3439834

MACHINE LEARNING TOOL SUCCESSFULLY CLASSIFIES TREATMENT RESPONSE IN HIGH-GRADE OSTEOSARCOMA

Patrick Leavey¹, Ka Yaw Teo², Karin Claussen¹, Kevin Cederberg³, Rami Hallac⁴, Anita Sengupta⁵, Alexandra Callan⁶, Ovidiu Daescu²

¹Pediatrics, UT Southwestern Medical Center, Dallas, Texas, UNITED STATES; ²UT Dallas, Dallas, Texas, UNITED STATES; ³Radiology, UT Southwestern Medical Center, Dallas, Texas, UNITED STATES; ⁴Children's Health, Children's Medical Center Dallas, Dallas, Texas, UNITED STATES; ⁵Pathology, UT Southwestern Medical Center, Dallas, Texas, UNITED STATES; ⁶Orthopedics, UT Southwestern Medical Center, Dallas, Texas, UNITED STATES

Poster #026 3440865

OUTCOME OF COMBINING RESECTION OF SARCOMA WITH INVOLVED BOWELS IN PATIENTS WITH PRIMARY RETROPERITONEAL LIPOSARCOMA

Jun Chen¹, Nannan Yan¹, Lili Feng¹, Wenqing Liu¹, Mei Huang¹, Chengli Miao¹, Chenghua Luo¹

¹Dept. of Retroperitoneal Tumor Surgery, Peking University International Hospital, Beijing, CHINA

Poster #027 3441221

A PHASE 1, MULTICENTER, OPEN-LABEL, FIRST-IN-HUMAN STUDY OF DS-6157A IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMOR

Suzanne George¹, Steven E. Cohen², Satoshi Nishioka³, Emarjola Bako², Li Liu², Prasanna Kumar², Yoichi Naito⁴

¹Dana-Farber Cancer Institute, Boston, Massachusetts, UNITED STATES; ²Daiichi Sankyo, Inc, Basking Ridge, New Jersey, UNITED STATES; ³Daiichi Sankyo, Co., Ltd, Tokyo, JAPAN; ⁴National Cancer Center Hospital East, Kashiwa, JAPAN

Poster #028 3441532

DUAL-ENERGY CT AS A QUANTITATIVE RESPONSE PARAMETER IN PATIENTS WITH GIST UNDERGOING TARGETED THERAPY – A PROSPECTIVE MULTI-CENTER TRIAL

Mathias Meyer², Hideki Ota¹, Christina Messiou³, Charlotte Benson³, Thomas Henzler², Stefan O. Schoenberg², Peter Hohenberger²

¹Tohoku University Hospital, Tohoku, JAPAN; ²University Medical Center Mannheim, Mannheim, GERMANY;

³Royal Marsden Hospital and Institute of Cancer Research, London, UNITED KINGDOM

Poster #029 3441865

PROGNOSES OF SUPERFICIAL SOFT TISSUE SARCOMA: THE IMPORTANCE OF FASCIA-TUMOR RELATIONSHIP ON MRI

Ilkyu Han¹, Jeong Hyun Lee¹, Han-Soo Kim¹

¹Orthopedic Surgery, Seoul National University Hospital, Seoul, KOREA (THE REPUBLIC OF)

Poster #030 3442000

OUTCOME OF CLINICAL GENETIC TESTING IN PATIENTS WITH SARCOMA

H. C. Miller¹, Lili Zhao², Erika Koeppe¹, Erin Cobain¹, Scott Schuetze¹, Laurence Baker¹, Elena Stoffel¹, Rashmi Chugh¹

¹Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, UNITED STATES;

²Department of Biostatistics, University of Michigan, Ann Arbor, Michigan, UNITED STATES

Poster #031 3442052

VARIANCE BETWEEN EXPERTS AND COMMUNITY PRACTITIONERS IN TREATING SOFT TISSUE SARCOMAS: ANALYSIS OF AN ONLINE DECISION SUPPORT TOOL

Ryan P. Topping¹, Vicki L. Keedy², Shreyaskumar Patel³, Richard F. Riedel⁴, Brian A. Van Tine⁵, Timothy A. Quill¹, William D. Tap⁶

¹Clinical Care Options, Reston, Virginia, UNITED STATES; ²Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, UNITED STATES; ³University of Texas MD Anderson Cancer Center, Houston, Texas, UNITED STATES; ⁴Duke Cancer Institute, Durham, North Carolina, UNITED STATES; ⁵Washington University School of Medicine, St Louis, Missouri, UNITED STATES; ⁶Memorial Sloan Kettering Cancer Center, New York, New York, UNITED STATES

Poster #032 3442782

ANTI-TUMOR EFFECT OF LAT1 INHIBITOR ON CLEAR CELL SARCOMA CELL LINE

Masayuki Morishita¹, Takuya Fujimoto¹, Teruya Kawamoto¹, Toshihiro Akisue¹, Ikuo Fujita², Toshiyuki Takemori¹, Shuichi Fujiwara¹, Kazumichi Kitayama¹, Shunsuke Yahiro¹, Tomohiro Miyamoto¹, Yohei Kawakami¹, Naomasa Fukase¹, Hitomi Hara¹, Ryosuke Kuroda¹

¹Graduate School of Medicine, Kobe University, Kobe, JAPAN;

²Orthopaedic Surgery, Hyogo Cancer Center, Akashi, JAPAN

Poster #033 3443018

OPPORTUNISTIC MUSCLE MEASUREMENTS ON STAGING CHEST CT FOR EXTREMITY AND TRUNCAL SOFT TISSUE SARCOMA ARE ASSOCIATED WITH SURVIVAL

Eileen Phan³, Steven W. Thorpe¹, Felix S. Wong⁴, Sandra Taylor⁵, Augustine M. Saiz⁸, Robert J. Canter⁶, Leon Lenchik⁷, R L. Randall¹, Robert Boutin²

¹Sarcoma Services, Department of Orthopaedic Surgery, University of California, Davis, Sacramento, California, UNITED STATES; ²Department of Radiology, Stanford University, Stanford, California, UNITED STATES; ³School of Medicine, University of California, Davis, Sacramento, California, UNITED STATES; ⁴Department of Radiology, University of California, Davis, Sacramento, California, UNITED STATES; ⁵Division of Biostatistics, Department of Public Health Sciences, University of California, Davis, Sacramento, California, UNITED STATES; ⁶Division of Surgical Oncology, Department of Surgery, University of California, Davis, Sacramento, California, UNITED STATES; ⁷Department of Radiology, Wake Forest School of Medicine, Winston-Salem, North Carolina, UNITED STATES; ⁸Department of Orthopaedic Surgery, University of California, Davis, Sacramento, California, UNITED STATES

Poster #034 3443510

IS SURGICAL RESECTION OF THE PRIMARY SITE ASSOCIATED WITH AN IMPROVED OVERALL SURVIVAL FOR PRIMARY MALIGNANT BONE TUMORS WITH METASTATIC DISEASE AT PRESENTATION?

Azeem T. Malik¹, John H. Alexander², Safdar N. Khan¹, **Thomas J. Scharschmidt¹**

¹Orthopaedics, The Ohio State University Wexner Medical Center, Columbus, Ohio, UNITED STATES;

²Moffit Cancer Center, Tampa, Florida, UNITED STATES

Poster #035 3443839

CRYOABLATION: AN EFFECTIVE AND SAFE OPTION IN THE TREATMENT ALGORITHM OF EXTRA-ABDOMINAL DESMOID TUMORS?

Yet Yen Yan¹, Paul Mallinson¹, Peter Munk¹, John P. Walsh¹, Paul Clarkson², Prem Jayaram¹, Manraj Heran¹, Hugue Ouellette¹, Christine Simmons²

¹Vancouver General Hospital, Vancouver, British Columbia, CANADA;

²BC Cancer Agency, Vancouver, British Columbia, CANADA

Poster #036 3445136

DEVELOPMENT OF A NOVEL ORGANS-ON-A-CHIP MODEL THAT ENABLES PREDICTIVE AND CLINICALLY RELEVANT DRUG SCREENING TO DETERMINE EWING SARCOMA ANTI-TUMOR EFFICACY AND CARDIAC SAFETY

Alan Chramiec¹, Diogo Teles¹, Keith Yeager¹, Alessandro Marturano-Kruik², Joseph Pak¹, Timothy Chen¹, Luke Hao¹, Miranda Wang¹, Roberta Lock¹, Daniel Naveed Tavakol¹, Marcus Busub Lee¹, Kacey Ronaldson-Bouchard¹, Gordana Vunjak-Novakovic¹, Jinho Kim³

¹Biomedical Engineering, Columbia University, Brooklyn, New York, UNITED STATES; ²Department of Chemistry, Materials and Chemical Engineering, Politecnico de Milano, Milan, ITALY; ³Department of Biomedical Engineering, Stevens Institute of Technology, Hoboken, New Jersey, UNITED STATES

Poster #037 3446023

THE NITRASARC TRIAL- A NON-RANDOMIZED, OPEN-LABEL PHASE II TRIAL EVALUATING EFFICACY AND FEASIBILITY OF COMBINED TREATMENT WITH TRABECTEDIN AND NIVOLUMAB IN PATIENTS WITH METASTATIC OR INOPERABLE SOFT TISSUE SARCOMAS AFTER FAILURE OF AN ANTHRACYCLINE-CONTAINING REGIMEN: INTERIM SAFETY ANALYSIS

Daniel Pink², Christian Schmidt³, Bernd Kasper⁴, Barbara Hermes⁵, Stephan Richter⁶, Thorsten Kessler⁷, Martin Kortüm⁸, Anne Flörcken⁹, Eva Wardelmann¹⁰, Daniel W. Müller¹¹, Martin Walker¹, Sascha Decker¹, Salah-Eddin Al-Batran¹¹, Peter Reichardt¹²

¹Project Management, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Frankfurt, GERMANY; ²Klinik für Hämatologie/Onkologie und Palliativmedizin, Helios Klinikum Bad Saarow, Bad Saarow, GERMANY; ³Klinik für Hämatologie/Onkologie und Palliativmedizin, Universitätsmedizin Greifswald, Greifswald, GERMANY; ⁴Interdisziplinäres Tumorzentrum, Sarkom Zentrum, Universität Heidelberg, Mannheim, GERMANY; ⁵Klinik für Innere Medizin VIII, Medizinische Onkologie und Pneumologie, Universitätsklinikum Tübingen, Tübingen, GERMANY; ⁶Medizinische Klinik I, Medizinische Fakultät "Carl Gustav Carus" der TU Dresden, Dresden, GERMANY; ⁷Medizinische Klinik A – Hämatologie/Onkologie/Pneumologie, Uniklinikum Münster, Münster, GERMANY; ⁸Medizinische Klinik und Poliklinik II – Hämatologie/Onkologie, Universitätsklinikum Würzburg, Würzburg, GERMANY; ⁹Campus Virchow Klinikum, Medizinische Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunologie (CC14), Charité - Universitätsmedizin Berlin, Berlin, GERMANY; ¹⁰Gerhard-Domagk-Institut für Pathologie, Universitätsklinikum Münster, Münster, GERMANY; ¹¹Clinical Trial Unit, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Frankfurt, GERMANY; ¹²Klinik für Onkologie und Palliativmedizin, Helios Klinikum Berlin-Buch, Berlin, GERMANY

Poster #038 3446269

TOPP: TENOSYNOVIAL GIANT CELL TUMOR OBSERVATIONAL PLATFORM PROJECT—PATIENT-REPORTED SYMPTOMS AND QUALITY OF LIFE (QOL) FROM A EUROPEAN AND US PROSPECTIVE REGISTRY

Emanuela Palmerini¹, Julio Lopez Bastida², Xin Ye³, Silvia Stacchiotti⁴, Eric Staals¹, Geert Spierenburg⁵, Petra Laeis⁶, Eva-Maria Fronk⁶, Hans Gelderblom⁵, Michiel van de Sande⁵

¹IRCCS Istituto Ortopedico Rizzoli, Bologna, ITALY; ²University of Castilla-La Mancha, Talavera de la Reina, Toledo, SPAIN; ³Daiichi Sankyo, Inc., Basking Ridge, New Jersey, UNITED STATES; ⁴Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, ITALY; ⁵Leiden University Medical Center, Leiden, NETHERLANDS; ⁶Daiichi Sankyo Europe GmbH, Munich, GERMANY

Poster #039 3446499

THE DIFFUSE-TYPE TGCT PATIENT JOURNEY: A PROSPECTIVE MULTICENTER STUDY

Geert Spierenburg¹, Nicholas M. Berthal², John H. Healey³, Petra Laeis⁴, Eva-Maria Fronk⁴, Silvia Stacchiotti⁵, Emanuela Palmerini⁶, Eric Staals⁶, Michiel van de Sande¹

¹Leiden University Medical Center, Leiden, NETHERLANDS; ²David Geffen School of Medicine at UCLA, Santa Monica, California, UNITED STATES; ³Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York, UNITED STATES; ⁴Daiichi Sankyo Europe GmbH, Munich, GERMANY; ⁵Fondazione IRCCS Istituto Nazionale, Milan, ITALY; ⁶IRCCS Istituto Ortopedico Rizzoli, Bologna, ITALY

Poster #040 3448478

TREATMENT OUTCOME OF SUPERFICIAL LEIOMYOSARCOMA

Elizabeth P. Wellings¹, Meagan E. Tibbo¹, Peter S. Rose¹, **Matthew T. Houdek**¹

¹Orthopedic Surgery, Mayo Clinic, Rochester, Minnesota, UNITED STATES

Poster #041 3449895

MOLECULAR ANALYSIS OF ARCHIVAL CLEAR CELL SARCOMA TISSUE SAMPLES FROM EORTC TRIAL 90101 "CREATE" AND CORRELATION WITH RESPONSE TO CRIZOTINIB

Che-Jui Lee¹, Agnieszka Wozniak¹, Elodie Modave², Bram Boeckx², Silvia Stacchiotti³, Piotr Rutkowski⁴, Jean-Yves Blay⁵, Maria Debiec-Rychter⁶, Raf Sciot⁷, Patrick Schöffski⁸

¹Department of Oncology, KU Leuven, Leuven, BELGIUM; ²Center for Cancer Biology / Department of Human Genetics, VIB / KU Leuven, Leuven, BELGIUM; ³Department of Medical Oncology, IRCCS Fondazione Istituto Nazionale Tumori, Milano, ITALY; ⁴Department of Soft Tissue / Bone Sarcoma and Melanoma, Maria Sklodowska-Curie Institute, Warsaw, POLAND; ⁵Department of Medical Oncology, Centre Léon Bérard / Université Claude Bernard Lyon I, Lyon, FRANCE; ⁶Department of Human Genetics, University Hospitals Leuven / KU Leuven, Leuven, BELGIUM; ⁷Department of Pathology, University Hospitals Leuven / KU Leuven, Leuven, BELGIUM; ⁸Department of General Medical Oncology / Department of Oncology, University Hospitals Leuven / KU Leuven, Leuven, BELGIUM

Poster #042 3450727

OPTICAL SENSOR FOR RAPID BACTERIAL DETECTION AND DIAGNOSIS OF IMPLANT ASSOCIATED INFECTIONS IN CANCER PATIENTS

Robert Hunter³, Mariam Taha¹, Emilio Alarcon³, Hesham Abdelbary², Hanan Anis³

¹The Ottawa Hospital Research Institute, Ottawa, Ontario, CANADA; ²The Ottawa Hospital, Ottawa, Ontario, CANADA; ³University of Ottawa, Ottawa, Ontario, CANADA

Poster #043 3451306

USE OF FDG POSITRON EMISSION TOMOGRAPHY TO PREDICT CHEMOTHERAPY RESPONSE AND OUTCOMES IN PEDIATRIC BONE SARCOMAS

Natalie L. Wu¹, Antoinette Lindberg², Anna Faino³, Sara Flash³, Douglas S. Hawkins¹, Catherine M. Albert¹

¹Pediatric Hematology/Oncology, Seattle Children's Hospital, Seattle, Washington, UNITED STATES; ²Orthopedic Surgery, Seattle Children's Hospital, Seattle, Washington, UNITED STATES; ³Seattle Children's Hospital, Seattle, Washington, UNITED STATES

Poster #044 3452161

THE AGE-RELATED IMPACT OF SURVIVING SARCOMA ON HEALTH-RELATED QUALITY OF LIFE: DATA FROM THE DUTCH SURVSARC STUDY

Cas Drabbe¹, Winette T. van der Graaf¹, Vicky Soomers², Winan J. van Houdt³, Olga Husson¹

AUTHORS/INSTITUTIONS: C. Drabbe, W.T. van der Graaf, O. Husson, Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, NETHERLANDS; V. Soomers, Department of Medical Oncology, Radboud University Medical Centre, Nijmegen, NETHERLANDS; W.J. van Houdt, Department of Surgical Oncology, Netherlands Cancer Institute, Amsterdam, NETHERLANDS

Poster #045 3452220

PROMISING ACTIVITY OF AN ENZYME-ACTIVATED DOXORUBICIN PRODRUG IN A PANEL OF PATIENT-DERIVED XENOGRAFT MODELS OF SOFT TISSUE SARCOMA

Britt Van Renterghem¹, Ludovica Tarantola¹, Agnieszka Wozniak¹, Jasmien Wellens¹, Madita Nysen¹, Ulla Vanleeuw¹, Che-Jui Lee¹, Yannick Wang¹, Andrea Casazza², Geert Reyns², Nele Kindt², Patrick Schöffski¹

¹Oncology, KU Leuven, Huldenberg, BELGIUM; ²CoBioRes, Leuven, BELGIUM

Poster #046 3452295

BACTERIOPHAGE COCKTAIL TO IMPROVE TREATMENT OF IMPLANT-ASSOCIATED BACTERIAL INFECTIONS IN CANCER PATIENTS

Mariam Taha¹, Joel Werier², Hesham Abdelbary²

¹The Ottawa Hospital Research Institute, Ottawa, Ontario, CANADA; ²The Ottawa Hospital, Ottawa, Ontario, CANADA

Poster #047 3452402

SYSTEMIC INFLAMMATION RESPONSE INDEX (SIRI) AS A PREDICTIVE FACTOR FOR OVERALL SURVIVAL IN ADVANCED SOFT TISSUE SARCOMA TREATED WITH ERIBULIN

Hiroshi Kobayashi¹, Tomotake Okuma², Koichi Okajima², Yuki Ishibashi³, Toshihide Hirai¹, Takahiro Ohki¹, Masachika Ikegami¹, Ryoko Sawada¹, Yusuke Shinoda¹, Toru Akiyama³, Takahiro Goto², Sakae Tanaka¹

¹Orthopaedic Department, The University of Tokyo Hospital, Tokyo, JAPAN; ²Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, JAPAN; ³Saitama Medical Center, Jichi Medical University, Saitama, JAPAN

Poster #048 3452426

STING ACTIVATION AS AN IMMUNOTHERAPEUTIC STRATEGY FOR SOFT TISSUE SARCOMA

Kayla Marritt¹, Karys Hildebrand¹, Arvind Singla¹, Bryan G. Yipp², Frank Jirik³, Michael Monument¹

¹Department of Surgery, Cumming School of Medicine, University of Calgary, Calgary, Alberta, CANADA; ²Department of Critical Care, Cumming School of Medicine, University of Calgary, Calgary, Alberta, CANADA; ³Department of Biochemistry and Molecular Biology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, CANADA

Poster #049 3452445

REGORAFENIB FOR PROGRESSIVE RELAPSED METASTATIC OSTEOSARCOMA IN AN ADOLESCENT

Ariel Glikberg¹, Allison Fraum², Molly M. Aguina³, Mary Lou Schmidt¹, Paul Kent³

¹Pediatric Hematology/Oncology, University Illinois Chicago, Chicago, Illinois, UNITED STATES; ²Radiology, UIC, Chicago, Illinois, UNITED STATES; ³Pediatric Hematology/Oncology, Rush University, Chicago, Illinois, UNITED STATES

Poster #050 3452498

OPTIMIZED PATIENT-DERIVED 3D SARCOMA MODEL – ROBUST SYSTEM FOR SARCOMA RESEARCH

Juergen Loskutov¹, Manuela Regenbrecht³, Saskia Scharf⁴, Philipp Stroebel⁵, Gerrit Erdmann⁶, Christian R. Regenbrecht², Maya Niethard⁴

¹CELLphenomics GmbH, Berlin, GERMANY; ²ASC Oncology GmbH, Berlin, GERMANY; ³Department of Oncology and Palliative Care, Helios Klinikum Berlin-Buch, Berlin, GERMANY; ⁴Department for Tumor Orthopedics, Helios Klinikum Berlin-Buch, Berlin, GERMANY; ⁵Department for Pathology, University Hospital Goettingen, Goettingen, GERMANY; ⁶NMI-TT, Berlin, GERMANY

Poster #051 3452630

SAFE CLINICAL COMPATIBILITY OF A NON-INVASIVE EXTENDIBLE ELECTROMAGNETIC PROSTHESIS WITH AN IN SITU VENTRICULAR ASSIST DEVICE

Nicholas P. Gannon¹, Kristy M. McHugh², Rebecca K. Ameduri³, Christian M. Ogilvie¹

¹Department of Orthopaedic Surgery, University of Minnesota, Minneapolis, Minnesota, UNITED STATES; ²Department of Solid Organ Transplant, Fairview, Minneapolis, Minnesota, UNITED STATES; ³Department of Pediatrics, University of Minnesota Masonic Children's Hospital, Minneapolis, Minnesota, UNITED STATES

Poster #052 3452817

SELINEXOR, A FIRST IN CLASS NUCLEAR EXPORT INHIBITOR, FOR THE TREATMENT OF ADVANCED MALIGNANT PERIPHERAL NERVE SHEATH TUMOR

Esmail Al-Ezzi¹, Mrinal Gounder², Albiruni Abdul Razak¹, Geoffrey Watson¹, Alessandro Mazzocca³, Bruno Vincenzi³

¹Toronto Sarcoma Program, Princess Margaret Cancer Centre, Toronto, Ontario, CANADA; ²Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, UNITED STATES; ³Department of Medical Oncology, University Campus Bio-Medico, Via Alvaro del Portillo, Rome, ITALY

Poster #053 3452862

UNRAVELLING THE HETEROGENEITY OF SARCOMA PATIENTS' HEALTH-RELATED QUALITY OF LIFE: IMPACT OF PRIMARY SARCOMA LOCATION

Dide den Hollander¹, Ilse van Eck², Vicky Soomers², Winette T. van der Graaf¹, Michiel van de Sande³, Jacco de Haan⁴, Cees Verhoef⁵, Ingeborg Vriens⁶, Winan J. van Houdt⁷, Han Bonenkamp⁸, Ingrid Desar², Olga Husson¹

¹Medical Oncology, Netherlands Cancer Institute, Amsterdam, NETHERLANDS; ²Medical Oncology, Radboud University Medical Center, Nijmegen, NETHERLANDS; ³Orthopaedics, Leiden University Medical Center, Leiden, NETHERLANDS; ⁴Medical Oncology, University Medical Center Groningen, Groningen, NETHERLANDS; ⁵Surgical Oncology, Erasmus Medical Center, Rotterdam, NETHERLANDS; ⁶Medical Oncology, Maastricht University Medical Center, Maastricht, NETHERLANDS; ⁷Surgical Oncology, Netherlands Cancer Institute, Amsterdam, NETHERLANDS; ⁸Surgical Oncology, Radboud University Medical Center, Nijmegen, NETHERLANDS

Poster #054 3453418

A RANDOMIZED, OPEN-LABEL PHASE 1/2 STUDY OF RAMUCIRUMAB IN COMBINATION WITH CHEMOTHERAPY IN PEDIATRIC PATIENTS AND YOUNG ADULTS WITH RELAPSED, RECURRENT, OR REFRACTORY DESMOPLASTIC SMALL ROUND CELL TUMOR OR SYNOVIAL SARCOMA

Emily K. Slotkin⁵, Michela Casanova¹, Andrea Ferrari¹, Douglas J. Harrison², Heather Wasserstrom³, Zachary Thomas³, Chunxiao Wang³, Bwana L. Brooks³, Brian A. Van Tine⁴

¹Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, ITALY; ²MD Anderson Cancer Center, Houston, Texas, UNITED STATES; ³Eli Lilly and Company, Indianapolis, Indiana, UNITED STATES; ⁴Washington University in St. Louis School of Medicine, St. Louis, Missouri, UNITED STATES; ⁵Memorial Sloan Kettering Cancer Center, New York, New York, UNITED STATES

Poster #055 3454087

A RETROSPECTIVE COHORT STUDY ON THE IMPACT OF REGIONAL ANESTHESIA IN SARCOMA RESECTION SURGERY

Bijan Abar¹, Amanda Fletcher¹, Junheng Gao², Andrew Wong², Chinedu Okafor², Sin-Ho Jung², William C. Eward¹, Brian E. Brigman¹, Amanda Kumar², Julia D. Visgauss¹

¹Orthopedic Surgery, Duke, Durham, North Carolina, UNITED STATES; ²Duke, Durham, North Carolina, UNITED STATES

Poster #056 3454710

CLINICAL AND MOLECULAR CHARACTERISTICS OF A CASE SERIES OF GIST WITH EXTRA-ABDOMINAL METASTASES

Andri Papakonstantinou¹, Sara Renberg¹, Felix Haglund², Fredrik Karlsson¹, Robert Bränström¹, Jan Åhlen¹, Li Jalmsell¹, Mikael Eriksson³, Christina Linder Stragliotto⁴

¹Section for Endocrine Tumors and Sarcoma, Karolinska University Hospital Solna, Stockholm, SWEDEN; ²Department of Clinical Pathology and Cytology, Karolinska University Hospital Solna, Stockholm, SWEDEN; ³Department of Oncology, Skane University Hospital and Lund University, Lund, SWEDEN; ⁴Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, SWEDEN

Poster #057 3454819

CIRCULATING TUMOUR DNA: A POTENTIAL TOOL FOR SARCOMA MANAGEMENT

Paige E. Darville-O'Quinn¹, Nalan Gokgoz¹, Ainaz Malektojar¹, Patrick Prochazka¹, Kim Tsoi², Peter Ferguson², Jay Wunder², Irene Andrulis¹

¹Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, Ontario, CANADA; ²University of Toronto Musculoskeletal Oncology Unit, Sinai Health System, Toronto, Ontario, CANADA

Poster #058 3455149

(GIST) PATIENTS WITH KNOWN MUTATION TRANSITION TO SUBSEQUENT TREATMENTS AT A HIGHER RATE AND HAVE SUPERIOR SURVIVAL COMPARED TO PATIENTS WITHOUT KNOWN MUTATION: RESULTS FROM THE LIFERAFT GROUP (LRG) GIST REGISTRY

Jerry W. Call¹, Denisse Montoya¹, Pete Knox¹, Mary Garland¹, Sara Rothschild¹, Norman J. Scherzer¹, **Jonathan Trent**²

¹The Life Raft Group, Wayne, New Jersey, UNITED STATES; ²Medicine, Sylvester Comprehensive Cancer Center, Miami, Florida, UNITED STATES

Poster #059 3455363

SUPERFICIAL FIBROMATOSIS LESION SIZE CORRELATES WITH MRI T2 MAPPING AND IMAGE TEXTURE FEATURES

Ty K. Subhawong¹, Amrutha Ramachandran¹, Terry Fox¹, Aaron Wolfson²

¹Radiology, Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida, UNITED STATES;

²Radiation Oncology, Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida, UNITED STATES

Poster #060 3455537

TARGETING THE CMG HELICASE AS A "NEVER" MUTATION TO REDUCE CELLULAR FITNESS IN OSTEOSARCOMA CELLS

Darcy Welch¹, Elliot Kahen¹, Mark Alexandrow¹, **Damon Reed**¹

¹Moffitt Cancer Center, Tampa, Florida, UNITED STATES

Poster #061 3455574

CHARACTERIZING GROWTH UNDER SELECTION FOR OSTEOSARCOMA HETEROGENEITY MODEL

Damon Reed¹, Elliot Kahen¹, Darcy Welch¹

¹Moffitt Cancer Center, Tampa, Florida, UNITED STATES

Poster #062 3455662

EXPLORATION OF IMAGING BIOMARKERS FOR METABOLICALLY-TARGETED OSTEOSARCOMA THERAPY

Shan Huang¹, Ling Ren¹, Tim Phelps⁴, Colleen Olkowski⁴, Anita T. Ton⁴, Jyoti Roy⁴, Maggie White², Aswini Cherukuri¹, Stephen Adler⁴, Karen Wong⁴, Xiang Zhang³, Falguni Basuli³, Peter Choyke⁴, Elaine Jagoda⁴, Amy LeBlanc¹

¹Comparative Oncology Program, Molecular Imaging Program, NIH/NCI, Bethesda, Maryland, UNITED STATES;

²Laboratory of Genitourinary Cancer Pathogenesis, NIH/NCI, Bethesda, Maryland, UNITED STATES; ³Chemistry and Synthesis Center, NIH/NHLBI, Bethesda, Maryland, UNITED STATES; ⁴Molecular Imaging Program, NIH/NCI, Bethesda, Maryland, UNITED STATES

Poster #063 3456222

FACTORS AFFECTING GENETIC CONSULTATION IN ADOLESCENT AND YOUNG ADULT PATIENTS WITH SARCOMA

Grace Shea¹, Anna L. Zakas², Fauzia Osman¹, Amanda Parkes¹

¹Department of Medicine, Section of Hematology/Oncology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, UNITED STATES; ²Department of Pediatrics, Section of Oncology Genetics, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, UNITED STATES

Poster #064 3457423

RETROSPECTIVE ANALYSIS OF 18 YEARS OF TREATMENT OF MYXOFIBROSARCOMAS IN THE NETHERLANDS

Thomas Schok¹, Marlies Keijzers¹, Paul Nijhuis¹, Frits Aarts¹

¹Surgery, VieCuri MC, Venlo, NETHERLANDS

Poster #065 3457767

OUTCOMES OF PATIENTS WITH SARCOMA AND COVID-19: A SINGLE INSTITUTION EXPERIENCE

Michael J. Wagner¹, Seth Pollack², Lee D. Cranmer¹, Matthew J. Thompson³, Shannon Maxwell¹, Stephanie Wright¹, Petros Grivas¹, Nicole Kuderer³, Gary Lyman⁴, Elizabeth T. Loggers²

¹Oncology, University of Washington, Seattle, Washington, UNITED STATES; ²Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, UNITED STATES; ³University of Washington, Seattle, Washington, UNITED STATES; ⁴Hutchinson Institute for Cancer Outcomes Research, Seattle, Washington, UNITED STATES

Poster #066 3457998

DECISIONAL CONTROL PREFERENCES IN PATIENTS WITH ADVANCED SOFT TISSUE SARCOMAS STARTING 1ST LINE PALLIATIVE CHEMOTHERAPY: RESULTS FROM THE HOLISTIC STUDY

Eugenie Younger¹, Robin L. Jones¹, Dide den Hollander², Vicky Soomers², Ingrid Desar², Robin J. Young³, Astrid W. Oosten⁴, Hans Gelderblom⁵, Jacco de Haan⁶, Neeltje Steeghs⁷, Olga Husson⁷, Winette T. van der Graaf⁷

¹Sarcoma Unit, Royal Marsden Hospital, London, UNITED KINGDOM; ²Sarcoma Unit, Radboudumc, Nijmegen, NETHERLANDS; ³Sarcoma Unit, Weston Park Hospital, Sheffield, UNITED KINGDOM; ⁴Sarcoma Unit, Erasmus MC, Rotterdam, NETHERLANDS; ⁵Sarcoma Unit, Leiden UMC, Leiden, NETHERLANDS; ⁶Sarcoma Unit, University Medical Center Groningen, Groningen, NETHERLANDS; ⁷Sarcoma Unit, Netherlands Cancer Institute, Amsterdam, NETHERLANDS

Poster #067 3458044

IMRIS: A PHASE II STUDY OF INTENSITY MODULATED RADIOTHERAPY (IMRT) IN EXTREMITY SOFT TISSUE SARCOMA (STS)

Beatrice Seddon⁵, Franel Le Grange⁵, Rita Simoes⁷, Chris Stacey⁵, Shumona Shelly¹, Sharon Forsyth¹, Laura White¹, Charles Candish², Peter Dickinson³, Aisha B. Miah⁴, Syed A. Moinuddin⁵, James Wylie⁶, Andre Lopes¹

¹UCL Cancer Trials Centre, London, UNITED KINGDOM; ²Cheltenham General Hospital, London, UNITED KINGDOM;

³Leeds Teaching Hospitals, Leeds, UNITED KINGDOM; ⁴Royal Marsden Hospital, London, UNITED KINGDOM;

⁵University College Hospital, London, UNITED KINGDOM; ⁶Christie Hospital, Manchester, UNITED KINGDOM;

⁷National Radiotherapy Trials Quality Assurance Group, Mount Vernon Hospital, London, UNITED KINGDOM

Poster #068

3458250

GENETIC MODELS REVEAL THAT THE NOVEL VGLL2-NCOA2 FUSION ONCOGENE LEVERAGES EMBRYONIC PROGRAMS FOR SARCOMAGENESIS

Genevieve Kendall¹, Sarah Watson², Lin Xu³, Collette LaVigne⁴, Whitney Murchison⁵, Dinesh Rakheja⁷, Franck Tirode⁶, Olivier Delattre², James F. Amatruda⁸

¹Center for Childhood Cancer & Blood Diseases, Nationwide Children's Hospital, Columbus, Ohio, UNITED STATES;

²Genetics and Biology of Cancer Unit, Institut Curie, Paris, FRANCE; ³Department of Population and Data Science, UT Southwestern Medical Center, Dallas, Texas, UNITED STATES; ⁴Department of Molecular Biology, UT Southwestern Medical Center, Dallas, Texas, UNITED STATES; ⁵Department of Pediatrics, UT Southwestern Medical Center, Dallas, Texas, UNITED STATES; ⁶Centre de Recherche en Cancérologie de Lyon, Université Claude Bernard Lyon 1, Lyon, FRANCE; ⁷Department of Pathology, UT Southwestern Medical Center, Dallas, Texas, UNITED STATES; ⁸Cancer and Blood Disease Institute, Children's Hospital Los Angeles, Los Angeles, California, UNITED STATES

Poster #069

3458308

CONTEMPORARY OUTCOMES AND SECONDARY AMPUTATION AFTER LOCAL RECURRENCE IN PATIENTS AFFECTED BY EXTREMITY SOFT TISSUE SARCOMA TREATED WITH LIMB-SPARING SURGERY AT A REFERENCE INSTITUTION

Fahmina Buriro¹, Sandro Pasquali², Raza Sayyed¹, Claudia Sangalli³, Elena Palassini⁴, Carlo Morosi⁵, Marta Barisella⁶, Chiara Colombo², Stefano Radaelli², Dario Callegaro², Alessandro Gronchi², Marco Fiore²

¹Patel Hospital & European School of Soft Tissue Sarcoma Surgery (ESSTSS), Karachi, PAKISTAN; ²Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, ITALY; ³Radiation Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, ITALY; ⁴Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, ITALY; ⁵Radiology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, ITALY; ⁶Pathology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, ITALY

Poster #070

3458516

HARNESSING THE ELECTRONIC MEDICAL RECORD TO IMPROVE THE EVALUATION OF SOFT TISSUE MASSES IN THE PRIMARY CARE SETTING: A PILOT STUDY ON THE IMPACT OF A BEST PRACTICE ALERT

Nicholas J. Reiners¹, Brandon Diessner¹, Robert Gao¹, Melissa Albersheim¹, Randolph W. Hurley¹

¹HealthPartners Cancer Care Center

Rein in Sarcoma, University of Minnesota, St Paul, Minnesota, UNITED STATES

Poster #071

3458545

TUMOR RESPONSE TO WINDOW THERAPY WITH TEMSIROLIMUS, IRINOTECAN, AND TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED HIGH-RISK EWING SARCOMA; A PHASE II SINGLE INSTITUTION STUDY

Jessica Gartrell², Fariba Navid³, Michael Dubrovin¹, Fang Wang², Haitao Pan², Beth McCarville², Barry Shulkin², Alberto Pappo², Sara Federico²

¹Columbia University, New York, New York, UNITED STATES; ²St. Jude Children's Research Hospital, Memphis, Tennessee, UNITED STATES; ³Cancer and Blood Disease Institute, Children's Hospital Los Angeles, Keck School of Medicine, University of Southern California, Los Angeles, California, UNITED STATES

Poster #072

3458703

RETROSPECTIVE ANALYSIS OF THE CLINICAL PRESENTATION, TREATMENT AND OUTCOME OF ANGIOSARCOMA IN A SARCOMA REFERRAL CENTER

Thomas Meyskens¹, Iris Timmermans¹, Che-Jui Lee¹, Raf Sciot², Herlinde Dumez¹, Hans Wildiers¹, Daphne Hompes³, Melissa Christiaens⁴, Patrick Schöffski¹

¹Oncology, UZ Leuven, Leuven, BELGIUM; ²Pathology, UZ Leuven, Leuven, BELGIUM; ³Surgical Oncology, UZ Leuven, Leuven, BELGIUM; ⁴Radiotherapy, UZ Leuven, Leuven, BELGIUM

Poster #073

3458722

POTENTIAL MOLECULAR BIOMARKERS OF RESPONSE TO ERIBULIN IN PATIENTS WITH LEIOMYOSARCOMA

Agnieszka Wozniak¹, Bram Boeckx², Elodie Modave², Amy Weaver³, Diether Lambrechts², Bruce A. Littlefield³, Patrick Schöffski¹

¹Laboratory of Exp.Oncology, Department of Oncology, KU Leuven, Leuven, BELGIUM; ²Laboratory of Translational Genetics, KU Leuven and VIB Center for Cancer Biology, Leuven, Leuven, BELGIUM; ³Global Oncology, Eisai Inc., Cambridge, Massachusetts, UNITED STATES

Poster #074 3458723

GENETIC PROFILE OF GASTROINTESTINAL STROMAL TUMORS (GIST) TREATED IN EORTC 1317 "CABOGIST" PHASE 2 TRIAL

Agnieszka Wozniak¹, Huiwen Che², Isabelle Vanden Bempt², Tatjana Jatsenko², Laura De Meulemeester³, Ionela Stanciu³, Olivier Mir⁴, Peter Hohenberger⁵, Hans Gelderblom⁶, Raf Sciot⁷, Joris Vermeesch², Patrick Schöffski¹
¹Lab of Exp.Oncology, Dept. of Oncology, KU Leuven, Leuven, BELGIUM; ²Department of Human Genetics, KU Leuven, Leuven, BELGIUM; ³European Organization for Research and Treatment of Cancer, Brussels, BELGIUM; ⁴Department of Medical Oncology, Gustave Roussy, Villejuif, FRANCE; ⁵Sarcoma Unit, Interdisciplinary Tumor Center Mannheim, Mannheim University Medical Center, Mannheim, GERMANY; ⁶Department of Medical Oncology, Leiden University Medical Center, Leiden, NETHERLANDS; ⁷Department of Pathology, University Hospitals Leuven, Leuven, BELGIUM

Poster #075 3458771

LONG-TERM OUTCOME OF PATIENTS WITH NONMETASTATIC BONE OSTEOSARCOMA: A CONDITIONAL SURVIVAL ANALYSIS

Ruoyu Miao¹, Haotong Wang¹, Edwin Choy², Gregory M. Cote², Kevin A. Raskin³, Joseph H. Schwab³, Francis J. Hornicek⁴, Thomas F. DeLaney¹, Yen-Lin E. Chen¹

¹Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts, UNITED STATES;

²Department of Medical Oncology, Massachusetts General Hospital, Boston, Massachusetts, UNITED STATES;

³Department of Orthopedic Oncology, Massachusetts General Hospital, Boston, Massachusetts, UNITED STATES;

⁴Department of Orthopedic Surgery, University of California Los Angeles, Los Angeles, California, UNITED STATES

Poster #076 3458918

EVALUATION OF PROGNOSTIC NOMOGRAMS FOR OUTCOMES AFTER RESECTION OF PRIMARY RETROPERITONEAL SARCOMA

Malcolm H. Squires¹, Erin E. Donahue¹, Megan H. Jagosky², Michael Livingston², William Ahrens³, Jennifer H. Benbow¹, Nicole L. Gower¹, Sally J. Trufan¹, Joshua S. Hill¹, Jonathan Salo¹

¹Division of Surgical Oncology, Levine Cancer Institute, Atrium Health, Charlotte, North Carolina, UNITED STATES;

²Division of Medical Oncology, Levine Cancer Institute, Atrium Health, Charlotte, North Carolina, UNITED STATES;

³Department of Pathology, Levine Cancer Institute, Atrium Health, Charlotte, North Carolina, UNITED STATES

Poster #077 3459835

DEVELOPMENT OF RHABDOMYOSARCOMA SPECIFIC SEQUENCING ASSAY

Kelly Klega¹, Samuel Abbou¹, Alanna Church², Alyaa Al-Ibraheemi², Junko Tsuji³, Alma Imamovic-Tuco⁴, Jusin Abreu³, David Hall⁵, Tammy Lo⁵, Don Barkauskas⁵, Carrie Cibulskis³, Erin Rudzinski⁶, Jack Shern⁷, Abha A. Gupta⁸, Brian Crompton¹

¹Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, UNITED STATES; ²Boston Children's Hospital, Boston, Massachusetts, UNITED STATES; ³Broad Institute, Cambridge, Massachusetts, UNITED STATES; ⁴Dana-Farber Cancer Institute, Boston, Massachusetts, UNITED STATES; ⁵Children's Oncology Group, Monrovia, California, UNITED STATES; ⁶Seattle Children's Hospital, Seattle, Washington, UNITED STATES; ⁷National Institutes of Health, Bethesda, Maryland, UNITED STATES; ⁸The Hospital for Sick Children, Toronto, Ontario, CANADA

Poster #078 3459966

THE PROGNOSTIC IMPORTANCE OF PATHOLOGIC FRACTURE IN LIMB SALVAGE SURGERY FOR OSTEOSARCOMA: A SINGLE-INSTITUTION REVIEW OF 304 PATIENTS

Danielle Greig¹, Rishi Trikha¹, Troy Sekimura¹, Jeffrey Eckardt¹, Nicholas Bernthal¹

¹Orthopaedic Surgery, University of California, Los Angeles, Los Angeles, California, UNITED STATES

Poster #079 3459977

SARCOMA IN YOUNG AGE – AN OVERVIEW OF CLINICAL, PATHOLOGICAL AND MOLECULAR FINDINGS IN A LARGE SINGLE CENTER COHORT

Samuele Renzi¹, Noelle Cullinan¹, Sarah Cohen-Gogo¹, Karin Langenberg-Ververgaert¹, Orli Michaeli¹, Jalila Alkendi¹, Anne L. Ryan¹, Bailey Gallinger², Katrina M. Ingley¹, Sevan Hopyan³, Rose Cham⁴, Abha A. Gupta¹

¹Pediatric Haematology/Oncology, Hospital for Sick Children, Toronto, Ontario, CANADA;

²Clinical and Metabolic Genetics, The Hospital for Sick Children, Toronto, Ontario, CANADA;

³Orthopaedic Surgery, The Hospital for Sick Children, Toronto, Ontario, CANADA;

⁴Paediatric Laboratory Medicine, The Hospital for Sick Children, Toronto, Ontario, CANADA

Poster #080 3460220

THE UTILITY OF FDG PET-CT SCAN IN OFF-TREATMENT SURVEILLANCE OF PEDIATRIC BONE TUMORS

Lucy E. Cain¹, Kevin London², Theo Kitsos², Geoff McCowage¹

¹Cancer Centre for Children, The Children's Hospital at Westmead, Sydney, New South Wales, AUSTRALIA;

²Department of Nuclear Medicine, The Children's Hospital at Westmead, Sydney, New South Wales, AUSTRALIA

Poster #081 3460229

NEUTROPHIL-LYMPHOCYTE AND PLATELET-LYMPHOCYTE RATIOS AS ROBUST PROGNOSTIC MARKERS IN SARCOMAS - A POPULATION-BASED ANALYSIS OF 3746 SARCOMA PATIENTS FROM HONG KONG

Herbert Loong¹, Sampson K. Kwan², Chu Wa Ho³, Yingjun Zhang², Teresa Tse¹, Yat-ming Lau¹, Gordon C. Tang¹, Teresa Tan⁴, Carlos K. Wong³

¹Department of Clinical Oncology, The Chinese University of Hong Kong, Hong Kong, HONG KONG;

²Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, HONG KONG;

³Department of Family Medicine & Primary Care, The University of Hong Kong, Hong Kong, HONG KONG;

⁴Department of Surgery, The Chinese University of Hong Kong, Hong Kong, HONG KONG

Poster #082 3460268

AGE RELATED DIFFERENCES OF ONCOLOGICAL OUTCOMES IN PRIMARY EXTREMITY SOFT TISSUE SARCOMA: A MULTISTATE MODEL INCLUDING 6260 PATIENTS

Ibtissam Acem¹, Cees Verhoef², Anja Ruten-Budde¹, Winan J. van Houdt³, Dirk Grunhagen², Michiel van de Sande¹

¹Leiden University Medical Centre, Leiden, NETHERLANDS; ²Erasmus Medical Centre, Rotterdam, NETHERLANDS;

³The Netherlands Cancer Institute, Amsterdam, NETHERLANDS

Poster #083 3460427

ANALYSIS OF TUMOR INFILTRATING NK AND T CELLS HIGHLIGHTS IL-15 STIMULATION AND TIGIT BLOCKADE AS A COMBINATION IMMUNOTHERAPY STRATEGY FOR SOFT TISSUE SARCOMAS

Sean Judge¹, Morgan A. Darrow², Steven W. Thorpe³, Alicia A. Gingrich¹, Edmond F. O'Donnell³, Alyssa R. Bellini¹, Ian R. Sturgill⁴, Logan V. Vick⁴, Cordelia Dunai⁴, Kevin M. Stoffel⁴, Yue Lyu⁵, Shuai Chen⁵, May Cho⁶, Robert B. Rebhun⁷, Arta M. Monjaze⁸, William J. Murphy⁴, Robert J. Canter¹

¹Surgery, University of California, Davis, Sacramento, California, UNITED STATES; ²Pathology and Laboratory Medicine, University of California, Davis, Sacramento, California, UNITED STATES; ³Orthopedic Surgery, University of California, Davis, Sacramento, California, UNITED STATES; ⁴Dermatology, University of California, Davis, Sacramento, California, UNITED STATES; ⁵Public Health Sciences, University of California, Davis, Sacramento, California, UNITED STATES; ⁶Internal Medicine, University of California, Davis, Sacramento, California, UNITED STATES; ⁷Center for Companion Animal Health, University of California, Davis, Davis, California, UNITED STATES; ⁸Radiation Oncology, University of California, Davis, Sacramento, California, UNITED STATES

Poster #084 3460650

MANAGEMENT AND OUTCOMES OF CIC-REARRANGED SARCOMA; AN AUSTRALIAN MULTI-CENTRE REVIEW

Elizabeth Connolly⁴, David Pryor¹, Stephen Thompson², Johnathan Wake³, Vivek Bhadri⁴, Peter Grimison⁴, Annabelle Mahar⁵, Fiona Maclean⁶, Madeleine Strach⁴, Angela Hong³

¹Radiation Oncology, Princess Alexandra Hospital, Brisbane, Queensland, AUSTRALIA; ²Radiation Oncology, Prince of Wales Hospital, Sydney, New South Wales, AUSTRALIA; ³Radiation Oncology, Chris O'Brien Lifehouse, Sydney, New South Wales, AUSTRALIA; ⁴Medical Oncology, Chris O'Brien Lifehouse, Sydney, New South Wales, AUSTRALIA;

⁵NSW Health Pathology, Pathology, Sydney, New South Wales, AUSTRALIA; ⁶Anatomical Pathology, Douglas Hanly Moir Pathology, Sydney, New South Wales, AUSTRALIA

Poster #085 3460865

IDENTIFICATION OF NOVEL THERAPEUTIC TARGETS FOR METASTATIC OSTEOSARCOMA

Rebekah Belayneh¹, Ivy John¹, Margaret Hankins¹, David Boone², Sarangarajan Ranganathan⁴, Rita Alaggio⁵, Vaidehi Patel³, Benjamin Martin³, Kurt R. Weiss¹, Rebecca Watters¹

¹UPMC, Pittsburgh, Pennsylvania, UNITED STATES; ²Department of Biomedical Informatics, University of Pittsburgh, Pittsburgh, Pennsylvania, UNITED STATES; ³University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, UNITED STATES; ⁴Cincinnati Children's Hospital, Cincinnati, Ohio, UNITED STATES; ⁵University-Hospital of Padua, Padua, ITALY

Poster #086 3460952

EVALUATION OF CIRCULATING TUMOR CELLS IN RECURRENT OSTEOSARCOMA PATIENTS TREATED ON A PHASE II TRIAL OF GEMCITABINE AND NAB-PACLITAXEL: A REPORT FROM THE NATIONAL PEDIATRIC CANCER FOUNDATION

Masanori Hayashi¹, Javier Oesterheld², David Loeb³, Damon Reed⁴, Leo Mascarenhas⁵, Michael Isakoff⁶, Bhuvana Setty⁷, Joanne Lagmay⁸, Emi Caywood⁹, Eric Sandler¹⁰, Matteo Trucco¹¹, Christine Pratilas¹², Tiffany Smith¹³, Brooke Fridley⁴, Lars M. Wagner¹⁴

¹Children's Hospital Colorado, Denver, Colorado, UNITED STATES; ²Carolinas Medical Center, Charlotte, North Carolina, UNITED STATES; ³Montefiore Medical Center, Bronx, New York, UNITED STATES; ⁴Moffitt Cancer Center, Tampa, Florida, UNITED STATES; ⁵Children's Hospital Los Angeles, Los Angeles, California, UNITED STATES; ⁶Connecticut Children's Medical Center, Hartford, Connecticut, UNITED STATES; ⁷Nationwide Children's Hospital, Columbus, Ohio, UNITED STATES; ⁸University of Florida, Gainesville, Florida, UNITED STATES; ⁹Alfred DuPont Hospital for Children, Wilmington, Delaware, UNITED STATES; ¹⁰Nemours Children's Clinic, Jacksonville, Florida, UNITED STATES; ¹¹Cleveland Clinic Foundation, Cleveland, Ohio, UNITED STATES; ¹²Johns Hopkins University, Baltimore, Maryland, UNITED STATES; ¹³National Pediatric Cancer Foundation, Tampa, Florida, UNITED STATES; ¹⁴Duke University Medical Center, Durham, North Carolina, UNITED STATES

Poster #087 3461000

UBIQUITIN-LIGASE ATROGIN MEDIATES ADAPTATION TO KIT TARGETED INHIBITION IN GASTROINTESTINAL STROMAL TUMOR

Alfonso García-Valverde¹, Jordi Rosell¹, Sergi Sayols³, David Gómez-Peregrina¹, Daniel Pilco-Janeta¹, Enrique de Álava⁸, Joan Maurel⁹, Claudia Valverde⁴, Anna Esteve³, Marta Gut³, Jordi Barretina², Joan Carles⁴, George Demetri⁵, Jonathan Fletcher⁶, Joaquín Arribas⁷, César Serrano¹

¹Sarcoma Translational Research Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, SPAIN; ²Institut d'Investigació Biomèdica de Girona (IDIBGI), Girona, SPAIN; ³Centro Nacional de Análisis Genómicos (CNAG), Barcelona, SPAIN; ⁴Medical Oncology, Vall d'Hebron University Hospital, Barcelona, SPAIN; ⁵Dana-Farber Cancer Institute/Harvard Medical School, Boston, Massachusetts, UNITED STATES; ⁶Brigham and Women's Hospital/Harvard Medical School, Boston, Massachusetts, UNITED STATES; ⁷Growth Factors Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, SPAIN; ⁸Hospital Virgen del Rocío, Sevilla, SPAIN; ⁹Hospital Clínic, Barcelona, SPAIN

Poster #088 3461083

BONE METASTASIS OF GASTROINTESTINAL STROMAL TUMOR: CASE REPORT AND REVIEW OF THE LITERATURE

Caroline Braunstein⁵, François Sirveaux⁶, Elsa Kalbacher¹, Sébastien Aubry², Delphine Delroeux⁷, Paul Hubert¹, Béatrice Marie³, Guillaume Meynard¹, Ionela Mihai⁴, Loïc Chaigneau¹

¹Oncology, University Hospital, Besançon, FRANCE; ²Radiology, University Hospital, Besançon, FRANCE; ³Pathology, University Hospital, Nancy, FRANCE; ⁴Pathology, General Hospital, Belfort-Montbéliard, FRANCE; ⁵Pathology, University Hospital, Besançon, FRANCE; ⁶Orthopedic surgery, University Hospital, Nancy, FRANCE; ⁷Visceral Surgery, University Hospital, Besançon, FRANCE

Poster #089 3461140

FIVE-YEAR SURVIVAL OF A PATIENT WITH DEDIFFERENTIATED CHONDROSARCOMA TREATED WITH CHEMOTHERAPY AND JOINT SPARING SURGERY

Charles D. Gomez³, Mark S. Anderson⁴, Scott C. Epperly¹, **Lee M. Zuckerman²**

¹Orthopaedic Surgery, Loma Linda University Medical Center, Loma Linda, California, UNITED STATES; ²Orthopaedic Surgery, City of Hope National Medical Center, Duarte, California, UNITED STATES; ³Georgia Pediatric Orthopaedics, Macon, Georgia, UNITED STATES; ⁴Orthopaedic Surgery, Lovelace Health System, Albuquerque, New Mexico, UNITED STATES

Poster #090 3461203

IMPACT OF IMMUNOTHERAPY AND TARGETED THERAPY ON TUMOR GROWTH RATE IN SARCOMA

Esmail Al-Ezzi¹, Geoffrey Watson¹, Zachary Veitch¹, Eitan Amir², Albiruni Abdul Razak¹

¹Toronto Sarcoma Program, Princess Margaret Cancer Centre, Toronto, Ontario, CANADA; ²Division of Medical Oncology, Princess Margaret Cancer Centre, Toronto, Ontario, CANADA

Poster #091 3461252

PRIMARY SITE SURGERY IS ASSOCIATED WITH IMPROVED SURVIVAL IN METASTATIC SOFT TISSUE SARCOMA OF THE EXTREMITY

Alicia A. Gingrich¹, Sarah Bateni¹, Steven W. Thorpe², Amanda Kirane¹, Arta M. Monjazez³, Morgan A. Darrow⁴, Richard Bold¹, R L. Randall², Robert J. Canter¹

¹Surgery, University of California, Davis, Sacramento, California, UNITED STATES; ²Orthopedic Surgery, UC Davis, Sacramento, California, UNITED STATES; ³Radiology, UC Davis, Sacramento, California, UNITED STATES;

⁴Pathology, UC Davis, Sacramento, California, UNITED STATES

Poster #092 3461276

CHARACTERIZATION OF TUMOR INFILTRATING IMMUNE CELLS FROM ADULT SOFT TISSUE SARCOMAS

Jacky H. Chen¹, Nalan Gokgoz³, Jay Wunder², Irene Andrulis¹

¹Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, CANADA; ²University of Toronto Musculoskeletal Oncology Unit, Sinai Health System, Toronto, Ontario, CANADA; ³Lunenfeld Tanenbaum Research Institute, Toronto, Ontario, CANADA

Poster #093 3461301

IMPACT OF NEOADJUVANT CHEMOTHERAPY FOR RETROPERITONEAL SARCOMAS: A PROPENSITY BASED ANALYSIS OF A RETROSPECTIVE INTERNATIONAL, MULTICENTER COHORT

Matthieu Faron¹, Charles Honoré¹, Dirk Strauss², Alessandro Gronchi³, Carol J. Swallow⁴, Peter Hohenberger⁵, Piotr Rutkowski⁶, Frits van Coevorden⁷, Winan J. van Houdt⁷, Sylvie Bonvalot⁸, Axel Le Cesne⁹

¹Surgical Oncology, Gustave Roussy Cancer Campus, Villejuif, FRANCE; ²Royal Marsden Hospital NHS Foundation Trust, London, UNITED KINGDOM; ³Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, ITALY; ⁴Mount Sinai Hospital and Princess Margaret Cancer Centre, Toronto, Ontario, CANADA; ⁵Mannheim University Hospital, Mannheim, GERMANY; ⁶Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, POLAND; ⁷Netherlands Cancer Institute, Amsterdam, NETHERLANDS; ⁸Institut Curie, Paris, FRANCE; ⁹Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, FRANCE

Poster #094 3461333

SURGICAL MANAGEMENT OF PRIMARY LESION OF SOFT TISSUE SARCOMA MAY IMPROVE OVERALL SURVIVAL OF PATIENTS WITH INITIAL METASTASIS

Liuzhe Zhang², Toru Akiyama¹, Hiroshi Kobayashi²

¹Orthopedics, Jichi Medical University Saitama Medical Center, Saitama, Saitama, JAPAN; ²The University of Tokyo Hospital, Tokyo, JAPAN

Poster #095 3461335

PATIENT-SPECIFIC CUTTING GUIDES AND 3D-PRINTED TECHNOLOGY FOR PELVIC AND SACRAL TUMOR RESECTION AND COMPLEX ALLOGRAFT RECONSTRUCTION: OUR EXPERIENCE IN THE RESECTION OF PELVIC AND SPINAL SARCOMA OF BONE

Matthew Gasparro¹, Obianuju Obioha¹, **Charles Gusho**¹, Steven Gitelis¹, Alan Blank¹, Matthew Colman¹

¹Department of Orthopedics, Division of Orthopedic Oncology, Rush University Medical Center, Chicago, Illinois, UNITED STATES

Poster #096 3461337

NON-RANDOM ASSOCIATION OF BREAST IMPLANT SURGERY AND DESMOID TUMOR FORMATION

Philippos A. Costa¹, Staci Marbin¹, Andrea Espejo-Freire¹, Bruna Costa², Eduardo Saul¹, Priscila Barreto-Coelho¹, Ahkeel Allen¹, Neha Goel¹, Ty K. Subhawong¹, Gina D'amato¹, Jonathan Trent¹

¹University of Miami, Miami, Florida, UNITED STATES; ²Univasf, Petrolina, Pe, BRAZIL

Poster #097 3461438

A PHASE 1B/3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF TAZEMETOSTAT PLUS DOXORUBICIN AS FRONTLINE THERAPY FOR PATIENTS WITH ADVANCED EPITHELIOID SARCOMA

Shiraj Sen¹, Meredith McKean², Laura Sierra³, Jessica Ainscough³, Jay Yang³, Anthony Hamlett⁴

¹Sarah Cannon Research Institute, Denver, Colorado, UNITED STATES; ²Tennessee Oncology, Nashville, Tennessee, UNITED STATES; ³Epizyme, Inc., Cambridge, Massachusetts, UNITED STATES; ⁴Sarcoma Oncology Center, Santa Monica, California, UNITED STATES

Poster #098 3461452

OUTCOMES OF EWING SARCOMA/ EWING'S-LIKE SARCOMA (ES) IN PATIENTS AGED OVER 25

Sudha Karanam¹, Jenny Sherriff¹, David Peake¹, Hassan Douis¹, Mariam Jafri¹

¹Oncology, University Hospitals Birmingham, Birmingham, UNITED KINGDOM

Poster #099 3461465

GRADE OF PRIMARY CUTANEOUS LEIOMYOSARCOMA DICTATES CLINICAL OUTCOME RISK

Michael J. Carr³, William A. Adams¹, James Sun², Ricardo J. Gonzalez³, John Mullinax³, Jonathan S. Zager³

¹Morsani College of Medicine, University of South Florida, Tampa, Florida, UNITED STATES; ²Department of Surgery, Case Western Reserve University, Cleveland, Ohio, UNITED STATES; ³Department of Sarcoma, Moffitt Cancer Center, Tampa, Florida, UNITED STATES

Poster #100 3461487

OXYGEN TENSION AND MACROPHAGES MEDIATE PROLIFERATION OF OSTEOSARCOMA CELLS IN 3-DIMENSIONAL CULTURE

Victoria Thai², Katherine H. Griffin², **Steven W. Thorpe**¹, R L. Randall¹, J. K. Leach²

¹Orthopaedic Surgery, University of California, Davis, Sacramento, California, UNITED STATES; ²Biomedical Engineering, University of California, Davis, Davis, California, UNITED STATES

Poster #101 3461493

PATIENT-SPECIFIC CUTTING GUIDES AND 3D-PRINTED TECHNOLOGY FOR INTERCALARY LONG BONE RESECTION AND ALLOGRAFT RECONSTRUCTION: OUR EXPERIENCE IN THE RESECTION OF EXTREMITY SARCOMA OF BONE

Matthew Gasparro¹, **Charles Gusho**¹, Obianuju Obioha¹, Marta Batus², Matthew Colman¹, Steven Gitelis¹, Alan Blank¹

¹Department of Orthopedics, Division of Orthopedic Oncology, Rush University Medical Center, Chicago, Illinois, UNITED STATES; ²Internal Medicine, Division of Hematology, Oncology and Cell Therapy, Rush University Medical Center, Chicago, Illinois, UNITED STATES

Poster #102 3461507

SHORTCOMINGS OF FUNCTIONAL IMAGING: FAILURE OF MIBG SCAN TO DETECT A BENIGN TRANSFORMATION OF SOFT-TISSUE MALIGNANCY IN THREE CHILDREN

Lauren Riggs¹, Janay McKnight¹, Paul Kent¹

¹Rush University Medical Center, River Forest, Illinois, UNITED STATES

Poster #103 3461555

SELINEXOR IS MORE ACTIVE THAN DOXORUBICIN IN PATIENT-DERIVED XENOGRAPHS OF DEDIFFERENTIATED LIPOSARCOMA

Valentina Zuco¹, Sandro Pasquali², Monica Tortoreto¹, Chiara Colombo², Roberta Sanfilippo³, Silvia Brich⁴, Marta Barisella⁴, Paolo Giovanni Casali³, Alessandro Gronchi², Silvia Stacchiotti³, **Nadia Zaffaroni**¹

¹Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale Tumori, Milano, ITALY; ²Department of Surgery, Fondazione IRCCS Istituto Nazionale Tumori, Milano, ITALY; ³Department of Cancer Medicine, Fondazione IRCCS Istituto Nazionale Tumori, Milano, ITALY; ⁴Department of Pathology, Fondazione IRCCS Istituto Nazionale Tumori, Milano, ITALY

Poster #104

3461563

AN UPDATED ANALYSIS OF THE CLINICAL EFFICACY AND SAFETY OF ENTRECTINIB IN NTRK FUSION-POSITIVE (NTRK-FP) SARCOMA

Sant P. Chawla¹, Luis Paz-Ares², Manish R. Patel³, Gary L. Buchschacher⁴, Ashley Cheng⁵, E G. Chiorean⁶, Christine H. Chung⁷, Anthony P. Conley⁸, Ignacio Garrido-Laguna⁹, Koichi Goto¹⁰, Arthur L. Hooberman¹¹, James Hu¹², John C. Krauss¹³, Maciej Krzakowski¹⁴, Herbert Loong¹⁵, Gregory A. Otterson¹⁶, Helen J. Ross¹⁷, Conor Steuer¹⁸, Matthew H. Taylor¹⁹, José Trigo²⁰, Jürgen Wolf²¹, Antonella Brunello²², Stuart Osborne²³, Brian Simmons²⁴, Stephen V. Liu²⁵
¹Sarcoma Oncology Center, Santa Monica, California, UNITED STATES; ²Hospital Universitario 12 de Octubre, Madrid, SPAIN; ³Department of Medicine, University of Minnesota, Minneapolis, Minnesota, UNITED STATES; ⁴Southern California Permanente Medical Group, Los Angeles, California, UNITED STATES; ⁵Department of Clinical Oncology, Princess Margaret Hospital, Kwai Chung, Hong Kong Special Administrative Region, CHINA; ⁶Fred Hutchinson Cancer Research Center, University of Washington School of Medicine, Seattle, Washington, UNITED STATES; ⁷Moffitt Cancer Center, Tampa, Florida, UNITED STATES; ⁸Department of Sarcoma Medical Oncology, MD Anderson Cancer Center, University of Texas, Houston, Texas, UNITED STATES; ⁹Huntsman Cancer Institute at the University of Utah, Salt Lake City, Utah, UNITED STATES; ¹⁰Department of Thoracic Oncology, National Cancer Center, Kashiwa, JAPAN; ¹¹Advocate Medical Group, Park Ridge, Illinois, UNITED STATES; ¹²University of Southern California/Norris Cancer Center, Los Angeles, California, UNITED STATES; ¹³University of Michigan, Ann Arbor, Michigan, UNITED STATES; ¹⁴Maria Sklodowska-Curie Institute of Oncology, Warsaw, POLAND; ¹⁵The Chinese University of Hong Kong, Hong Kong Special Administrative Region, CHINA; ¹⁶Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, UNITED STATES; ¹⁷Mayo Clinic Arizona, Phoenix, Arizona, UNITED STATES; ¹⁸Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia, UNITED STATES; ¹⁹Earle A Chiles Research Institute, Providence Cancer Institute, Portland, Oregon, UNITED STATES; ²⁰Hospital Universitario Virgen de la Victoria de Málaga, Málaga, SPAIN; ²¹Center for Integrated Oncology, University Hospital of Cologne, Cologne, GERMANY; ²²Department of Oncology, Medical Oncology 1, Veneto Institute of Oncology, IOV-IRCCS, Padua, ITALY; ²³F. Hoffmann-La Roche Ltd, Basel, SWITZERLAND; ²⁴Genentech Inc., South San Francisco, California, UNITED STATES; ²⁵Georgetown University Medical Center, Washington, District of Columbia, UNITED STATES

Poster #105

3461635

LAROTRECTINIB EFFICACY AND SAFETY IN ADULT PATIENTS WITH TRK FUSION SARCOMAS

Shivaani Kummar¹, David S. Hong², Ray McDermott³, Vicki L. Keedy⁴, George Demetri⁵, Robert C. Doebele⁶, Afshin Dowlati⁷, Victor Moreno⁸, Ulrik Lassen⁹, Edward Chu¹⁰, Serge Leyvraz¹¹, Soledad Gallego Melcón¹², Jyoti D. Patel¹³, Atrayee Basu Mallick¹⁴, John A. Reeves¹⁵, Marc Fellous¹⁵, Nicoletta Brega¹⁵, Alexander Drilon¹⁶, Daniel S.W. Tan¹⁷
¹Stanford Cancer Institute, Stanford University, Palo Alto, California, UNITED STATES; ²The University of Texas MD Anderson Cancer Center, Houston, Texas, UNITED STATES; ³St. Vincent's University Hospital & University College Dublin, Dublin, IRELAND; ⁴Vanderbilt University Medical Center, Nashville, Tennessee, UNITED STATES; ⁵Dana-Farber Cancer Institute and Ludwig Center at Harvard Medical School, Boston, Massachusetts, UNITED STATES; ⁶University of Colorado Cancer Center, Denver, Colorado, UNITED STATES; ⁷University Hospitals Ahuja Medical Center, Beachwood, Ohio, UNITED STATES; ⁸START MADRID-FJD, Hospital Fundación Jiménez Díaz, Madrid, SPAIN; ⁹Rigshospitalet, Copenhagen, DENMARK; ¹⁰UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, UNITED STATES; ¹¹Charité – Universitätsmedizin Berlin, Berlin, GERMANY; ¹²Vall d'Hebron Children's Hospital, Barcelona, SPAIN; ¹³Northwestern University, Chicago, Illinois, UNITED STATES; ¹⁴Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania, UNITED STATES; ¹⁵Bayer HealthCare Pharmaceuticals, Whippany, New Jersey, UNITED STATES; ¹⁶Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York, UNITED STATES; ¹⁷National Cancer Center, Singapore, SINGAPORE

Poster #106

3461675

IMPACT OF NEXT GENERATION SEQUENCING (NGS) ON THE TREATMENT OF PATIENTS WITH SARCOMA

Brian Schulte¹, Neelima Katam², Amir Behdad², Massimo Cristofanilli¹, Jeffrey Wayne³, Karl Bilimoria³, Terrance Peabody³, Samer Attar³, John Hayes⁴, Jean-Paul Wolinsky⁵, Borislav Alexiev², Firas Wehbe², Mark Agulnik¹
¹Oncology, Northwestern University, Chicago, Illinois, UNITED STATES; ²Pathology, Northwestern University, Chicago, Illinois, UNITED STATES; ³Surgical Oncology, Northwestern University, Chicago, Illinois, UNITED STATES; ⁴Radiation Oncology, Northwestern University, Chicago, Illinois, UNITED STATES; ⁵Neurological Surgery, Northwestern University, Chicago, Illinois, UNITED STATES

Poster #107 3461682

HISTOLOGY AND TUMOUR BIOLOGY ARE MORE IMPORTANT IN PREDICTING OVERALL SURVIVAL THAN MARGINS OF RESECTION

Boaz Wong¹, Sameer Apte¹, Fabio Tirota², Alessandro Parente², Johanne Mathieu¹, Sam Ford², Anant Desai², Max Almond², Carolyn Nessim¹

¹Surgical Oncology, The Ottawa Hospital, Ottawa, Ontario, CANADA; ²University Hospital Birmingham NHS Foundation Trust, Birmingham, UNITED KINGDOM

Poster #108 3461698

HISTOLOGIC MARKERS PREDICTIVE OF WOUND HEALING COMPLICATIONS IN SOFT TISSUE SARCOMA TREATED WITH PREOPERATIVE RADIATION

Jacob Gylten¹, Stephanie Chen¹, Jane Persons¹, Qiang An¹, Munir Tanas¹, Benjamin J. Miller¹

¹University of Iowa, Iowa City, Iowa, UNITED STATES

Poster #109 3461710

INTEGRATED SAFETY ANALYSIS OF TAZEMETOSTAT 800 MG TWICE DAILY IN ADULT PATIENTS WITH HEMATOLOGIC AND SOLID TUMORS

Franck Morschhauser¹, Pamela McKay², Gilles Salles³, Silvia Stacchiotti⁴, Gary Schwartz⁵, Hervé Tilly⁶, Marjorie Zauderer⁷, Dean Fennell⁸, Robin L. Jones⁹, Patrick Schöffski¹⁰, Tycel Phillips¹¹, Aristeidis Chaidos¹², Victor Villalobos¹³, George Demetri¹⁴, Gregory M. Cote¹⁵, Laura Sierra¹⁶, Jay Yang¹⁶, Pam Slatcher¹⁶, Shefali Agarwal¹⁶, Mrinal Gounder⁷

¹Université Lille, CHU Lille, ULR 7365 – GRITA – Groupe de Recherche sur les formes Injectables et les Technologies Associées, Lille, FRANCE; ²Beatson West of Scotland Cancer Centre, Glasgow, Scotland, UNITED KINGDOM; ³Lyon-Sud Hospital, University of Lyon, Pierre-Bénite, FRANCE; ⁴Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, ITALY; ⁵Herbert Irving Comprehensive Care Center, Columbia University Irving Medical Center, New York, New York, UNITED STATES; ⁶Centre Henri Becquerel and Rouen University, Rouen, FRANCE; ⁷Memorial Sloan Kettering Cancer Center, New York, New York, UNITED STATES; ⁸University of Leicester and University Hospitals of Leicester NHS Trust, Leicester, UNITED KINGDOM; ⁹The Royal Marsden Hospital and Institute for Cancer Research, London, UNITED KINGDOM; ¹⁰Department of General Medical Oncology, University Hospitals Leuven, Leuven Cancer Institute, Leuven, BELGIUM; ¹¹University of Michigan, Ann Arbor, Michigan, UNITED STATES; ¹²Imperial College London & Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, UNITED KINGDOM; ¹³University of Colorado School of Medicine, Boulder, Colorado, UNITED STATES; ¹⁴Dana Farber Cancer Institute and Ludwig Center at Harvard Medical School, Boston, Massachusetts, UNITED STATES; ¹⁵Massachusetts General Hospital, Boston, Massachusetts, UNITED STATES; ¹⁶Epizyme, Inc., Cambridge, Massachusetts, UNITED STATES

Poster #110 3461748

RECRUITMENT PATTERNS IN A LARGE INTERNATIONAL RANDOMIZED CONTROLLED TRIAL OF PERIOPERATIVE CARE IN CANCER PATIENTS

Aaron M. Gazendam¹, Anthony Bozzo¹, Tricia Schneider¹, Victoria Giglio¹, David Wilson¹, Michelle Ghert¹

¹Orthopaedic Surgery, McMaster University, Hamilton, Ontario, CANADA

Poster #111 3461782

FACTORS INFLUENCING UNPLANNED READMISSION AFTER SURGERY IN SOFT TISSUE SARCOMAS

David L. Kerr¹, Alexander L. Lazarides¹, Mark M. Cullen², Preet Patel², Sneha Rao¹, Marcelo Cerullo³, Dan G (Trey) Blazer³, Brian E. Brigman¹, Julia D. Visgauss¹, William C. Eward¹

¹Orthopedic Surgery, Duke University Hospital, Durham, North Carolina, UNITED STATES; ²Duke University School of Medicine, Durham, North Carolina, UNITED STATES; ³General Surgery, Duke University Hospital, Durham, North Carolina, UNITED STATES

Poster #112 3461852

18F-FDG PET/CT CAN HELP SOLVE THE GRADING DILEMMAS IN CARTILAGE BONE NEOPLASMS? SURGEON'S INTERPRETATION FOR TREATMENT PLANNING

Manit K. Gundavda¹, Manish Agarwal¹, Rajeev Reddy¹, Rajat Gupta¹, Ashik Bary¹

¹Orthopaedic Oncology, P.D. Hinduja Hospital and Medical Research Centre, Mumbai, INDIA

Poster #113

3461875

CLINICOPATHOLOGICAL FEATURES AND TREATMENT OUTCOME OF OESOPHAGEAL GASTROINTESTINAL STROMAL TUMOUR (GIST): A LARGE, RETROSPECTIVE MULTICENTER EUROPEAN STUDY

Mahmoud Mohammadi¹, Nikki Ijzerman², **Peter Hohenberger**³, Piotr Rutkowski⁴, Robin L. Jones⁶, Javier Martin-Broto⁵, Alessandro Gronchi⁷, Patrick Schöffski⁸, Nikolaos Vassos⁹, Sheima Farag¹⁰, Marco Baia¹¹, Astrid W. Oosten¹², Neeltje Steeghs², Ingrid Desar¹³, An K. Reyners¹⁴, Johanna W. van Sandick¹⁵, Esther Bastiaannet¹⁶, Hans Gelderblom¹, Yvonne Schrage¹⁵

¹Medical Oncology, Leiden University Medical Center, Leiden, NETHERLANDS; ²Medical Oncology, Netherlands Cancer Institute, Amsterdam, NETHERLANDS; ³Surgical Oncology & Thoracic Surgery, Mannheim University Medical Center, Mannheim, GERMANY; ⁴Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, POLAND; ⁵Medical Oncology, Virgen del Rocio University Hospital, Seville, SPAIN; ⁶The Royal Marsden NHS Foundation Trust / Institute of Cancer Research, London, UNITED KINGDOM; ⁷Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, ITALY; ⁸General Medical Oncology, University Hospitals Leuven, Leuven Cancer Institute, Leuven, Leuven, BELGIUM; ⁹Surgical Oncology & Thoracic Surgery, Mannheim University Medical Center, Mannheim, GERMANY; ¹⁰Sarcoma Unit, The Royal Marsden NHS Foundation Trust, London, UNITED KINGDOM; ¹¹Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, ITALY; ¹²Erasmus MC Cancer Institute, Rotterdam, NETHERLANDS; ¹³Radboud University Medical Center, Nijmegen, NETHERLANDS; ¹⁴University Medical Center Groningen, Groningen, NETHERLANDS; ¹⁵Surgical Oncology, Antoni van Leeuwenhoek – Netherlands Cancer Institute, Amsterdam, NETHERLANDS; ¹⁶Surgery/ Medical Oncology, Leiden University Medical Center, Leiden, NETHERLANDS

Poster #114

3461883

AVAPRITINIB VS REGORAFENIB IN PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE OR METASTATIC GASTROINTESTINAL STROMAL TUMOR (GIST): EFFICACY AND SAFETY DATA FROM PHASE 3 VOYAGER STUDY

Yoon-Koo Kang¹, Suzanne George², Robin L. Jones³, Piotr Rutkowski⁴, Lin Shen⁵, Olivier Mir⁶, Shreyaskumar Patel⁷, Yongjian Zhou⁸, Margaret von Mehren⁹, Peter Hohenberger¹⁰, Victor Villalobos¹¹, Mehdi Brahmi¹², William D. Tap¹³, Jonathan Trent¹⁴, Maria Pantaleo¹⁵, Patrick Schöffski¹⁶, Kevin He¹⁷, Paggy Hew¹⁷, Kate Newberry¹⁷, Maria Roche¹⁷, Michael Heinrich¹⁸, Sebastian Bauer¹⁹

¹Asan Medical Center, University of Ulsan College of Medicine, Seoul, KOREA (THE REPUBLIC OF); ²Sarcoma Center, Dana Farber Cancer Institute, Boston, Massachusetts, UNITED STATES; ³Royal Marsden Hospital and Institute of Cancer Research, London, UNITED KINGDOM; ⁴Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, POLAND; ⁵Peking University Cancer Hospital and Institute, Beijing, CHINA; ⁶Institut Gustave Roussy, Villejuif, FRANCE; ⁷MD Anderson Cancer Center, Houston, Texas, UNITED STATES; ⁸Fujian Medical University Union Hospital, Fuzhou, CHINA; ⁹Fox Chase Cancer Center, Philadelphia, Pennsylvania, UNITED STATES; ¹⁰University of Heidelberg (UMM), Mannheim, GERMANY; ¹¹University of Colorado Denver – Anschutz Medical Campus, Aurora, Colorado, UNITED STATES; ¹²Centre Léon Bérard, Lyon, FRANCE; ¹³Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York, UNITED STATES; ¹⁴University of Miami-Sylvester Comprehensive Cancer Center, Miami, Florida, UNITED STATES; ¹⁵University of Bologna, Bologna, ITALY; ¹⁶University Hospitals Leuven, Leuven, BELGIUM; ¹⁷Blueprint Medicines Corporation, Cambridge, Massachusetts, UNITED STATES; ¹⁸Portland VA Health Care System and OHSU Knight Cancer Institute, Portland, Oregon, UNITED STATES; ¹⁹Sarcoma Center, West German Cancer Center, DKTK-Partner-Site, University of Duisburg, Essen, GERMANY

Poster #115

3462029

LAROTRECTINIB EFFICACY AND SAFETY IN PEDIATRIC PATIENTS WITH TRK FUSION SARCOMAS

Theodore W. Laetsch¹, Stefan Bielack², Daniel Orbach³, Steven DuBois⁴, Noah Federman⁵, Birgit Georger⁶, Leo Mascarenhas⁷, Ramamoorthy Nagasubramanian⁸, Daniel Morgenstern⁹, Alberto Pappo¹⁰, Johannes Schulte¹¹, Neerav Shukla¹², John A. Reeves¹³, Laura Dima¹⁴, Esther De La Cuesta¹³, Catherine M. Albert¹⁵, Cornelis M. van Tilburg¹⁶

¹University of Texas Southwestern Medical Center/Children's Health, Dallas, Texas, UNITED STATES; ²Klinikum Stuttgart-Olgahospital, Stuttgart, GERMANY; ³Institut Curie and Paris University, Paris, FRANCE; ⁴Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, Massachusetts, UNITED STATES; ⁵David Geffen School of Medicine, University of California, Los Angeles, California, UNITED STATES; ⁶Gustave Roussy Cancer Center, Université Paris-Saclay, INSERM U1015, Villejuif, FRANCE; ⁷Children's Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, California, UNITED STATES; ⁸Nemours Children's Hospital, Orlando, Florida, UNITED STATES; ⁹Hospital for Sick Children and University of Toronto, Toronto, Ontario, CANADA; ¹⁰St. Jude Children's Research Hospital, Memphis, Tennessee, UNITED STATES; ¹¹Charité-Universitätsmedizin Berlin, Berlin, GERMANY; ¹²Memorial Sloan Kettering Cancer Center, New York, New York, UNITED STATES; ¹³Bayer HealthCare Pharmaceuticals, Inc., Whippany, New Jersey, UNITED STATES; ¹⁴Bayer Pharmaceuticals, Basel, SWITZERLAND; ¹⁵Seattle Children's Hospital, University of Washington, Fred Hutchinson Cancer Research Center, Seattle, Washington, UNITED STATES; ¹⁶Hopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg University Hospital and German Cancer Research Center (DKFZ), Heidelberg, GERMANY

Poster #116 3462147

MANAGEMENT OF HEMANGIOENDOTHELIOMA AT A DEDICATED SARCOMA CLINIC IN INDIA: TIME TO LOOK TOWARDS ANTI-ANGIOGENIC THERAPY

Ghazal Tansir¹, Sameer Rastogi¹, Adarsh Barwad², Ekta Dhamija³, Shamim A. Shamim⁴

¹Medical Oncology, All India Institute of Medical Sciences, New Delhi, Delhi, INDIA; ²Pathology, All India Institute of Medical Sciences, New Delhi, INDIA; ³Radiodiagnosis, All India Institute of Medical Sciences, New Delhi, Delhi, INDIA; ⁴Department of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, Delhi, INDIA

Poster #117 3462149

MODELING THE EFFICACY OF NY-ESO-1 TCRT CELLS (LETETRESGENE AUTOLEUCEL; GSK3377794) IN PATIENTS WITH SYNOVIAL SARCOMA: CORRELATIONS OF RESPONSE WITH TRANSDUCED CELL KINETICS AND BIOMARKERS

Alexandra Gyurdieva¹, Stefan Zajic¹, Ya-Fang Chang¹, E. Andres Houseman¹, Shan Zhong¹, Jaegil Kim¹, David C. Turner¹, Laura A. Johnson¹, Ioanna Eleftheriadou¹, Jenna Tress¹, Aisha Hasan¹, Victoria L. Chiou¹, Naimish Pandya¹, John Glod², Dejka Araujo³, Warren Chow⁴, Mihaela Druta⁵, George Demetri⁶, Brian A. Van Tine⁷, Sandra D'Angelo⁸

¹GlaxoSmithKline, Collegeville, Pennsylvania, UNITED STATES; ²National Cancer Institute, Bethesda, Maryland, UNITED STATES; ³University of Texas/MD Anderson Cancer Center, Houston, Texas, UNITED STATES; ⁴City of Hope Comprehensive Cancer Center, Duarte, California, UNITED STATES; ⁵H. Lee Moffitt Cancer Center, Tampa, Florida, UNITED STATES; ⁶Dana Farber Cancer Institute and Ludwig Center at Harvard, Boston, Massachusetts, UNITED STATES; ⁷Washington University in St. Louis, St. Louis, Missouri, UNITED STATES; ⁸Memorial Sloan Kettering Cancer Center, New York, New York, UNITED STATES

Poster #118 3462192

CAN PATIENTS AT HIGH RISK FOR R2 RESECTION OF RETROPERITONEAL SARCOMA (RPS) BE IDENTIFIED PREOPERATIVELY?

Deanna Ng¹, Dario Callegaro², Chandrajit Raut³, Dirk Strauss⁴, Charles Honoré⁵, Eberhard Stoeckle⁶, Sylvie Bonvalot⁷, Winan J. van Houdt⁸, Piotr Rutkowski⁹, Marco Fiore², Carol J. Swallow¹

¹University of Toronto, Toronto, Ontario, CANADA; ²Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, ITALY; ³Brigham and Women's Hospital Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, UNITED STATES; ⁴Royal Marsden NHS Foundation Trust, London, UNITED KINGDOM; ⁵Gustave Roussy, Paris, FRANCE; ⁶Institut Bergonie, Bordeaux, FRANCE; ⁷Institut Curie, Paris, FRANCE; ⁸The Netherlands Cancer Institute, Amsterdam, NETHERLANDS; ⁹Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, POLAND

Poster #119 3462260

ADDED VALUE OF SURGICAL NAVIGATION FOR CHALLENGING INTRA-ABDOMINAL OR PELVIC SARCOMA

Sophie Reijers¹, Wouter J. Heerink¹, Ruben van Veen¹, Jasper Nijkamp¹, Nikie J. Hoetjes¹, Yvonne Schrage¹, Alexander van Akkooi¹, Geerard L. Beets¹, Frits van Coevorden¹, Theo J. Ruers¹, Harald C. Groen¹, Winan J. van Houdt¹

¹Surgical Oncology, Antoni van Leeuwenhoek ziekenhuis, Amsterdam, Noord Holland, NETHERLANDS

Poster #120 3462325

MANAGEMENT OF HIGH-GRADE EXTREMITY SOFT TISSUE SARCOMAS: AN EXPERT SURVEY

Ibtissam Acem¹, **Merel Smit**¹, Cees Verhoef³, Winan J. van Houdt², Dirk Grunhagen², Michiel van de Sande¹

¹Leiden University Medical Centre, Leiden, NETHERLANDS; ²The Netherlands Cancer Institute, Amsterdam, NETHERLANDS; ³Erasmus Medical Center, Rotterdam, NETHERLANDS

Poster #121 3462376

COMPLETE PATHOLOGICAL RESPONSE TO NEOADJUVANT TREATMENT IS ASSOCIATED WITH BETTER SURVIVAL OUTCOMES IN PATIENTS WITH SOFT TISSUE SARCOMA

Sylvie Bonvalot¹, Jay Wunder², Alessandro Gronchi³, Javier Martin-Broto⁴, Robert Turcotte⁵, Marco Rastrelli⁶, Zsuzsanna Papai⁷, Stefano Radaelli³, Lars Lindner⁸, Felix Shumelinsky⁹, Antonio Cubillo¹⁰, Piotr Rutkowski¹¹, Danielle Strens¹², Clémentine Demaire¹², Georgi Nalbantov¹²

¹Surgery, Institut Curie, Paris, FRANCE; ²Surgery, Sinai Health System, Toronto, Ontario, CANADA; ³Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, ITALY; ⁴Medical Oncology, Hospital Virgen del Rocio, Sevilla, SPAIN; ⁵Surgery, McGill University Health centre, Montreal, Quebec, CANADA; ⁶Surgical Oncology, Istituto Oncologico Veneto, Padova, ITALY; ⁷Oncology, Honved Hospital - Hungarian Defence Forces Military Hospital, Budapest, HUNGARY; ⁸Internal Medicine, University Hospital of Munich, Munich, GERMANY; ⁹Surgery-- Bone and Connective Tissue Tumour Surgery, Jules Bordet Institute, Brussels, BELGIUM; ¹⁰Medical Oncology, Hospital Universitario Sanchinarro. Centro Integral Oncológico Clara Campal HM CIOCC, Madrid, SPAIN; ¹¹Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie Institute-Oncology Center, Warsaw, POLAND; ¹²Health Economics & Outcome Research Team, Monitor Deloitte, Zaventem, BELGIUM

Poster #122 3462419

OVERALL SURVIVAL AFTER PERIOPERATIVE CHEMOTHERAPY IN THE MANAGEMENT OF PULMONARY METASTASIS IN OSTEOSARCOMA

Zeba Siddiqui¹, Megan Delisle², Amirrtha Srikanthan³, Ying Wang⁴

¹Internal Medicine Residency Training Program, University of Ottawa, Ottawa, Ontario, CANADA; ²General Surgery Residency Program Department, University of Manitoba, Winnipeg, Manitoba, CANADA; ³The Ottawa Hospital Cancer Centre, University of Ottawa, Ottawa, Ontario, CANADA; ⁴BC Cancer Vancouver, University of British Columbia, Vancouver, British Columbia, CANADA

Poster #123 3462424

PRECLINICAL ASSESSMENT AND ANALYSIS OF ANTI-SEMA4D TREATMENT FOR OSTEOSARCOMA

Gabrielle Robbins¹, Branden Smeester¹, Branden Moriarity¹

¹Department of Pediatrics, University of Minnesota, Minneapolis, Minnesota, UNITED STATES

Poster #124 3462442

NCI PROTOCOL 10330: A PHASE 2 STUDY OF BELINOSTAT AND SGI-110 (GUADECITABINE) FOR THE TREATMENT OF UNRESECTABLE AND METASTATIC CONVENTIONAL CHONDROSARCOMA

Jay H. Oza¹, Matthew Ingham¹, Shing Lee³, Tahir Sheikh¹, Richard Piekarz², Gary Schwartz¹

¹Department of Medicine (Division of Hematology and Oncology), Columbia University, New York, New York, UNITED STATES; ²National Cancer Institute, Bethesda, Maryland, UNITED STATES; ³Department of Biostatistics, Mailman School of Public Health, Columbia University, New York, New York, UNITED STATES

Poster #125 3462457

D-3-PHOSPHOGLYCERATE DEHYDROGENASE (PHGDH) INHIBITION DRIVES PRO-SURVIVAL MTOR DEPENDENCY IN OSTEOSARCOMA

Richa Rathore¹, Katharine E. Caldwell¹, Caitlyn B. Brashears¹, Brian A. Van Tine¹

¹Medical Oncology, Washington University in St. Louis, University City, Missouri, UNITED STATES

Poster #126 3462463

TARGETING PARACRINE FIBROBLASTIC NETWORKS IN GASTROINTESTINAL STROMAL TUMOR INHIBITS CANCER GROWTH AND METASTASIS

Hyunho Yoon¹, Chih-Min Tang¹, Sudeep Banerjee², Mayra Yebra¹, Sangkyu Noh¹, Adam M. Burgoyne¹, Jorge De la Torre¹, Martina De Siena¹, Mengyuan Liu³, Lilli Klug⁴, Yoon Young Choi⁵, Antonio Delgado¹, Zhiyong Wang⁵, Randall P. French¹, Andrew M. Lowy¹, Ronald deMatteo³, Michael Heinrich⁴, Alfredo A. Molinolo⁵, J. Silvio Gutkind⁵, Olivier Harismendy⁵, Jason K. Sicklick¹

¹Department of Surgery, Division of Surgical Oncology, University of California, San Diego, La Jolla, California, UNITED STATES; ²UCLA, Los Angeles, California, UNITED STATES; ³University of Pennsylvania, Philadelphia, Pennsylvania, UNITED STATES; ⁴Oregon Health and Science University, Portland, Oregon, UNITED STATES; ⁵Moore's Cancer Center, San Diego, California, UNITED STATES

Poster #127 3462528

DIRECT INTERACTION OF THE ATP-SENSITIVE K⁺ CHANNEL BY THE TYROSINE KINASE INHIBITOR IMATINIB, SUNITINIB AND Nilotinib

Robin Fröbom¹, Erik Berglund¹, **Robert Bränström**¹

¹Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Stockholm, SWEDEN

Poster #128 3462552

TP53 AS PROGNOSTIC MARKER IN PATIENTS WITH ADVANCED SARCOMA: A POOLED ANALYSIS OF MOSCATO AND PROFILER STUDIES

Elise Nassif¹, Rastilav Bahleda¹, Edouard Auclin³, Charles Honoré², Sarah Dumont², Mehdi Brahmi⁴, Olivier Tredan⁴, Olivier Mir², Isabelle Ray-Coquard⁴, Axel Le Cesne², Jean-Yves Blay⁴, Christophe Massard¹, Armelle Dufresne⁴

¹DITEP, Institut Gustave Roussy, Paris, FRANCE; ²Gustave Roussy, Villejuif, FRANCE; ³APHP, Paris, FRANCE;

⁴Centre Léon Bérard, Lyon, FRANCE

Poster #129 3462565

DIAGNOSTIC CHALLENGES OF INFANTILE SARCOMAS DRIVEN BY EGFR INTERNAL TANDEM DUPLICATIONS: A CASE SERIES

Ajay Gupta¹, Ryan D. Roberts², Catherine Cottrell³, Kathleen Schieffer³, Selene Koo⁴, Elaine Mardis³, Mark Ranalli², Bhuvana Setty²

¹Pediatric Oncology, Roswell Park Cancer Institute, Buffalo, New York, UNITED STATES; ²Hematology, Oncology, Blood and Marrow Transplant, Nationwide Children's Hospital, Columbus, Ohio, UNITED STATES; ³The Steve and Cindy Rasmussen Institute for Genomic Medicine, Nationwide Children's Hospital, Columbus, Ohio, UNITED STATES;

⁴Pathology, Nationwide Children's Hospital, Columbus, Ohio, UNITED STATES

Poster #130 3462585

GENOMIC CHARACTERISTICS RELATED TO THE EFFICACY OF ANLOTINIB IN LEIOMYOSARCOMA

Wenshuai Liu¹, Qingping Zou⁴, Hanxing Tong³, Rongyuan Zhuang², Chenlu Zhang², Xi Guo², Chentao Lv¹, Hua Yang¹, Qiaowei Lin³, Zhiming Wang², Feng Shen², Lijie Ma¹, Chun Dai⁴, Jun Liu⁴, Guan Wang⁴, Yong Zhang³, Weiqi Lu³, **Yuhong Zhou**²

¹Department of General Surgery, Shanghai Public Health Clinical Center, Fudan University, Shanghai, CHINA;

²Department of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, CHINA; ³Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, CHINA; ⁴GenomiCare Biotechnology, Shanghai, CHINA

Poster #131 3462616

DESPITE ADVANCES IN TUMOR MANAGEMENT MODALITIES, SURGERY SEEMS TO BE THE BEST PREDICTOR OF SURVIVAL FOR OSTEOSARCOMA: AN ANALYSIS OF PRIMARY OSSEOUS TUMOR CHARACTERISTICS, MANAGEMENT, AND OUTCOMES FROM THE NATIONAL CANCER DATABASE (NCDB)

Taylor D. Ottesen¹, Blake S. Shultz¹, Alana M. Munger¹, Cosmas Sibindi¹, Alp Yurter¹, Arya R. Varthi¹, Jonathan N. Grauer¹

¹Orthopaedics and Rehabilitation, Yale School of Medicine, Orem, Utah, UNITED STATES

Poster #132 3462658

THE EFFECT OF EXTENSOR MECHANISM REPAIR ON FUNCTIONAL OUTCOME FOLLOWING PROXIMAL TIBIA REPLACEMENT

Rishi Trikha¹, Danielle Greig¹, Troy Sekimura¹, Michael Arnold¹, Alexandra Stavrakis¹, Jeffrey Eckardt¹, Nicholas Bernthal¹

¹Orthopaedics, University of California, Los Angeles, Santa Monica, California, UNITED STATES

Poster #133 3462660

SURVIVAL FOLLOWING EPITHELIOID SARCOMA DIAGNOSIS: A SEER DATABASE ANALYSIS

Elizabeth T. Loggers¹, Michael J. Wagner³, Bonny Chau², Seth Pollack¹, Matthew J. Thompson³, Edward Kim³, Gabrielle Kane³, Jared Harwood³, Teresa Kim³, Lee D. Cranmer³

¹Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, UNITED STATES;

²Seattle Cancer Care Alliance, Seattle, Washington, UNITED STATES; ³University of Washington, Seattle, Washington, UNITED STATES

Poster #134 3462671

THE INCIDENCE, RISK FACTORS AND MICROBIAL PROFILE OF INFECTED ENDOPROSTHETIC RECONSTRUCTRIONS

Rishi Trikha¹, Danielle Greig¹, Troy Sekimura¹, Jeffrey Eckardt¹, Nicholas Bernthal¹

¹Orthopaedics, University of California, Los Angeles, Santa Monica, California, UNITED STATES

Poster #135 3462922

SURGICAL TREATMENT PATTERNS AND HEALTHCARE RESOURCE UTILIZATION IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMORS WHO UNDERWENT JOINT SURGERY IN THE UNITED STATES

Feng Lin¹, Winghan J Kwong¹, Willy Wynant², Raluca Ionescu-Ittu², Sherry Shi², Irina Pivneva², Eric Q. Wu³, John A. Abraham⁴

¹Daiichi Sankyo, Inc., Basking Ridge, New Jersey, UNITED STATES; ²Analysis Group, Inc., Montreal, Quebec, CANADA;

³Analysis Group, Inc., Boston, Massachusetts, UNITED STATES; ⁴Rothman Institute and Fox Chase Cancer Center, Philadelphia, Pennsylvania, UNITED STATES

Poster #136 3462983

GEMCITABINE-CONTAINING REGIMENS FOR THE TREATMENT OF METASTATIC MYXOFIBROSARCOMA REFRACTORY TO DOXORUBICIN

Arielle Elkrief¹, Suzanne Kazandjian¹, Thierry Alcindor¹

¹Oncology, McGill University Health Centre, Montreal, Quebec, CANADA

Poster #137 3463019

TNT: A PHASE 2 STUDY USING TALIMOGENE LAHERPAREPVEC, NIVOLUMAB AND TRABECTEDIN AS FIRST, SECOND/THIRD LINE THERAPY FOR ADVANCED SOFT TISSUE SARCOMA, INCLUDING DESMOID TUMOR AND CHORDOMA [NCT03886311]

Sant P. Chawla¹, Victoria Chua-Alcala¹, Ted T. Kim¹, Kelly Wang¹, Paul S. Dy¹, Nicole L. Angel¹, Micaela K. Paz¹, Ania M. Moradkhani¹, Doris M. Quon¹, Steven M. Wong¹, Omid Jafari¹, Erlinda M. Gordon¹

¹Sarcoma Oncology Center, Santa Monica, California, UNITED STATES

Poster #138 3463040

THE PROGNOSTIC IMPORTANCE OF PATHOLOGIC FRACTURE IN LIMB SALVAGE SURGERY FOR CHONDROSARCOMA

Danielle Greig¹, Rishi Trikha¹, Troy Sekimura¹, Jeffrey Eckardt¹, Nicholas Bernthal¹

¹Orthopaedic Surgery, University of California, Los Angeles, Los Angeles, California, UNITED STATES

Poster #139 3463046

ASEPTIC LOOSENING FOLLOWING LIMB SALVAGE SURGERY FOR TUMOR: A REVIEW OF 245 PRIMARY CEMENTED STEM DISTAL FEMORAL REPLACEMENTS IMPLANTED OVER A 40-YEAR PERIOD

Danielle Greig¹, Rishi Trikha¹, Samuel Clarkson¹, Troy Sekimura¹, Adam A. Sassoon¹, Jeffrey Eckardt¹, Nicholas Bernthal¹

¹Orthopaedic Surgery, University of California, Los Angeles, Los Angeles, California, UNITED STATES

Poster #140 3463093

THE OUTCOMES AND PROGNOSTIC FACTORS IN PATIENTS WITH OSTEOASRCOMA ACCORDING TO AGE* A JAPANESE NATIONWIDE STUDY WITH FOCUSING ON THE AGE DIFFERENCES

Yusuke Tsuda¹, Hiroshi Kobayashi¹, Yusuke Shinoda¹, Sakae Tanaka¹

¹Tokyo University, Tokyo, JAPAN

Poster #141 3463134

COMBINING SHELF OSTEOTOMY WITH PROXIMAL FEMORAL RECONSTRUCTION AFTER ONCOLOGIC RESECTION

Joanne Zhou¹, Cara Lai¹, Stephanie Pun¹, Raffi Avedian¹, Robert Steffner¹

¹Orthopaedic Surgery, Stanford University, Redwood City, California, UNITED STATES

Poster #142 3463148

COMPREHENSIVE MASSIVELY PARALLEL SEQUENCING OF SARCOMAS: EXPERIENCE FROM AN AUSTRALIAN TERTIARY HOSPITAL LABORATORY AND STATE SARCOMA SERVICE

Daniel Wong¹, Tindaro Giardina¹, Cleo Robinson¹, Marc Thomas¹, Timothy Humphries², Peter Robbins¹, Anne Long², Michael Millward², Richard Carey-Smith³, Benhur Amanuel¹

¹Anatomical Pathology, PathWest, Perth, Western Australia, AUSTRALIA; ²Medical Oncology, Sir Charles Gairdner Hospital, Perth, Western Australia, AUSTRALIA; ³Orthopaedic Surgery, Sir Charles Gairdner Hospital, Perth, Western Australia, AUSTRALIA

Poster #143 3463161

TARGETING CYCLIN DEPENDENT KINASE 8 IN FUSION POSITIVE RHABDOMYOSARCOMA

Marissa Just¹, Seth Zimmerman³, Christian Cerda Smith⁴, Kris Wood³, Chris Counter³, Corinne Linardic²

¹Pediatrics, Duke University, Durham, North Carolina, UNITED STATES; ²Pediatrics and Pharmacology and Cancer Biology, Duke University, Durham, North Carolina, UNITED STATES; ³Pharmacology and Cancer Biology, Duke University, Durham, North Carolina, UNITED STATES; ⁴School of Medicine, Duke University, Durham, North Carolina, UNITED STATES

Poster #144 3463166

CLINICAL BENEFIT WITH RIPRETINIB AS ≥4TH LINE TREATMENT IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMOR: UPDATE FROM THE PHASE 3 INVICTUS STUDY

Hans Gelderblom¹, Michael Heinrich², Suzanne George³, John Zalcborg⁴, Sebastian Bauer⁵, Patrick Schöffski⁶, César Serrano⁷, Robin L. Jones⁸, Steven Attia⁹, Gina D'amato¹⁰, Ping Chi¹¹, Peter Reichardt¹², Julie Meade¹³, Vienna L. Reichert¹³, Kelvin Shi¹³, Rodrigo Ruiz-Soto¹³, Margaret von Mehren¹⁴, Jean-Yves Blay¹⁵

¹Medical Oncology, Leiden University Medical Center, Leiden, NETHERLANDS; ²OHSU Knight Cancer Institute, Portland, Oregon, UNITED STATES; ³Dana-Farber Cancer Institute, Boston, Massachusetts, UNITED STATES; ⁴Monash University, Melbourne, Victoria, AUSTRALIA; ⁵Sarcoma Center, West German Cancer Center, Essen, GERMANY; ⁶General Medical Oncology, University Hospitals Leuven, Leuven, GERMANY; ⁷Medical Oncology, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, SPAIN; ⁸Sarcoma Unit, Royal Marsden and Institute of Cancer Research, London, UNITED KINGDOM; ⁹Oncology, Mayo Clinic, Jacksonville, Florida, UNITED STATES; ¹⁰Sylvester Comprehensive Cancer Center/University of Miami, Miami, Florida, UNITED STATES; ¹¹Human Oncology and Pathogenesis Program & Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, UNITED STATES; ¹²Oncology and Palliative Care, Sarcoma Center, Helios Klinikum Berlin-Buch, Berlin, GERMANY; ¹³Deciphera Pharmaceuticals, LLC, Waltham, Massachusetts, UNITED STATES; ¹⁴Hematology Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, UNITED STATES; ¹⁵Medecine, Centre Léon Bérard, Lyon, FRANCE

Poster #145 3463185

INCIDENCE OF SARS-COV-2 IN PEDIATRIC ONCOLOGY CLINIC AT THE EPICENTER OF THE PANDEMIC

Molly M. Aguina¹, Ariel Gliksberg¹, Samantha Bents¹, Janay McKnight¹, Paul Kent¹

¹Pediatric Hematology/Oncology, Rush University Hospital, Chicago, Illinois, UNITED STATES

Poster #146 3463241

DEDIFFERENTIATION WITHIN A WELL DIFFERENTIATED LIPOSARCOMA OF THE EXTREMITY OR TRUNK – IMPLICATIONS FOR CLINICAL MANAGEMENT

William W. Tseng¹, Francesco Barretta³, Marco Baia², Marco Fiore², Alessandro Gronchi²

¹Surgery, Division of Breast, Endocrine and Soft Tissue Surgery, University of Southern California, Keck School of Medicine, Los Angeles, California, UNITED STATES; ²Surgery, Sarcoma Service, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, ITALY; ³Clinical Epidemiology and Trials Organization Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, ITALY

Poster #147 3463247

LOCAL RECURRENCE OF SOFT TISSUE SARCOMA REVISITED: IS THERE A ROLE FOR "SELECTIVE" RADIATION?

Nathan Saxby¹, Qiang An¹, Benjamin J. Miller¹

¹University of Iowa, Iowa City, Iowa, UNITED STATES

Poster #148 3463515

A NOVEL METHOD FOR THREE-DIMENSIONAL GROWTH AND ASSAY OF PAX3-FOXO1 FUSION-POSITIVE RHABDOMYOSARCOMA CELLS ENRICHES IN CANCER STEM CELL CHARACTERISTICS

Kristianne M. Oristian¹, Katherine Slemmons¹, Michael Deel², Yi-Tzu Lin², Napasorn Kuprasertku³, Lisa Crose², Katia Genadry², Po-Han Chen⁴, Jen-Tsan Ashley Chi⁴, Corinne Linardic²

¹Pediatrics-Hematology/Oncology Pharmacology & Cancer Biology, Duke University School of Medicine, Durham, North Carolina, UNITED STATES; ²Pediatrics-Hematology/Oncology, Duke University School of Medicine, Durham, North Carolina, UNITED STATES; ³Biology, Duke University, Durham, North Carolina, UNITED STATES; ⁴Molecular Genetics and Microbiology, Duke University School of Medicine, Durham, North Carolina, UNITED STATES

Poster #149 3463549

ARID1A DELETION ENHANCES OSTEOSARCOMAGENESIS IN HUMAN CELL LINES AND MURINE MODEL

Jared J. Barrott¹, Yanliang Wang², Kaniz Fatema¹, Shawn Plyler¹, Christopher Nartker¹, Kevin B. Jones²

¹Biomedical and Pharmaceutical Sciences, Idaho State University, Pocatello, Idaho, UNITED STATES; ²Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, UNITED STATES

Poster #150 3463551

EFFICACY AND SAFETY OF TAZEMETOSTAT IN PATIENTS WITH INI1/SMARCB1- OR BRG1/SMARCA4-NEGATIVE TUMORS, OR RELAPSED/REFRACTORY SYNOVIAL SARCOMA

Mrinal Gounder¹, Robin L. Jones², Silvia Stacchiotti³, Patrick Schöffski⁴, George Demetri⁵, Victor Villalobos⁶, Gregory M. Cote⁷, Mark Agulnik⁸, Rashmi Chugh⁹, Thierry Jahan¹⁰, Abha A. Gupta¹¹, Tom Wei-Wu Chen¹², Ravin Ratan¹³, Palma Dileo¹⁴, Jay Yang¹⁵, E. Argon¹⁵, Shefali Agarwal¹⁵, Nizar M Tannir¹³

¹Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York, UNITED STATES; ²Royal Marsden Hospital and Institute of Cancer Research, London, UNITED KINGDOM; ³Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, ITALY; ⁴University Hospitals Leuven, Department of General Medical Oncology, and Laboratory of Experimental Oncology, KU Leuven, Leuven Cancer Institute, Leuven, BELGIUM; ⁵Dana Farber Cancer Institute and Ludwig Center at Harvard Medical School, Boston, Massachusetts, UNITED STATES; ⁶University of Colorado Denver, Denver, Colorado, UNITED STATES; ⁷Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, UNITED STATES; ⁸Northwestern University, Feinberg School of Medicine, Chicago, Illinois, UNITED STATES; ⁹Michigan Medicine Comprehensive Cancer Center, Ann Arbor, Michigan, UNITED STATES; ¹⁰University of California San Francisco, San Francisco, California, UNITED STATES; ¹¹The Hospital for Sick Children and Princess Margaret Cancer Center, Toronto, Ontario, CANADA; ¹²National Taiwan University Hospital, Taipei City, TAIWAN; ¹³MD Anderson Cancer Center, Houston, Texas, UNITED STATES; ¹⁴University College London Hospitals, London, UNITED KINGDOM; ¹⁵Epizyme, Cambridge, Massachusetts, UNITED STATES

Poster #151 3463563

BIOMARKERS FOR DELTAREX-G, THE SAFER CHECKPOINT INHIBITOR FOR SARCOMA: A SINGLE CENTER EXPERIENCE

Paul S. Dy¹, Kelly Wang¹, Ted T. Kim¹, Sant P. Chawla¹, Sheng Xiao², Frederick L. Hall³, Erlinda M. Gordon¹

¹Sarcoma Oncology Center, Santa Monica, California, UNITED STATES; ²Cytogenetics Laboratory, Brigham and Womens Hospital, Boston, Massachusetts, UNITED STATES; ³Oncology, Delta Next-Gene, LLC, Santa Monica, California, UNITED STATES

Poster #152 3463590

TARGETING SPHINGOLIPID METABOLISM IN SYNOVIAL SARCOMA

Jared J. Barrott¹, Sarah Luelling¹, Farjana Afrin¹, Adriene Pavek¹, Austen Kalivas¹, Srinath Pashikanti¹

¹Biomedical and Pharmaceutical Sciences, Idaho State University, Pocatello, Idaho, UNITED STATES

Poster #153 3463619

30-YEAR FOLLOW-UP RESULTS OF 170 CEMENTED ENDOPROTHETIC RECONSTRUCTIONS FOR TUMORS OF THE UPPER EXTREMITY

Danielle Greig¹, Rishi Trikha¹, Troy Sekimura¹, Michael Arnold¹, Jeffrey Eckardt¹, Nicholas Bernthal¹

¹Orthopaedic Surgery, University of California, Los Angeles, Los Angeles, California, UNITED STATES

Poster #154 3463673

ACIDIC MICROENVIRONMENTS IN SOFT TISSUE SARCOMA PROMOTES FOXM1 EXPRESSION AND TUMORIGENESIS

Toshihiko Nishisho¹, Shunichi Toki¹, Ryo Miyagi¹, Koichi Sairyo¹

¹Orthopedics, Tokushima University, Tokushima, JAPAN

Poster #155 3463677

KAPOSI SARCOMA AFTER SOLID ORGAN TRANSPLANTATION, A SINGLE CENTRE EXPERIENCE

Sara Damaso¹, Raquel L. Brás¹, Cecilia M. Alvim¹, Pedro M. Garrido², Luis Costa¹, João Borges-Costa², Isabel Fernandes¹

¹Medical Oncology Department, Centro Hospitalar Universitário Lisboa Norte – Hospital Santa Maria, Lisboa, PORTUGAL; ²Dermatology Department, Centro Hospitalar Universitário Lisboa Norte – Hospital Santa Maria, Lisboa, PORTUGAL

Poster #156 3463723

NEOADJUVANT CHEMORADIOTHERAPY IN ADVANCED SOFT TISSUE SARCOMA: NASAR STUDY

Jeronimo Martinez-Garcia¹, Pablo Puertas-Sandoval², Antonio Valcarcel², Juan Angel Fernandez³, Pilar Sanchez-Henarejos¹, Ana Puertes¹, M Dolores Jimenez¹, Ana Sanchez-Saura¹, Jose Emilio Hernandez⁴, David Lopez⁴, M Dolores Abellan⁵, Andres Lopez-Sanchez⁵, Begoña Torregrosa⁵, Isabel de la Fuente⁶, Enrique Cardenas⁶, Jose Luis Navarro⁷, Clemente Fernandez-Pascual⁸, M Jose Roca⁹, Thelmo Quiros¹, Antia Lopez¹, Domingo Sanchez¹, Irene Martinez¹, Blanca Sanchez¹, Jose Luis Alonso¹

¹Medical Oncology, Clinical University Hospital Virgen de la Arrixaca, El Palmar, Murcia, SPAIN; ²Traumatologia, Clinical University Hospital Virgen de la Arrixaca, Murcia, SPAIN; ³Surgery, Clinical University Hospital Virgen de la Arrixaca, Murcia, SPAIN; ⁴Pathology, Clinical University Hospital Virgen de la Arrixaca, Murcia, SPAIN; ⁵Radiology, Clinical University Hospital Virgen de la Arrixaca, Murcia, SPAIN; ⁶Raditherapy, Clinical University Hospital Virgen de la Arrixaca, Murcia, SPAIN; ⁷Nuclear Medicine, Clinical University Hospital Virgen de la Arrixaca, Murcia, SPAIN; ⁸Plastic Surgery, Clinical University Hospital Virgen de la Arrixaca, Murcia, SPAIN; ⁹Thoracic Surgery, Clinical University Hospital Virgen de la Arrixaca, Murcia, SPAIN

Poster #157 3463757

GENOMIC LANDSCAPE OF METASTATIC SOFT TISSUE SARCOMA

Erik Wiemer¹, Melissa Vos¹, Harmen J. van de Werken², Job van Riet², Neeltje Steeghs³, Martijn P. Lolkema¹, Carla M. van Herpen⁴, Derk J. de Groot⁵, Hans Gelderblom⁶, Vivianne C. Tjan-Heijnen⁷, Edwin Cuppen⁸, Stefan Sleijfer¹

¹Medical Oncology, Erasmus Medical Center, Rotterdam, NETHERLANDS; ²Cancer Computational Biology Center, Erasmus Medical Center, Rotterdam, NETHERLANDS; ³Medical Oncology, Antoni van Leeuwenhoek - Netherlands Cancer Institute, Amsterdam, NETHERLANDS; ⁴Medical Oncology, Radboud University Medical Center, Nijmegen, NETHERLANDS; ⁵Medical Oncology, University Medical Center Groningen, Groningen, NETHERLANDS; ⁶Medical Oncology, Leiden University Medical Center, Leiden, NETHERLANDS; ⁷Medical Oncology, Maastricht University Medical Center, Maastricht, NETHERLANDS; ⁸Center for Molecular Medicine and OncoCode Institute, University Medical Center Utrecht, Utrecht, NETHERLANDS

Poster #158 3463788

IDENTIFICATION AND AUTHENTICATION OF A NOVEL "FET/ETS" FUSION ONCOPROTEIN IN EWING SARCOMA

Mark Winstanley², **Megann Boone**¹, Cenny Taslim¹, Mike Watson³, James Hamil², Peter Heppner², Andrew Wood², Jesse Crow¹, Julia Selich-Anderson¹, Stephen L. Lessnick¹

¹Center for Childhood Cancer, Nationwide Children's Hospital, Columbus, Ohio, UNITED STATES; ²Starship Paediatric Blood & Cancer Centre, Auckland, NEW ZEALAND; ³LabPlus, Auckland District Health Board, Auckland, NEW ZEALAND

Poster #159 3463800

CUTANEOUS ANGIOSARCOMA: CLINICAL AND MOLECULAR PROFILE AND IMMUNOTHERAPY IN A CASE SERIES

Jacob N. Stein¹, Francie Jenkins², Stergios Moschos¹, Paul Googe³, Bradley Merritt², Juneko E. Grilley-Olson¹

¹Medicine/Oncology, UNC Chapel Hill, Durham, North Carolina, UNITED STATES; ²School of Medicine, University of North Carolina, CHAPEL HILL, North Carolina, UNITED STATES; ³Dermatology, Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, North Carolina, UNITED STATES

Poster #160 3463802

FEWER THAN TWO PULMONARY MICRONODULES IDENTIFIED ON PRESENTATION IN PATIENTS WITH OSTEOSARCOMA HAVE NO EFFECT ON 5 YEAR OVERALL SURVIVAL

Reid Davison¹, Fadi Hamati¹, Paul Kent¹

¹College of Medicine, Rush Medical College, Chicago, Illinois, UNITED STATES

Poster #161 3463844

MALIC ENZYME 1 ABSENCE IN SYNOVIAL SARCOMA ALTERS GLUCOSE METABOLISM AND THE GLUTATHIONE-THIOREDOXIN AXIS

Caitlyn B. Brashears¹, Bethany Prudner¹, Richa Rathore¹, Anthony Robinson¹, Brian A. Van Tine¹

¹Oncology, Washington University in St. Louis School of Medicine, St. Louis, Missouri, UNITED STATES

Poster #162 3463876

PROXIMAL FEMORAL REPLACEMENT IN THE TREATMENT OF ONCOLOGIC DISORDERS OF THE PROXIMAL FEMUR: THE EXPERIENCE OF A SINGLE INSTITUTION

Charles Gusho¹, Bishir Clayton¹, Mick P. Kelly¹, Pedro Escobedo¹, Matthew Colman¹, Steven Gitelis¹, Alan Blank¹

¹Department of Orthopedics, Division of Orthopedic Oncology, Rush University Medical Center, Chicago, Illinois, UNITED STATES

Poster #163 3463885

DISTAL FEMORAL REPLACEMENT FOR TREATMENT OF ONCOLOGIC DISORDERS OF THE LOWER EXTREMITY: THE EXPERIENCE OF A SINGLE INSTITUTION

Charles Gusho¹, Bishir Clayton¹, Joshua Greenspoon¹, Jonathan Bauer¹, Matthew Colman¹, Steven Gitelis¹, Alan Blank¹

¹Department of Orthopedics, Division of Orthopedic Oncology, Rush University Medical Center, Chicago, Illinois, UNITED STATES

Poster #164 3463926

LURBINECTEDIN IN COMBINATION WITH IRINOTECAN IN PATIENTS (PTS) WITH SOFT TISSUE SARCOMAS (STS)

Gregory M. Cote², Santiago Ponce³, Alejandro F. Falcon⁴, Inmaculada Sánchez Simón³, Elisabeth Jimenez³, Rafael Nunez¹, Javier Gómez¹, Jesús R Fernández¹, Martin Cullell-Young¹, Carmen Kahatt¹, Ali Zeaiter¹, Luis Paz-Ares³

¹PharmaMar, Madrid, Colmenar Viejo, SPAIN; ²Massachusetts General Hospital, Boston, Massachusetts, UNITED STATES;

³Hospital Universitario 12 de Octubre, Madrid, SPAIN; ⁴Hospital Universitario Virgen del Rocío, Sevilla, SPAIN

Poster #165 3463955

SPATIAL DETECTION OF CELLULAR CROSS-PRESENTATION AS A PROGNOSTIC TOOL IN SOFT TISSUE SARCOMA

Monika Ehnman¹, Panagiotis Tsagkozis², Yanhong Su¹, Nicholas P. Tobin¹, Okan Gultekin³, Anna Malmerfelt¹, Katrine Ingelshed³, Johanna Lundquist¹, Wiem Chaabane¹, Maya H. Nisancioglu¹, Lina W. Leiss¹, Arne Östman^{1,4}, Jonas Bergh^{1,5}, Kaisa Lehti^{3,6}, Saikiran Sedimbi³, Felix Haglund¹

¹Department of Oncology-Pathology, Karolinska Institutet, Stockholm, SWEDEN; ²Department of Molecular Medicine and Surgery, Karolinska Institutet and Muskuloskeletal Tumor Service, Karolinska University Hospital, Stockholm, SWEDEN;

³Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, SWEDEN; ⁴Centre for Cancer Biomarkers CCBIO, University of Bergen, Bergen, NORWAY; ⁵Department of Oncology-Pathology, Karolinska Institutet, Radiumhemmet, Karolinska University Hospital, Stockholm, SWEDEN; ⁶Department of Biomedical Laboratory Science, Norwegian University of Science and Technology, Trondheim, NORWAY

Poster #166 3464017

DEMOGRAPHICS AND OUTCOME OF PATIENTS WITH ADULT HEAD AND NECK SARCOMA: THE OTTAWA EXPERIENCE

Taylor Barrett¹, Samy El-Sayed², Prudence Buchanan¹, Ionut Busca¹

¹The Ottawa Hospital Research Assistant, Ottawa, Ontario, CANADA; ²University of Ottawa, Ottawa, Ontario, CANADA

Poster #167 3464033

RIPRETINIB DEMONSTRATED ACTIVITY ACROSS ALL KIT/PDGFR α MUTATIONS IN PATIENTS WITH FOURTH-LINE ADVANCED GASTROINTESTINAL STROMAL TUMOR: ANALYSIS FROM THE PHASE 3 INVICTUS STUDY

Patrick Schöffski¹, Sebastian Bauer², Michael Heinrich³, Suzanne George⁴, John Zalberg⁵, Hans Gelderblom⁶, César Serrano⁷, Robin L. Jones⁸, Steven Attia⁹, Gina D'amato¹⁰, Ping Chi¹¹, Peter Reichardt¹², Julie Meade¹³, Kelvin Shi¹³, Ying Su¹³, Rodrigo Ruiz-Soto¹³, Margaret von Mehren¹⁴, Jean-Yves Blay¹⁵

¹General Medical Oncology, University Hospitals Leuven, Leuven, BELGIUM; ²Sarcoma Center, West German Cancer Center, Essen, GERMANY; ³Hematology/Medical Oncology, OHSU Knight Cancer Institute, Portland, Oregon, UNITED STATES; ⁴Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, UNITED STATES; ⁵School of Public Health, Faculty of Medicine, Monash University, Melbourne, Victoria, AUSTRALIA; ⁶Medical Oncology, Leiden University Medical Center, Leiden, NETHERLANDS; ⁷Medical Oncology, Vall d'Hebron Institute of Oncology, Barcelona, SPAIN; ⁸Sarcoma Unit, Royal Marsden and Institute of Cancer Research, London, UNITED KINGDOM; ⁹Oncology, Mayo Clinic, Jacksonville, Florida, UNITED STATES; ¹⁰Medical Oncology, Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida, UNITED STATES; ¹¹Human Oncology and Pathogenesis Program & Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, UNITED STATES; ¹²Oncology and Palliative Care, Sarcoma Center, Helios Klinikum Berlin-Buch, Berlin, GERMANY; ¹³Deciphera Pharmaceuticals, LLC, Waltham, Massachusetts, UNITED STATES; ¹⁴Hematology Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, UNITED STATES; ¹⁵Centre Leon Berard, Lyon, FRANCE

Poster #168 3464034

REFINING THE APPROACH TO PATIENTS WITH PRIMARY SOFT TISSUE SARCOMA OF THE EXTREMITIES AND TRUNK WALL (ESTSTS): OUTCOME IMPROVEMENT OVER 30 YEARS AT A SINGLE INSTITUTION

Maria Danielli², Francesco Barretta¹, Marco Fiore², Stefano Radaelli², Claudia Sangalli⁴, Marta Barisella⁵, Silvia Stacchiotti³, Elena Palassini³, Rosalba Miceli¹, Dario Callegaro², Paolo Giovanni Casali³, Alessandro Gronchi²

¹Department of Clinical Epidemiology and Trial Organisation, Istituto Nazionale dei Tumori, Milan, ITALY; ²Surgery, Istituto Nazionale dei Tumori, Milan, ITALY; ³Department of Cancer Medicine, Istituto Nazionale dei Tumori, Milan, ITALY; ⁴Radiotherapy, Istituto Nazionale dei Tumori, Milan, ITALY; ⁵Pathology, Istituto Nazionale dei Tumori, Milan, ITALY

Poster #169 3464091

CARDIOTOXICITY AMONG PATIENTS WITH SARCOMA TREATED WITH DOXORUBICIN: A REAL-WORLD DATABASE STUDY

Lee D. Cranmer², Lisa M. Hess¹, Tomoko Sugihara³, Yajun E. Zhu¹, Howard G. Muntz¹

¹Eli Lilly and Company, Indianapolis, Indiana, UNITED STATES; ²University of Washington, Seattle, Washington, UNITED STATES; ³Syneos Health, Austin, Texas, UNITED STATES

Poster #170 3464158

NOVEL GENE FUSIONS IN PEDIATRIC RHABDOMYOSARCOMAS

Kelsi Willis¹, Naseem Uddin¹, Jason Park¹, **Dinesh Rakheja**¹

¹Pathology, University of Texas Southwestern Medical Center, Dallas, Texas, UNITED STATES

Poster #171 3464160

A NOVEL PATIENT-DERIVED, AGGRESSIVE, EXTRAOSSEOUS EWING SARCOMA CELL LINE

Kelsi Willis¹, Lindsay Mendyka², Lane Beeman², Patricia Tiburcio², Deyssy Carrillo³, Jennifer Wagenfuehr³, Jason Park¹, Kenneth Chen², **Dinesh Rakheja**¹

¹Pathology, University of Texas Southwestern Medical Center, Dallas, Texas, UNITED STATES; ²Pediatrics, University of Texas Southwestern Medical Center, Dallas, Texas, UNITED STATES; ³Pathology, Children's Health, Dallas, Texas, UNITED STATES

Poster #172 3464216

SOFT-TISSUE SARCOMA IN ELDERLY PATIENTS: PATTERNS OF CARE AND SURVIVAL

Toshihiko Nishisho¹, Shunichi Toki¹, Ryo Miyagi¹, Koichi Sairyō¹

¹Orthopedics, Tokushima Prefectural Central Hospital, Tokushima, JAPAN

Poster #173 3464222

THE FREQUENCY OF TP53 GERMLINE PATHOGENIC VARIANTS IN RHABDOMYOSARCOMA EXHIBITING ANAPLASIA: A REPORT FROM THE CHILDREN'S ONCOLOGY GROUP

Douglas Fair¹, Luke Maese¹, Yueh-Yun Chi², Minjie Li³, Douglas S. Hawkins⁴, Rajkumar Venkatramani⁵, Erin Rudzinski⁶, David Parham⁷, Lisa Teot⁸, David Malkin⁹, Sharon Plon¹⁰, **Hurley Li**¹³, Aniko Sabo¹¹, Philip Lupo¹², Joshua Schiffman¹
¹Pediatrics, University of Utah, Primary Children's Hospital | Huntsman Cancer Institute, Salt Lake City, Utah, UNITED STATES; ²Pediatric and Preventative Medicine, University of Southern California, Los Angeles, California, UNITED STATES; ³Statistics and Data Center, Children's Oncology Group, Gainesville, Florida, UNITED STATES; ⁴Fred Hutchinson Cancer Research Center, Seattle Children's Hospital, Seattle, Washington, UNITED STATES; ⁵Department of Pediatrics, Baylor College of Medicine, Texas Children's Hospital, Houston, Texas, UNITED STATES; ⁶Department of Laboratories, Seattle Children's Hospital, Seattle, Washington, UNITED STATES; ⁷Pathology and Laboratory Medicine, Children's Hospital Los Angeles and Keck School of Medicine, Los Angeles, California, UNITED STATES; ⁸Pathology, Boston Children's Hospital, Boston, Massachusetts, UNITED STATES; ⁹Pediatrics, The Hospital for Sick Children, Toronto, Ontario, CANADA; ¹⁰Pediatrics, Baylor College of Medicine, Houston, Texas, UNITED STATES; ¹¹Human Genome Sequencing Center, Baylor College of Medicine, Houston, Texas, UNITED STATES; ¹²Division of Hematology/Oncology, Department of Pediatrics, Baylor College of Medicine, Houston, Texas, UNITED STATES; ¹³Human Genome Sequencing Center, Baylor College of Medicine, Houston, Texas, UNITED STATES

Poster #174 3464228

OSTEOSARCOMA HEALTH LITERACY: A QUANTITATIVE ASSESSMENT OF ONLINE PATIENT EDUCATION MATERIAL

Trevor R. Gulbrandsen¹, Mary K. Skalitzky¹, Alan Shamrock¹, Burke Gao¹, Obada Hasan¹, Benjamin J. Miller¹
¹Orthopedic Surgery, University of Iowa Hospitals and Clinics, Iowa City, Iowa, UNITED STATES

Poster #175 3464247

DEMOGRAPHICS AND OUTCOME OF PATIENTS WITH GYNAE SARCOMA (GS), THE OTTAWA EXPERIENCE

Samy El-Sayed¹, Prudence Buchanan¹
¹Radiation Oncology, University of Ottawa, Ottawa, Ontario, CANADA

Poster #176 3464274

MIFAMURTIDE CUMULATIVE DOSE AND PROGNOSIS IN THE ADJUVANT TREATMENT OF PATIENTS WITH NON METASTATIC EXTREMITY HIGH GRADE OSTEOSARCOMA: RESULTS OF THE ITALIAN SARCOMA GROUP (ISG), MULTICENTRIC, PROSPECTIVE, ISG/OS-2 TRIAL

Emanuela Palmerini¹, Cristina Meazza², Angela Tamburini³, Gianni Bisogno⁴, Virginia Ferraresi⁵, Sebastian Asaftei⁶, Giuseppe Maria Milano⁷, Luca Coccoli⁸, Carla Manzitti⁹, Roberto Luksch², Davide M. Donati¹, Massimo Serra¹, Rossella Bertulli², Marco Gambarotti¹, Claudio Favre¹⁰, Alessandra Longhi¹, Massimo Eraldo Abate¹¹, Silverio Perrotta¹², Maurizio Mascarin¹³, Paolo D'angelo¹⁴, Marilena Cesari¹, Paolo Giovanni Casali², Piero Picci¹⁵, Franca Fagioli¹⁶, Stefano Ferrari¹
¹IRCCS Istituto Ortopedico Rizzoli, Bologna, ITALY; ²IRCCS Istituto Nazionale dei Tumori, Milan, ITALY; ³Azienda Ospedaliera Universitaria A. Meyer, Florence, ITALY; ⁴Clinica di Oncoematologia Pediatrica,, Padua, ITALY; ⁵Istituto Nazionale Tumori Regina Elena, Rome, ITALY; ⁶Ospedale Infantile Regina Margherita,, Turin, ITALY; ⁷L' Ospedale Pediatrico Bambino Gesù, Rome, ITALY; ⁸Azienda Ospedaliera Universitaria Pisana, Pisa, ITALY; ⁹IRCCS Istituto G. Gaslini - Ospedale Pediatrico, Genoa, ITALY; ¹⁰Azienda Ospedaliera Universitaria A. Meyer, Pisa, ITALY; ¹¹Ospedale Pausillipon, Naples, ITALY; ¹²AOU Università degli Studi della Campania "Luigi Vanvitelli, Napli, ITALY; ¹³CRO, Aviano, ITALY; ¹⁴Oncoematologia Pediatrica Palermo, Palermo, ITALY; ¹⁵Italian Sarcoma Group, Bologna, ITALY; ¹⁶Ospedale Infantile Regina Margherita, Turin, ITALY

Poster #177 3464351

PAZOPANIB IN METASTATIC BONE SARCOMAS - A UNICENTRIC RETROSPECTIVE ANALYSIS AT A TERTIARY UNIVERSITY HOSPITAL

Raquel L. Brás¹, Sara Damaso¹, Rita Paiva¹, Daniela Macedo¹, Luis Costa¹, Isabel Fernandes¹
¹Oncology, Hospital Santa Maria, CHULN, Lisboa, PORTUGAL

Poster #178 3464362

PROGNOSIS OF PATIENTS WITH GENITO-URINARY SOFT TISSUE SARCOMAS (GUSTS), 10 YEARS EXPERIENCES IN A TERTIARY CARE CANCER CENTRE.

Samy El-Sayed¹, Prudence Buchanan¹

¹Radiation Oncology, University of Ottawa, Ottawa, Ontario, CANADA

Poster #179 3464399

RADIATION-INDUCED SARCOMA: A RETROSPECTIV POPULATION-BASED STUDY OVER 34 YEARS IN A SINGLE INSTITUTION

Louise Bach Callesen¹, Akmal Safwat¹, Thomas Baad Hansen², Flemming Brandt Sørensen³, Hanne Krog Rose¹, **Ninna Aggerholm-Pedersen¹**

¹Department of Oncology, Aarhus University Hospital, Aarhus, DENMARK; ²Department of Orthopaedic Surgery, Aarhus University Hospital, Aarhus, DENMARK; ³Department of Pathology, Aarhus University Hospital, Aarhus, DENMARK

Poster #180 3464414

FAVORABLE INITIAL TUMOR RESPONSE WITH COMBINATION CABOZANTINIB AND NIVOLUMAB IN STAGE 4 ALVEOLAR SOFT PART SARCOMA

Kristen Obiakor¹, Alicia Obiakor², Paul Kent¹

¹Pediatric Hematology/Oncology, Rush University Medical Center, Chicago, Illinois, UNITED STATES;

²Shorewood High School, Shorewood, Wisconsin, UNITED STATES

Poster #181 3464415

UNDERSTANDING A RARE SUBTYPE: A REVIEW OF 46 PATIENTS WITH GASTROINTESTINAL LEIOMYOSARCOMA TREATED AT A TERTIARY CARE CENTRE

Alannah Smrke¹, Myles Smith¹, Dirk Strauss¹, Andrew Hayes¹, Khin Thway¹, Cyril Fisher², Christina Messiou¹, Charlotte Benson¹, Robin L. Jones¹

¹The Royal Marsden Hospital, London, UNITED KINGDOM; ²University Hospitals Birmingham, Birmingham, UNITED KINGDOM

Poster #182 3464422

POSTERIOR KNEE ARTHROSCOPY FOR PIGMENTED VILLONODULAR SYNOVITIS UTILIZING ULTRASOUND GUIDANCE

Lee M. Zuckerman¹, Hasan M. Syed⁴, Nadine L. Williams³, Christopher M. Jobe²

¹Orthopaedic Surgery, City of Hope National Medical Center, Duarte, California, UNITED STATES; ²Orthopaedic Surgery, Oroville Hospital, Oroville, California, UNITED STATES; ³Orthopaedic Surgery, Loma Linda University Medical Center, Loma Linda, California, UNITED STATES; ⁴Orthopaedic Surgery, VA Loma Linda Healthcare System, Loma Linda, California, UNITED STATES

Poster #183 3464440

USE OF MAGNETIC GROWING INTRAMEDULLARY NAILS WITH INTERCALARY ALLOGRAFT RECONSTRUCTION AFTER TUMOR RESECTION

Lee M. Zuckerman¹, Nadine L. Williams²

¹Orthopaedic Surgery, City of Hope National Medical Center, Duarte, California, UNITED STATES;

²Orthopaedic Surgery, Loma Linda University Medical Center, Loma Linda, California, UNITED STATES

Poster #184 3464444

ONCOLOGIC INDICATIONS FOR ELECTROMAGNETIC INTRAMEDULLARY NAILS

Lee M. Zuckerman¹

¹Orthopaedic Surgery, City of Hope National Medical Center, Duarte, California, UNITED STATES

Poster #185 3464465

SUPPORTING CLINICAL DECISION-MAKING FOR PI3K/AKT/MTOR INHIBITORS FOR HIGH-RISK PAEDIATRIC AND AYA SARCOMA

Emmy D. Fleuren¹, Emmy Dolman¹, Loretta Lau¹, Jinhan Xie¹, Daniel Batey¹, Chelsea Mayoh¹, Paulette Barahona¹, Alexandra Sherstyuk¹, Dong Anh Khuong Quang², Marie Wong¹, ZERO Preclinical Drug Testing Team¹, ZERO Omics Team¹, David Thomas³, Emily Mould¹, Murray Norris¹, Michelle Haber¹, Toby Trahair¹, Glenn Marshall¹, David Ziegler¹, Vanessa Tyrrell¹, Mark Cowley¹, Richard Lock¹, Paul G. Ekert¹

¹Personalised Medicine, Children's Cancer Institute, Sydney, New South Wales, AUSTRALIA; ²Royal Children's Hospital, Melbourne, Victoria, AUSTRALIA; ³Garvan Institute of Medical Research, Sydney, New South Wales, AUSTRALIA

Poster #186 3464494

ADJUVANT PALBOCICLIB FOR THE PREVENTION OF LOCAL RECURRENCE IN RESECTED LIPOSARCOMA

Luke V. Selby¹, David A. Liebner¹, James Chen¹, Gabriel Tinoco¹, Joal Beane¹, Raph Pollock¹, Valerie Grignol¹

¹Medical Oncology, The Ohio State University, Columbus, Ohio, UNITED STATES

Poster #187 3464514

EARLY DIAGNOSIS OF UTERINE SARCOMA IS ASSOCIATED WITH GRAVIDITY, PARITY, AND HISPANIC ETHNICITY

Caroline Hana¹, Gina D'amato², Jonathan Trent²

¹Internal Medicine, University of Miami, Boynton Beach, Florida, UNITED STATES; ²Oncology, University of Miami, Miami, Florida, UNITED STATES

Poster #188 3464550

TRANSFORMED CANINE AND MURINE MESENCHYMAL STEM CELLS AS A MODEL FOR HIGH GRADE SARCOMA WITH COMPLEX GENOMICS

Natasja Franceschini¹, Bas Verbruggen¹, Marianna Tryfonidou², Alwine B. Kruisselbrink¹, Hans Baelde¹, Karin de Visser³, Karoly Szuhai¹, Anne-Marie Cleton-Jansen¹, Judith V. Bovee¹

¹Leiden University Medical Center, Leiden, NETHERLANDS; ²Utrecht University, Utrecht, NETHERLANDS;

³Netherlands Cancer Institute, Amsterdam, NETHERLANDS

Poster #189 3464563

PATIENT ADVOCATES TRANSFORMING SARCOMA CARE IN INDIA

Priyanka Banga¹, Pankaj Banga¹

¹Sarcoma Cancer Care Foundation, Faridabad, INDIA

Poster #190 3464611

CHARACTERIZING THE EFFICACY OF IMMUNE CHECKPOINT INHIBITOR-BASED TREATMENT IN SELECTIVE SUBTYPES OF ADVANCED SARCOMA PATIENTS

Yang You¹, Xi Guo¹, Rongyuan Zhuang¹, Chenlu Zhang¹, Zhiming Wang¹, Feng Shen¹, Yan Wang¹, Yong Zhang¹, Weiqi Lu¹, Yingyong Hou¹, **Yuhong Zhou**¹

¹Oncology Department, Zhongshan Hospital, Shanghai, Shanghai, CHINA

Poster #191 3464643

IMMUNE-MATRIX GENE EXPRESSION SIGNATURES OF CYTOKINES, CHEMOKINES, IMMUNE CHECKPOINTS, MATRIX METALLOPROTEINASES AND TISSUE INHIBITORS OF METALLOPROTEINASES IN FORMALIN-FIXED PARAFFIN-EMBEDDED HUMAN CHONDROSARCOMA SAMPLES

Paulo Rodrigues-Santos², Patricia Couceiro², Jani Sofia Almeida¹, Paulo Freitas-Tavares³, José Manuel Casanova³

¹Instituto de Imunologia, Faculdade de Medicina da Universidade de Coimbra, Coimbra, PORTUGAL; ²Laboratório de Imunologia e Oncologia, Centro de Neurociencias e Biologia Celular, Universidade de Coimbra, Coimbra, PORTUGAL;

³Unidade de Tumores do Aparelho Locomotor, Serviço de Ortopedia, Centro Hospitalar e Universitário de Coimbra, Coimbra, PORTUGAL

Poster #192 3464670

THE MUSCULOSKELETAL TUMOR REGISTRY: LESSONS, BARRIERS, AND FUTURE GOALS

Benjamin J. Miller¹, Eric Henderson², Adam Levin³, George Calvert⁴, Joel Mayerson⁵, Nathan Mesko⁶, Lukas Nystrom⁶, Robert Steffner⁷

¹University of Iowa, Iowa City, Iowa, UNITED STATES; ²Dartmouth, Lebanon, New Hampshire, UNITED STATES;

³Johns Hopkins, Baltimore, Maryland, UNITED STATES; ⁴Norton, Louisville, Kentucky, UNITED STATES; ⁵Ohio State, Columbus, Ohio, UNITED STATES; ⁶Cleveland Clinic, Cleveland, Ohio, UNITED STATES; ⁷Stanford, Redwood City, California, UNITED STATES

Poster #193 3464730

PATTERN OF PRESENTATIONS, OUTCOME OF TREATMENT, AND PATTERN OF FAILURE OF PATIENTS WITH GASTROINTESTINAL ADULT SOFT TISSUE SARCOMAS: A 10 YEARS' EXPERIENCE IN A TERTIARY CANCER CENTRE

Dalia Ibrahim¹, Prudence Buchanan¹, Samy El-Sayed²

¹Ottawa Hospital Research Institute, Ottawa, Ontario, CANADA; ²University of Ottawa, Ottawa, Ontario, CANADA

Poster #194 3464830

ASSOCIATIONS OF KNOWN SUSCEPTIBILITY LOCI AND GENETIC ANCESTRY ON EWING SARCOMA RISK IN LATINOS

Brandon Diessner¹, Patrick Monnahan¹, Brenda Weigel¹, Stephen Lessnick², Joshua Schiffman³, Logan Spector¹

¹University of Minnesota, Minneapolis, Minnesota, UNITED STATES; ²Nationwide Children's Hospital, Columbus, Ohio, UNITED STATES; ³Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, UNITED STATES

Poster #195 3464895

DETERMINING THE CONTRIBUTIONS OF GENES CO-EXPRESSED WITH PD-L1 IN UNDIFFERENTIATED PLEOMORPHIC SARCOMA (UPS) CASES IN THE TUMOUR-IMMUNE MICROENVIRONMENT

Victoria Coward¹, Alice Ko², Maisha Syed⁵, Nalan Gokgoz³, Jay Wunder⁴, Irene Andrulis¹

¹Molecular Genetics, University of Toronto, Toronto, Ontario, CANADA; ²Laboratory Medicine and Pathology, University of Toronto, Toronto, Ontario, CANADA; ³Lunenfeld-Tanenbaum Research Institute, Toronto, Ontario, CANADA; ⁴Mount Sinai Hospital, Toronto, Ontario, CANADA; ⁵Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, CANADA

Poster #196 3464925

SARCOMA OF BONE ABOUT THE KNEE AND LIMB LENGTH IN PRE-ADOLESCENT PATIENTS: ALL OPTIONS STILL ON THE TABLE

Sean P. Kelly², Dipak B. Ramkumar², Brooke Crawford³, Santiago A. Lozano-Calderon¹, Megan E. Anderson², Mark C. Gebhardt²

¹Massachusetts General Hospital, Powhatan, Virginia, UNITED STATES; ²Boston Childrens Hospital, Boston, Massachusetts, UNITED STATES; ³UCLA Medical Center, Santa Monica, California, UNITED STATES

Poster #197 3464936

REPEAT SURGICAL RESECTION FOR PATIENTS WITH RE-RECURRENT RETROPERITONEAL LIPOSARCOMA

Wenqing Liu¹, Jun Chen¹, Chengli Miao¹, Mei Huang¹, Yue Hu², Chenghua Luo¹

¹Dept. of Retroperitoneal Tumor Surgery, Peking University International Hospital, Beijing, CHINA; ²Beijing Spanal Medical Scientific Co. Ltd., Beijing, CHINA

Poster #198 3464946

PATTERNS OF FAILURE IN PATIENTS WITH MYXOFIBROSARCOMA TREATED WITH PERIOPERATIVE RADIATION

Yu M. Zhou¹, Alan Blank², Yixiang Liao¹, Steven Gitelis², Matthew Colman², Marta Batus², Dian Wang¹

¹Radiation Oncology, Rush University Medical Center, Chicago, Illinois, UNITED STATES; ²Rush University Medical Center, Chicago, Illinois, UNITED STATES

Poster #199 3464982

ATRX PROMOTES AGGRESSIVE FEATURES OF OSTEOSARCOMA ACROSS SPECIES

Suzanne Bartholf DeWitt¹, Sarah Hoskinson¹, Dharshan Sivaraj¹, Elaina J. Martz¹, Maya Sheth¹, Hailey E. Brighton¹, Robert W. Floyd², Brian E. Brigman¹, Ben Alman¹, Jason A. Somarelli², William C. Eward¹

¹Orthopaedic Surgery, Duke University, Durham, North Carolina, UNITED STATES; ²Medicine, Duke University, Durham, North Carolina, UNITED STATES

Poster #200 3465022

TREATMENT STRATEGIES IN PATIENTS WITH DESMOPLASTIC SMALL ROUND CELL TUMORS (DSRCT) IN THE FIRST LINE SETTING: A SYSTEMATIC REVIEW

Tomás J. Soulé¹, Federico Waisberg¹, Martin Angel¹, Andres Rodriguez¹, Yanina Pfluger¹, Matias Chacon¹

¹Oncology, Instituto Alexander Fleming, Ciudad Autonoma de Buenos Aires, ARGENTINA

Poster #201 3465049

THE PROGNOSTIC VALUE OF A NEW 4 GENE MOLECULAR PROFILE OF SEVERE HYPOXIA IN LOCALIZED HIGH GRADE SOFT TISSUE SARCOMA PATIENTS

Ninna Aggerholm-Pedersen¹, Anna Jensen², Steffen Nielsen², Akmal Safwat¹, Brita Singer Sørensen²

¹Department of Oncology, Aarhus University Hospital, Aarhus N, DENMARK; ²Department of Experimental Clinical Oncology, Aarhus University Hospital, Aarhus N, DENMARK

Poster #202 3465050

**THE DIAGNOSIS AND MANAGEMENT OF GASTROINTESTINAL STROMAL TUMORS IN INDIA:
A SCOPING REVIEW**

Azgar A. Rasheed¹, Sameer Rastogi¹

¹Medical Oncology, All India Institute of Medical Sciences, New Delhi, New Delhi, INDIA

Poster #203 3465057

**THE DIAGNOSIS AND MANAGEMENT OF GASTROINTESTINAL STROMAL TUMORS IN INDIA:
A PHASE 1/2 STUDY OF ABI-009 (NAB-SIROLIMUS) WITH PAZOPANIB IN PATIENTS WITH ADVANCED
NONADIPOCYTIC SOFT TISSUE SARCOMAS**

Lee D. Cranmer¹, Elizabeth T. Loggers², Seth Pollack², Roxanne O. Moore¹, Sarah Duffy¹, Michael J. Wagner¹

¹Division of Oncology, University of Washington, Seattle, Washington, UNITED STATES; ²Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, UNITED STATES

Poster #204 3465078

**SAINT: AN EXPANDED PHASE 2 STUDY USING SAFE AMOUNTS OF IPILIMUMAB (I), NIVOLUMAB (N),
AND TRABECTEDIN (T) AS FIRST-LINE TREATMENT OF ADVANCED SOFT TISSUE SARCOMA [NCT03138161]**

Erlinda M. Gordon¹, Victoria Chua-Alcala¹, Kelly Wang¹, Paul S. Dy¹, Micaela K. Paz¹, Ted T. Kim¹, Nicole L. Angel¹,
Ania M. Moradkhani¹, Omid Jafari¹, Doris M. Quon¹, Steven M. Wong¹, William Tseng², Sant P. Chawla¹

¹Sarcoma Oncology Center, Santa Monica, California, UNITED STATES;

²Surgery, USC Keck School of Medicine, Los Angeles, California, UNITED STATES

Poster #205 3465091

LANDSCAPE OF ALK FUSIONS IN SOFT-TISSUE SARCOMAS (STS)

Roman Groisberg¹, James Chen², Zhijie Jiang⁴, Michelle Churchman⁴, Ming Poi⁴, Santosh Mishra⁴, Oliver Hampton⁴,
Ashley B. Anderson⁵, Michael Cavner⁶, Rebecca Dodd⁷, Stephen Edge⁸, Kevin B. Jones⁹, Vipul G. Pareek¹⁰,
Damon Reed³, Breelyn A. Wilky¹¹, Andrew Brohl³, David A. Liebner²

¹Medical Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, UNITED STATES; ²The Ohio State University, Columbus, Ohio, UNITED STATES; ³Sarcoma Department, Moffitt, Tampa, Florida, UNITED STATES;

⁴M2Gen, Tampa, Florida, UNITED STATES; ⁵Uniformed Services University of the Health Sciences and Walter Reed, Bethesda, Maryland, UNITED STATES; ⁶University of Kentucky, Lexington, Kentucky, UNITED STATES; ⁷University of Iowa, Iowa City, Iowa, UNITED STATES; ⁸Roswell Park, Buffalo, New York, UNITED STATES; ⁹Huntsman Cancer Institute, Salt Lake City, Utah, UNITED STATES; ¹⁰Stephenson Cancer Center, Oklahoma City, Oklahoma, UNITED STATES;

¹¹University of Colorado, Aurora, Colorado, UNITED STATES

Poster #206 3465105

ANGIOSARCOMA TREATMENT USING PROPRANOLOL: A SINGLE INSTITUTION EXPERIENCE IN ARGENTINA

Andres Rodriguez¹, Tomás J. Soulé¹, Martin Angel¹, Federico Waisberg¹, Enrico Diego¹, Yanina Pfluger¹,
Reinaldo Chacón¹, Matias Chacon¹

¹Clinical Oncology, Instituto Alexander Fleming, Buenos Aires, ARGENTINA

Poster #207 3465109

**SQ3370, A NOVEL APPROACH TO LOCALLY CAPTURE AND ACTIVATE CYTOTOXIC DRUGS, PRODUCES
SUSTAINED RESPONSES IN INJECTED AND NON-INJECTED LESIONS VIA IMMUNE ACTIVATION IN
PRECLINICAL MODELS**

Sangeetha Srinivasan¹, Nathan Yee¹, Kui Wu², Amir Mahmoodi¹, Michael Zakharian¹, Maksim Royzen², Jose Mejia Oneto¹

¹Shasqi, Inc., San Francisco, California, UNITED STATES;

²University of Albany (SUNY), Albany, New York, UNITED STATES

Poster #208 3465112

EWS/FLI DRIVES DYNAMIC REORGANIZATION OF LSD1 AND REST IN EWING SARCOMA CELLS

Julia Selich-Anderson¹, Stephen L. Lessnick¹, **Emily R. Theisen¹**

¹Center for Childhood Cancer, Nationwide Children's Hospital, Columbus, Ohio, UNITED STATES

Poster #209 3465136

HEAD AND NECK ALVEOLAR RHABDOMYOSARCOMA – A RARE ENTITY

Raquel L. Brás¹, Gonçalo Fernandes², Daniela Macedo¹, Dolores López³, Ana Rita Santos⁴, Luis Costa¹, Isabel Fernandes¹
¹Oncology, Hospital Santa Maria, CHULN, Lisboa, PORTUGAL; ²Oncology, Hospital da Luz, Lisbon, PORTUGAL;
³Pathology, Hospital Santa Maria, CHULN, Lisbon, PORTUGAL; ⁴Otorhinolaryngology, Hospital Santa Maria, CHULN, Lisbon, PORTUGAL

Poster #210 3465158

PROMIS-10 SURVEY T-SCORES AND UNPLANNED HOSPITAL ADMISSION/EMERGENCY ROOM VISITS

Marium Husain¹, Audra Phillips¹, David A. Liebner¹

¹Medical Oncology, The Ohio State University James Comprehensive Cancer Center, Columbus, Ohio, UNITED STATES

Poster #211 3465174

SORAFENIB IN DESMOID TUMOR: A BRAZILIAN CANCER CENTER EXPERIENCE

Maria F. Simões¹, Celso Mello¹, Ulisses R. Nicolau¹, Maria Nirvana Formiga¹, Cassia Silva¹, **Fernando Campos¹**

¹Medical Oncology, A.C. Camargo Cancer Center, São Paulo, Sao Paulo, BRAZIL

Poster #212 3465223

SILVER-COATED MEGAPROTHESES IN THE MITIGATION OF PROSTHETIC JOINT INFECTIONS – A COST-EFFECTIVENESS ANALYSIS

Dipak B. Ramkumar¹, Sean P. Kelly¹, Marcel Brown³, Niveditta Ramkumar², Kevin A. Raskin¹, Santiago A. Lozano-Calderon¹

¹Massachusetts General Hospital, Boston, Massachusetts, UNITED STATES; ²The Dartmouth Institute for Health Policy and Clinical Practice, Lebanon, New Hampshire, UNITED STATES; ³Dartmouth Geisel School of Medicine, Lebanon, New Hampshire, UNITED STATES

Poster #213 3465226

LEVERAGING EVOLUTIONARY FITNESS BOTTLENECKS AS THERAPEUTIC VULNERABILITIES IN DOXORUBICIN-RESISTANT OSTEOSARCOMA

Etienne M. Flamant¹, Anika Agarwal², Anna Slingerland², Ella Gunnady², Abbey Milwicz², Cameron Bozdog², Maya Sheth², Kathryn E. Ware², Mark M. Cullen¹, David Corcoran³, Joseph Prinz³, Nicolas Devos³, William C. Eward⁴, So Young Kim⁵, Jason A. Somarelli²

¹Duke University School of Medicine, Durham, North Carolina, UNITED STATES; ²Department of Medicine, Duke University, Durham, North Carolina, UNITED STATES; ³Center for Genomic and Computational Biology, Duke University, Durham, North Carolina, UNITED STATES; ⁴Department of Orthopaedic Surgery, Duke University Medical Center, Durham, North Carolina, UNITED STATES; ⁵Department of Molecular Genetics and Microbiology, Duke University, Durham, North Carolina, UNITED STATES

Poster #214 3465233

ADJUNCT DIAGNOSTIC STRATEGIES IN IMPROVING DIAGNOSTIC YIELDS IN IMAGE-GUIDED BIOPSIES – A COST-EFFECTIVENESS ANALYSIS

Dipak B. Ramkumar¹, Sean P. Kelly¹, Soterios Gyftopoulos², Kevin A. Raskin¹, Santiago A. Lozano-Calderon¹, Connie Y. Chang¹

¹Massachusetts General Hospital, Boston, Massachusetts, UNITED STATES; ²NYU Langone Health, New York, New York, UNITED STATES

Poster #215 3465243

CIRCULATING TUMOR DNA IN CYTOGENETICALLY COMPLEX SOFT TISSUE SARCOMAS

Gabriel Tinoco¹, Katharine Collier¹, David A. Liebner¹, Daniel Stover¹, James Chen¹, Raph Pollock¹, Claire Verschraegen²

¹Surgery, The Ohio State University, Columbus, Ohio, UNITED STATES; ²Oncology, The Ohio State University, Columbus, Ohio, UNITED STATES

Poster #216 3465258

EVALUATION OF PATIENT AND HEALTHCARE PROVIDER KNOWLEDGE, ATTITUDES, AND BEHAVIOR (KAB) FOR SAFETY AND USE OF PEXIDARTINIB

Maribel Salas^{1,2}, Michele Julian⁴, Youngsook Choi³, Zahid Islam³, Mackenzie Henderson^{1,5}, Annette Stemhagen⁴, Natalie O'Donnell⁴, Nora Tu³

¹Epidemiology, Clinical Safety and Pharmacovigilance, Daiichi Sankyo, Inc, Basking Ridge, New Jersey, UNITED STATES;

²CCEB. CPeRT, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, UNITED STATES;

³Epidemiology, Clinical Safety and Pharmacovigilance, Daiichi Sankyo Inc, Basking Ridge, New Jersey, UNITED STATES;

⁴Safety, Epidemiology, Registries & Risk Management, United BioSource LLC, McLean, Virginia, UNITED STATES;

⁵Rutgers Institute for Pharmaceutical Industry Fellowships, Piscataway, New Jersey, UNITED STATES

Poster #217 3465259

PATIENT-DERIVED SARCOMA MODELS TOWARDS NOVEL BIOLOGY AND TREATMENT

Tadashi Kondo¹, Rei Noguchi¹, Yuki Yoshimatsu¹, Ryuto Tsuchiya¹, Takuya Ono¹, Yooksil Sin¹, Aakne Sei¹, Mami Takahashi², Jun Sugaya³, Akihiko Yoshida⁴, Kaoru Hirabayashi⁵, Iwao Ozawa⁶, Hidetaka Kosako⁸, Hitoshi Ichikawa⁹, Kazutaka Kikuta⁷, Akira Kawai³

¹Division of Rare Cancer Research, National Cancer Center, Tokyo, JAPAN; ²Central Animal Division, National Cancer

Center, Tokyo, JAPAN; ³Department of Musculoskeletal Oncology, National Cancer Center Hospital, Tokyo, JAPAN;

⁴Department of Diagnosis Pathology, National Cancer Center Hospital, Tokyo, JAPAN; ⁵Division of Diagnostic Pathology,

Tochigi Cancer Center, Tochigi, JAPAN; ⁶Division of Hepato-Biliary-Pancreatic Surgery, Tochigi Cancer Center, Tochigi,

JAPAN; ⁷Division of Musculoskeletal Oncology and Orthopaedics Surgery, Tochigi Cancer Center, Tochigi, JAPAN;

⁸Fuji Memorial Institute of Medical Science, Tokushima University, Tokushima, JAPAN; ⁹Fundamental Innovative Oncology Core, National Cancer Center, Tokyo, JAPAN

Poster #218 3465280

OUTCOMES OF WOUND HEALING WITH A TOPICAL SKIN ADHESIVE AFTER TUMOR RESECTION

Lee M. Zuckerman¹, Nadine L. Williams²

¹Orthopaedic Surgery, City of Hope National Medical Center, Duarte, California, UNITED STATES;

²Orthopaedic Surgery, Loma Linda University Medical Center, Loma Linda, California, UNITED STATES

Poster #219 3465283

A NEW INDUCIBLE ZEBRAFISH MODEL OF EWING SARCOMA REVEALS THE IMPORTANCE OF ECM IN DEVELOPMENT OF THE DISEASE

Elena Vasileva¹, Timothy J. Triche², James F. Amatruda¹

¹HemOncBMT, Children's Hospital of Los Angeles, Los Angeles, California, UNITED STATES; ²Children's Hospital

Los Angeles, Los Angeles, California, UNITED STATES

Poster #220 3465290

SQ3370-001: A MULTI-CENTER, OPEN-LABEL PHASE I DOSE-ESCALATION STUDY OF SQ3370, A NOVEL INTRATUMORAL AND SYSTEMIC APPROACH TO ADMINISTER ANTHRACYCLINES FOR TREATING SOFT TISSUE SARCOMAS AND OTHER ADVANCED SOLID TUMORS

Nam Bui², Vivek Bhadri³, Alexander D. Guminski⁴, Jose Mejia Oneto¹, Ravi Murthy⁵, Kamallesh K. Sankhala⁶, Sangeetha Srinivasan¹, Robert Steffner⁷, Vivek Subbiah⁵, Ding Wang⁸, Nathan Yee¹

¹Shasqi, Inc., San Francisco, California, UNITED STATES; ²Stanford Cancer Institute, Palo Alto, California, UNITED

STATES; ³Chris O'Brien Lifehouse, Camperdown, New South Wales, AUSTRALIA; ⁴Royal North Shore Hospital,

St. Leonards, New South Wales, AUSTRALIA; ⁵MD Anderson Cancer Center., Houston, Texas, UNITED STATES;

⁶Cedar Sinai Angeles Clinic, Los Angeles, California, UNITED STATES; ⁷Stanford Medicine, Redwood City, California,

UNITED STATES; ⁸Henry Ford Hospital., Detroit, Michigan, UNITED STATES

Poster #221 3465303

PEDIATRIC ONCOLOGY PROVIDERS' MENTAL HEALTH IN THE EPICENTER OF THE PANDEMIC, PRELIMINARY REPORT

Alexandra Arca¹, Paige Reilly², Janay McKnight¹, Paul Kent¹

¹Pediatric Oncology/Hematology, Rush, Chicago, Illinois, UNITED STATES; ²University of Illinois at Chicago,

Chicago, Illinois, UNITED STATES

Poster #222 3465305

A META-ANALYTIC EVALUATION OF THE CORRELATION BETWEEN SURROGATE ENDPOINTS AND OVERALL SURVIVAL IN RANDOMIZED CONTROLLED TRIALS OF NEWLY DIAGNOSED OSTEOSARCOMA

Kazuhiro Tanaka¹, Masanori Kawano¹, Tatsuya Iwasaki¹, Yuta Kubota¹, Ichiro Itonaga¹, Hiroshi Tsumura¹

¹Department of Orthopaedic Surgery, Oita University, Yufu, Oita, JAPAN

Poster #223 3465320

IMMUNE-CHECKPOINT GENES AS PREDICTIVE BIOMARKERS OF TRABECTEDIN IN ADVANCED SOFT-TISSUE SARCOMA (STS): A SPANISH GROUP FOR RESEARCH ON SARCOMAS (GEIS) TRANSLATIONAL STUDY

David S. Moura¹, Nadia Hindi¹, Maria Lopez-Alvarez¹, Paloma Sanchez-Bustos¹, Irene Carrasco-Garcia², Paloma Santos-Fernandez², Paula Martinez-Delgado¹, Serena Lacerenza¹, Elena Blanco-Alcaina¹, José L. Mondaza-Hernandez¹, Antonio Gutierrez³, Rosa Alvarez-Alvarez⁴, Magda Conceicao¹, Luis M. De Sande-Gonzalez⁵, Gloria Marquina⁶, Juana M. Cano⁷, Josefina Cruz⁸, Claudia Valverde⁹, Javier Martinez-Trufero¹⁰, Javier Martin-Broto¹

¹Oncohematology and genetics, Institute of Biomedicine of Seville, Seville, Seville, SPAIN; ²P. Santos-Fernandez, University Hospital Virgen del Rocío, Seville, SPAIN; ³University Hospital Son Espases, Mallorca, SPAIN;

⁴University Hospital Gregorio Marañón, Madrid, SPAIN; ⁵University Hospital of Leon, Leon, SPAIN; ⁶Hospital Clinico San Carlos, Madrid, SPAIN; ⁷Hospital Ciudad Real, Ciudad Real, SPAIN; ⁸Canarias University Hospital, Santa Cruz de Tenerife, SPAIN; ⁹Vall d'Hebron University Hospital, Barcelona, SPAIN; ¹⁰University Hospital Miguel Servet, Zaragoza, SPAIN

Poster #224 3465381

HETEROGENEITY OF CHEMOTHERAPY EFFECT IN HIGH-RISK PATIENTS WITH EXTREMITY SOFT TISSUE SARCOMA

Ibtissam Acem¹, Cees Verhoef², Winan J. van Houdt³, Dirk Grunhagen², Michiel van de Sande¹

¹Leiden University Medical Centre, Leiden, NETHERLANDS; ²Erasmus Medical Center, Rotterdam, NETHERLANDS;

³The Netherlands Cancer Institute, Amsterdam, NETHERLANDS

Poster #225 3465410

DEFINING A TEXTBOOK SURGICAL OUTCOME FOR PATIENTS FOR UNDERGOING SURGICAL RESECTION OF INTERMEDIATE AND HIGH-GRADE SOF TISSUE SARCOMAS OF THE EXTREMITIES

Alexander L. Lazarides¹, Marcelo Cerullo², Dimitrios Moris², Brian E. Brigman¹, Dan G (Trey) Blazer², William C. Eward¹

¹Department of Orthopaedic Surgery, Duke University Medical Center, Durham, North Carolina, UNITED STATES;

²Department of Surgery, Duke University Medical Center, Durham, North Carolina, UNITED STATES

Poster #226 3465411

FUNCTIONAL CONSEQUENCES OF OVEREXPRESSION OF MIR-26A AND MIR-3913 IN WDLPS ANDDDLPS

Erik Wiemer¹, Melissa Vos¹, Anne Vriends¹, Patricia F. van Kuijk¹, Dirk Grunhagen², Cees Verhoef², Stefan Sleijfer¹

¹Medical Oncology, Erasmus Medical Center, Rotterdam, NETHERLANDS; ²Surgical Oncology, Erasmus Medical Center, Rotterdam, NETHERLANDS

Poster #227 3465438

MISMATCH REPAIR DEFICIENCY IN BONE AND SOFT TISSUE TUMORS: IS THERE A RATIONALE FOR ROUTINE TESTING IN ADVANCED SARCOMA?

Suk Wai Lam¹, Marie Kostine², Noel de Miranda¹, Hans Morreau¹, Judith V. Bovee¹

¹Pathology, LUMC, Leiden, NETHERLANDS; ²Centre Hospitalier Universitaire de Bordeaux Groupe hospitalier Pellegrin, Bordeaux, FRANCE

Poster #228 3465449

PROGNOSTIC VALUE OF PGP AS STRATIFICATION FACTOR FOR THE TREATMENT OF PATIENTS WITH NON-METASTATIC EXTREMITY HIGH-GRADE OSTEOSARCOMA: A SPANISH SOCIETY OF PEDIATRIC HEMATOLOGY AND ONCOLOGY (SEHOP) AND SPANISH GROUP FOR RESEARCH IN SARCOMAS (GEIS) STUDY

Catalina Marquez¹, Francisco J. Bautista², Robert D. Beveridge³, Adela Cañete³, Maria A. Vaz¹⁶, Aizpea Echebarria⁴, Maria E. Llinares⁵, Cristina Mata⁶, Alexandra Regueiro⁷, Jose A. Villegas⁹, Mercedes Guibelalde¹⁰, Guiomar Gutierrez¹¹, Ascension Muñoz¹², Jeronimo Martinez-Garcia⁵, Rosa Alvarez-Alvarez⁶, Montserrat Torrent⁸, Claudia Valverde¹³, Elisa Carretta¹⁴, Stefano Ferrari¹⁴, Piero Picci¹⁵, Emanuela Palmerini¹⁴, Javier Martin-Broto¹, **Luis Gros Subias**¹³, Oscar Gallego⁸

¹Hospital Universitario Virgen del Rocio, Seville, SPAIN; ²Hospital Infantil Universitario Niño Jesus, Madrid, SPAIN; ³Hospital Universitari i Politecnic La Fe, Valencia, SPAIN; ⁴Hospital Universitario Cruces, Baracaldo, SPAIN; ⁵Hospital Clinico Universitario Virgen de la Arrixaca, Murcia, SPAIN; ⁶Hospital General Universitario Gregorio Marañón, Madrid, SPAIN; ⁷Complejo Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela, SPAIN; ⁸Hospital de la Santa Creu i Sant Pau, Barcelona, SPAIN; ⁹Hospital Universitario Central de Asturias, Oviedo, SPAIN; ¹⁰Hospital Universitari Son Espases, Palma de Mallorca, SPAIN; ¹¹Hospital Regional Universitario de Malaga, Malaga, SPAIN; ¹²Hospital Universitario Miguel Servet, Zaragoza, SPAIN; ¹³Hospital Universitari Vall d'Hebron, Barcelona, SPAIN; ¹⁴IRCCS Istituto Ortopedico Rizzoli, Bologna, ITALY; ¹⁵Italian Sarcoma Group, Bologna, ITALY; ¹⁶Hospital Universitario Ramon y Cajal, Madrid, SPAIN

Poster #229 3465504

LATE CENTRAL NERVOUS SYSTEM AND LUNG RECURRENCE OF EWING'S SARCOMA: A CASE REPORT

Roberto Carmagnani Pestana¹, Francinne Luiza Teixeira Tostes¹, Andre Felix Gentil¹, Eduardo Santamaria Carvalhal Ribas¹, Fabiana Hirata¹, Vitor Ribeiro Paes¹, Carla Macedo², Antonio Sergio Petrilli², Suzana Malheiros¹, Guilherme Carvalhal Ribas¹, Ludmila Koch¹

¹Hospital Israelita Albert Einstein, Sao Paulo, BRAZIL; ²Institute of Pediatric Oncology (GRAAC), Federal University of Sao Paulo, Sao Paulo, BRAZIL

Poster #230 3465518

LYMPHOVASCULAR INVASION AND HISTOPATHOLOGIC PROFILE PORTENDS WORSE PROGNOSIS IN CHONDROSARCOMA

Alexander L. Lazarides¹, Bijan Abar¹, Bruce Leckey², Alexis Musick¹, William C. Eward¹, Brian E. Brigman¹, Diana Cardona², Julia D. Visgauss¹

¹Department of Orthopaedic Surgery, Duke University Medical Center, Durham, North Carolina, UNITED STATES; ²Department of Pathology, Duke University Medical Center, Durham, North Carolina, UNITED STATES

Poster #231 3465549

IMPACT OF PATHOLOGICAL STRATIFICATION OF ADVANCED WELL DIFFERENTIATED/DEDIFFERENTIATED (WD/DD) LIPOSARCOMA (LPS) ON THE RESPONSE TO TRABECTEDIN (T)

Roberta Sanfilippo¹, Chiara Fabbroni¹, Francesca Ligorio¹, Elena Fumagalli¹, Paola Collini¹, Giovanni Fucà¹, Marta Barisella¹, Rossella Bertulli¹, Salvatore Provenzano¹, Carlo Morosi¹, Silvia Stacchiotti¹, Alessandro Gronchi¹, Angelo Paolo Dei Tos², Paolo Giovanni Casali¹

¹Istituto Nazionale dei Tumori di Milano, Milan, Milan, ITALY; ²Università degli Studi di Padova, Padua, ITALY

Poster #232 3465550

COMPREHENSIVE IMMUNOPHENOTYPING OF SOFT TISSUE SARCOMA PATIENTS DEFINES ASSOCIATION WITH FUNCTIONALLY DISTINCT LYMPHOCYTE SUBSETS AND MAJOR SUPPRESSOR CELLS

Paulo Rodrigues-Santos¹, Jani Sofia Almeida¹, Patricia Costa-Martins³, Patricia Couceiro², Vera Alves¹, Manuel Santos-Rosa¹, Paulo Freitas-Tavares³, José Manuel Casanova³

¹Instituto de Imunologia, Faculdade de Medicina da Universidade de Coimbra, Coimbra, PORTUGAL; ²Laboratório de Imunologia e Oncologia, Centro de Neurociencias e Biologia Celular, Universidade de Coimbra, Coimbra, PORTUGAL; ³P. Freitas-Tavares, J. Casanova, Unidade de Tumores do Aparelho Locomotor, Serviço de Ortopedia, Centro Hospitalar e Universitário de Coimbra, Coimbra, PORTUGAL

Poster #233 3465551

ADVANCED DERMATOFIBROSARCOMA PROTUBERANS: EXPERIENCE FROM A SARCOMA CLINIC IN INDIA

Azgar A. Rasheed¹, Saurav Verma¹, Anshul Gupta¹, Ankur Varshney¹, Adarsh Barwad¹, Ekta Dhamija¹, Sameer Rastogi¹

¹All India Institute of Medical Sciences, New Delhi, New Delhi, INDIA

Poster #234 3465565

NKT-LIKE CELLS DISPLAY ALTERED PATTERNS OF MATURATION, MIGRATION, ACTIVATION AND EXPRESSION OF IMMUNE CHECKPOINTS IN SOFT TISSUE SARCOMA

Jani Sofia Almeida¹, Paulo Rodrigues-Santos¹, Patricia Couceiro², Vera Alves¹, Manuel Santos-Rosa¹, Paulo Freitas-Tavares³, José Manuel Casanova³

¹Instituto de Imunologia, Faculdade de Medicina da Universidade de Coimbra, Coimbra, PORTUGAL; ²Laboratório de Imunologia e Oncologia, Centro de Neurociencias e Biologia Celular, Universidade de Coimbra, Coimbra, PORTUGAL;

³Unidade de Tumores do Aparelho Locomotor, Serviço de Ortopedia, Centro Hospitalar e Universitário de Coimbra, Coimbra, PORTUGAL

Poster #235 3465580

SOCIOECONOMIC STATUS AND CANCER-RELATED MORTALITY IN SOFT TISSUE SARCOMA: AN ANALYSIS OF THE SEER DATABASE

Dipak B. Ramkumar¹, Sean P. Kelly¹, Niveditta Ramkumar², Kevin A. Raskin¹, Santiago A. Lozano-Calderon¹

¹Massachusetts General Hospital, Boston, Massachusetts, UNITED STATES; ²Dartmouth Institute for Health Policy and Clinical Practice, Lebanon, New Hampshire, UNITED STATES

Poster #236 3465593

USE OF A HUMANIZED XENOGRFT MURINE MODEL TO CHARACTERIZE THE TREATMENT EFFECT OF CYTOTOXIC CHEMOTHERAPY AND IMMUNOTHERAPY ON OSTEOSARCOMA

Simon Yaguare¹, **Valentina Viscarret**¹, Osama Aldahamsheh¹, Jichuan Wang¹, Hasibagan Borjihan¹, Janet Tingling¹, Dana Kamens¹, Robert Schneider¹, Daniel Weiser², Rui Yang¹, Bang Hoang¹, David S. Geller¹

¹Orthopaedic Surgery, Montefiore Medical Center, Bronx, New York, UNITED STATES; ²Pediatrics, Children's Hospital at Montefiore, Bronx, New York, UNITED STATES

Poster #237 3465607

DEVELOPMENT OF AN UPDATED INTERNATIONAL CONSENSUS ON THE MANAGEMENT OF PRIMARY RETROPERITONEAL SARCOMA (RPS) BY TARPSWG

Carol J. Swallow¹, Dirk Strauss², Sylvie Bonvalot³, Piotr Rutkowski⁴, Anant Desai⁵, Rebecca Gladdy¹, Ricardo J. Gonzalez⁶, David E. Gyorki⁷, Mark Fairweather⁸, Winan J. van Houdt⁹, Eberhard Stoeckle¹⁰, Jae Berm Park¹¹, Markus Albersmeier¹², Carolyn Nessim¹³, Kenneth Cardona¹⁴, Marco Fiore¹⁵, Andrew Hayes², Dmitri Tzanis³, Jacek Skoczylas⁴, Samuel Ford⁵, Deanna Ng¹, John Mullinax¹⁴, Hayden Snow⁷, Rick L. Haas⁹, Dario Callegaro¹⁵, Myles Smith², Toufik Bouhadiba³, Silvia Stacchiotti¹⁵, Robin L. Jones², Thomas F. DeLaney¹⁶, Christina Roland¹⁷, Chandrajit Raut⁸, Alessandro Gronchi¹⁵

¹University of Toronto, Toronto, Ontario, CANADA; ²Royal Marsden NHS Foundation Trust, London, UNITED KINGDOM;

³Institut Curie, Paris, FRANCE; ⁴Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, POLAND;

⁵University of Birmingham, Birmingham, UNITED KINGDOM; ⁶H. Lee Moffitt Cancer Center, Tampa, Florida, UNITED STATES;

⁷Peter MacCallum Cancer Centre, Melbourne, Victoria, AUSTRALIA; ⁸Brigham and Women's Hospital Center for Sarcoma and Bone Oncology, Boston, Massachusetts, UNITED STATES; ⁹The Netherlands Cancer Institute, Amsterdam, NETHERLANDS;

¹⁰Institut Bergonie, Bordeaux, FRANCE; ¹¹Samsung Medical Center, Seoul, KOREA (THE REPUBLIC OF);

¹²Ludwig-Maximilians-Universität, University Hospital, Munich, GERMANY; ¹³University of Ottawa, Ottawa, Ontario, CANADA;

¹⁴Winship Cancer Institute, Emory University, Atlanta, Georgia, UNITED STATES; ¹⁵Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, ITALY; ¹⁶Massachusetts General Hospital, Boston, Massachusetts, UNITED STATES;

¹⁷The University of Texas MD Anderson Cancer Center, Houston, Texas, UNITED STATES

Poster #238 3465625

THE INTERACTION OF SKP2 WITH P27 ENHANCES IN THE PROGRESSION AND TUMOR-INITIATING PROPERTIES OF OSTEOSARCOMA

Jichuan Wang¹, Osama Aldahamsheh¹, Simon Yaguare¹, Hasibagan Borjihan¹, Janet Tingling¹, Hongling Zhao², Rui Yang¹, David S. Geller¹, **Bang Hoang**¹

¹Orthopedic Surgery, Montefiore Medical Center, Bronx, New York, UNITED STATES; ²Department of Developmental and Molecular Biology, Albert Einstein College of Medicine, Bronx, New York, UNITED STATES

Poster #239 3465637

LONG-TERM RESULTS OF ADJUVANT MIFAMURTIDE ALONGSIDE CHEMOTHERAPY IN THE TREATMENT OF PEDIATRIC AND ADULT PATIENTS WITH OSTEOSARCOMA

Robert D. Beveridge¹, Carlos Puchades Olmos¹, Alba Torres Martinez¹, Benjamin Domingo Arrue¹, Guillermo Suay Montagud¹, Diego Soriano Polo¹, Antonio Juan², Ana Ferrero¹, Javier Perea Rojo¹, Julio Linares Diaz¹, Nuria Gómez Sepúlveda¹, Adela Cañete²

¹Medical Oncology Department, University Hospital La Fe, Valencia, Valencia, SPAIN; ²Pediatric Oncology Department, University Hospital La Fe, Valencia, SPAIN, SPAIN

Poster #240 3465660

ACCURACY OF X-RAY AND MAGNETIC RESONANCE IMAGING IN DEFINING THE TUMOR MARGIN IN PRIMARY BONE SARCOMA

Theodore H. Katz¹, Obada Hasan¹, Benjamin J. Miller¹

¹Orthopedics and Rehabilitation, University of Iowa, Johnston, Iowa, UNITED STATES

Poster #241 3465668

IDENTIFICATION AND EVALUATION OF NOVEL RHABDOMYOSARCOMA ANTIGENS FOR USE IN ONCOLYTIC VACCINES

Birdi Harsimrat Kaur¹, Daniel Serrano², Andrew Chen², Mohsen Hooshyar², Youra Kim³, Nicole Forbes², Zaid Taha², Shashi Gujjar⁴, Joel Werier¹, Jean Simon S. Diallo²

¹Department of Surgery, The Ottawa Hospital, Ottawa, Ontario, CANADA; ²Centre for Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa, Ontario, CANADA; ³Virica Biotech Inc, Ottawa, Ontario, CANADA; ⁴Dalhousie University, Halifax, Nova Scotia, CANADA

Poster #242 3465674

PILOT STUDY OF THE EFFECT OF HIGH DOSES OF RADIATION ON BONE METABOLISM AND STRUCTURE IN PATIENTS TREATED WITH ADJUVANT RADIOTHERAPY AND SURGERY FOR SACRAL TUMORS.

Quirina Thio¹, Olivier van Wulfften Palthe¹, Kevin A. Raskin¹, Santiago A. Lozano-Calderon¹, Thomas F. DeLaney², Francis J. Hornicek³, David Dempster⁵, Hua Zhou⁴, Joseph H. Schwab¹

¹Orthopaedic Surgery, Massachusetts General Hospital, Boston, Massachusetts, UNITED STATES; ²Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts, UNITED STATES; ³Orthopaedic Surgery, UCLA, Los Angeles, California, UNITED STATES; ⁴Helen Hayes Hospital, New York, New York, UNITED STATES; ⁵Clinical Pathology and Cell Biology, Columbia University, New York, New York, UNITED STATES

Poster #243 3465693

NEURONAL INFLUENCES IN AN UNDIFFERENTIATED TUMOR: THE NERVOUS MICROENVIRONMENT OF UNDIFFERENTIATED PLEOMORPHIC SARCOMA

Candace L. Haddox¹, Ben Alman²

¹Internal Medicine, Duke University, Durham, North Carolina, UNITED STATES; ²Orthopedic Surgery, Duke University, Durham, North Carolina, UNITED STATES

Poster #244 3465698

EVALUATION OF CANCER-TESTIS ANTIGENS IN OSTEOSARCOMA AND DEDIFFERENTIATED LIPOSARCOMA AS TARGETS FOR IMMUNOTHERAPY

Anna Jirovec², Ashley Flaman², Bibiana Purgina², Fanny Tzelepis³, Jean-Simon Diallo³, Joel Werier¹

¹Department of Surgery, The Ottawa Hospital, Ottawa, Ontario, CANADA; ²Department of Pathology and Laboratory Medicine, University of Ottawa, Ottawa, Ontario, CANADA; ³Centre for Innovative Cancer Research, Ottawa Hospital Research Institute, Ottawa, Ontario, CANADA

Poster #245 3465699

EVALUATION OF BASELINE NEUTROPHIL TO LYMPHOCYTE (NLR), PLATELET TO LYMPHOCYTE (PLR) AND LYMPHOCYTE TO MONOCYTE RATIOS (LMR) AS PROGNOSTIC FACTORS IN OSTEOSARCOMA – THE TORONTO SARCOMA PROGRAM EXPERIENCE

Olubukola Ayodele¹, Anthony Griffin², Peter Ferguson², Abha A. Gupta¹, Jay Wunder², Albiruni Abdul Razak¹

¹Medical Oncology, Princess Margaret Cancer Center, Toronto, Ontario, CANADA; ²Orthopedics, Mount Sinai Hospital, Toronto, Ontario, CANADA

Poster #246 3465717

ANCHOR CELLS: A MINOR SUBPOPULATION OF OSTEOSARCOMA CELLS WITH A SENESENCE-LIKE PHENOTYPE THAT FACILITATES LUNG COLONIZATION

James B. Reinecke¹, John M. Hinckley¹, Sanjana Rajan¹, Amy C. Gross¹, Maren Cam¹, **Ryan D. Roberts**¹

¹Center for Childhood Cancer and Blood Disease, Nationwide Children's Hospital, Columbus, Ohio, UNITED STATES

Poster #247 3465718

IMMUNE SIGNATURE AND MOLECULAR PROFILING OF EPITHELIOID HEMANGIOENDOTHELIOMA (EHE): A TORONTO SARCOMA PROGRAM STUDY

Olubukola Ayodele¹, Rima Al-Bati², Brendan Dickson², Albiruni Abdul Razak¹

¹Medical Oncology, Princess Margaret Cancer Center, Toronto, Ontario, CANADA; ²Pathology, Mount Sinai Hospital, Toronto, Ontario, CANADA

Poster #248 3465772

CAN INTRAOPERATIVE USE OF INDOCYANINE GREEN DYE ANGIOGRAPHY PREDICT RATES OF WOUND COMPLICATIONS IN PATIENTS UNDERGOING SOFT TISSUE RESECTION?

Joanne Zhou¹, Ann Richey¹, Cara Lai¹, Subhro Sen², David Mohler¹, Robert Steffner¹

¹Orthopaedic Surgery, Stanford University, Redwood City, California, UNITED STATES;

²Plastic and Reconstructive Surgery, Stanford University, Palo Alto, California, UNITED STATES

Poster #249 3465776

20-YEAR EXPERIENCE IN THE MANAGEMENT OF PATIENTS WITH EXTRASKELETAL MYXOID CHONDROSARCOMA IN A SARCOMA REFERENCE CENTRE

Robert D. Beveridge¹, Benjamin Domingo Arrue¹, Javier Perea Rojo¹, Ana Ferrero¹, Nuria Gómez Sepúlveda¹,

Alba Torres Martinez¹, Carlos Puchades Olmos¹, Diego Soriano Polo¹, Guillermo Suay Montagud¹, Julio Linares Diaz¹

¹Medical Oncology Department, University Hospital La Fe, Valencia, Valencia, SPAIN

Poster #250 3465785

SAFETY OF DISCHARGE AT HIGHER SERUM METHOTREXATE LEVELS IN PEDIATRIC OSTEOSARCOMA PATIENTS

Nathaniel P. Rice¹, Janay McKnight¹, Paul Kent¹

¹Rush University Medical Center, Hampton, Connecticut, UNITED STATES

Poster #251 3465792

IDENTIFYING MODIFIABLE AND NON-MODIFIABLE RISK FACTORS FOR READMISSION AND SHORT TERM MORTALITY IN OSTEOSARCOMA

Alexander L. Lazarides¹, Daniel Evans¹, Mark M. Cullen¹, Marcelo Cerullo², Dan G (Trey) Blazer², Brian E. Brigman¹, William C. Eward¹

¹Department of Orthopaedic Surgery, Duke University Medical Center, Durham, North Carolina, UNITED STATES;

²Department of Surgery, Duke University Medical Center, Durham, North Carolina, UNITED STATES

Poster #252 3465794

SURVIVAL OUTCOMES IN PATIENTS WITH RETROPERITONEAL SARCOMA (RPS): AN ANALYSIS OF THE SURVEILLANCE, EPIDEMIOLOGY, AND END RESULTS (SEER) DATABASE

Nicholas Damico¹, Andrew Gross¹, David Mansur¹, Aashish Bhatt¹

¹Radiation Oncology, University Hospitals Cleveland Medical Center, Cleveland, Ohio, UNITED STATES

Poster #253 3465805

CLINICAL OUTCOMES OF PATIENTS WITH SARCOMA HARBORING TP53 GERMINATIVE MUTATION – A SINGLE CENTER RETROSPECTIVE ANALYSIS

Fernando Campos¹, Maria Nirvana Formiga¹, Elizabeth Santana dos Santos¹, Joyce Lisboa¹,

José Cláudio Casali da Rocha², Ulisses R. Nicolau¹, Celso Mello¹

¹Medical Oncology, A.C. Camargo Cancer Center, São Paulo, Sao Paulo, BRAZIL; ²Oncogenetics, A.C. Camargo Cancer Center, Sao Paulo, Sao Paulo, BRAZIL

Poster #254 3465814

WHY DO ORTHOPAEDIC ONCOLOGY PATIENTS UNDERGOING PROSTHETIC RECONSTRUCTION GET READMITTED?

Alexander L. Lazarides¹, Etienne M. Flamant¹, Mark M. Cullen¹, Harrison R. Ferlauto¹, Julia D. Visgauss¹, Brian E. Brigman¹, William C. Eward¹

¹Department of Orthopaedic Surgery, Duke University Medical Center, Durham, North Carolina, UNITED STATES

Poster #255 3465821

DENOSUMAB IN THE MULTIDISCIPLINARY MANAGEMENT OF GIANT-CELL BONE TUMOURS. LONG-TERM EFFICACY AND TOXICITY DATA

Robert D. Beveridge¹, Alba Torres Martinez¹, Carlos Puchades Olmos¹, Benjamin Domingo Arrue¹, Diego Soriano Polo¹, Guillermo Suay Montagud¹, Ana Ferrero¹, Javier Perea Rojo¹, Nuria Gómez Sepúlveda¹, Julio Linares Diaz¹

¹Medical Oncology Department, University Hospital La Fe, Valencia, Valencia, SPAIN

Poster #256 3465823

SYNCHRONOUS CO-LOCALIZATION OF GIST AND PERITONEAL MESOTHELIOMA: A SINGLE INSTITUTION CASE SERIES

Asimina S. Courelli³, Yoon Young Choi⁴, Shirley Sarno¹, Kaitlyn Kelly¹, Santiago Horgan², Olivier Harismendy⁴, Joel Baumgartner¹, Jason K. Sicklick¹

¹Department of Surgery, Division of Surgical Oncology, University of California, San Diego, La Jolla, California, UNITED STATES; ²Department of Surgery, Division of Minimally Invasive Surgery, University of California, San Diego, La Jolla, California, UNITED STATES; ³School of Medicine, University of California, San Diego, La Jolla, California, UNITED STATES; ⁴Moore's Cancer Center, San Diego, California, UNITED STATES

Poster #257 3465847

PEDIATRIC NON-MYOFIBROBLASTIC MESENCHYMAL NEOPLASMS WITH ALK AND ROS1 GENE REARRANGEMENTS

Rebecca Collins¹, Ameet Thaker¹, Naseem Uddin¹, Jason Park¹, Dinesh Rakheja¹

¹Pathology, University of Texas Southwestern Medical Center, Dallas, Texas, UNITED STATES

Poster #258 3465855

UPDATED ANALYSIS OF GENETIC ALTERATIONS IN SARCOMA PATIENTS OF HISPANIC AND NON-HISPANIC ETHNICITY: ANALYSIS OF 174 PATIENTS, A SINGLE INSTITUTION EXPERIENCE

Emily E. Jonczak², Caroline Hana¹, Andrea Espejo¹, Junaid Arshad¹, Philippos Costa¹, Priscila Barreto-Coelho¹, Konstantinos Sdrimas¹, Brianna Valdes¹, Gina D'amato¹, Jonathan Trent¹

¹Medical Oncology, University of Miami, Sylvester Comprehensive Cancer Center, North Bay Village, Florida, UNITED STATES; ²Medical Oncology, University of Miami, Sylvester Comprehensive Cancer Center, Miami, Florida, UNITED STATES

Poster #259 3465859

PREOPERATIVE RADIOTHERAPY IN LOWER EXTREMITY SOFT TISSUE SARCOMA TO REDUCE MAJOR WOUND HEALING COMPLICATIONS – THE ROLE OF NORMAL TISSUE DOSE REDUCTION

Lulwah Abduljabbar¹, Anthony Griffin¹, Zhihui Amy Liu¹, Peter Chung¹, Charles Catton¹, David Shultz¹, Philiip Wong¹, Kim Tsoi², Peter Ferguson², Jay Wunder², Brian O'Sullivan¹

¹Radiation Oncology, Princess Margaret cancer center, Toronto, Ontario, CANADA; ²Surgery, Princess Margaret Cancer Center, Toronto, Ontario, CANADA

Poster #260 3465872

DESPITE EXTENSIVE CLONAL SELECTION, METASTASIS ENRICHES FOR OSTEOSARCOMA CELLS WITH HIGHLY DIVERSE PHENOTYPES

Sanjana Rajan¹, Maren Cam¹, Amy C. Gross¹, Meng Wang¹, Cenny Taslim¹, **Ryan D. Roberts**¹

¹Center for Childhood Cancer and Blood Disease, Nationwide Children's Hospital, Columbus, Ohio, UNITED STATES

Poster #261 3465888

SUPERIOR MESENTERIC ARTERY BRANCHES AS A READOUT FOR PREDICTING FUTURE SMALL BOWEL LENGTH DURING ABDOMINAL AND RETROPERITONEAL LIPOSARCOMA RESECTIONS

Jeremiah Adie¹, Robert Mallory¹, Jason K. Sicklick¹

¹Department of Surgery, Division of Surgical Oncology, University of California, San Diego, La Jolla, California, UNITED STATES

Poster #262 3465890

THE IMPACT OF RADIATION THERAPY ON SURVIVAL IN MYXOID LIPOSARCOMA

David L. Kerr¹, Alexander L. Lazarides¹, Preet Patel³, Mark M. Cullen³, Sneha Rao¹, Marcelo Cerullo², Dan G (Trey) Blazer², Brian E. Brigman¹, Julia D. Visgauss¹, William C. Eward¹

¹Orthopedic Surgery, Duke University Hospital, Durham, North Carolina, UNITED STATES; ²General Surgery, Duke University Hospital, Durham, North Carolina, UNITED STATES; ³Duke University School of Medicine, Durham, North Carolina, UNITED STATES

Poster #263 3465898

DOES ATTACHMENT STYLE (RELATIONSHIP STATUS) IMPACT OUTCOME IN ADULTS WITH SARCOMA?

Abha A. Gupta¹, Madeline Li¹, Nicole Byers¹, Caroline Rodrigues¹, Kupere Pathmanathan¹, Osvaldo Espin-Garcia¹, Jay Wunder¹, Peter Ferguson¹, Kim Tsoi¹, Rebecca Gladdy¹, Carol J. Swallow¹, Savtaj Brar¹, Peter Chung¹, Charles Catton¹, David Shultz¹, Philip Wong¹, Albiruni Razak¹, Hagit Peretz¹, Bob Maunder¹, Anthony Griffin¹, Jon Hunter¹

¹Princess Margaret, Toronto, Ontario, CANADA

Poster #264 3465900

WHAT IS THE LIKELIHOOD OF NON-PULMONARY METASTASIS OCCURRING IN THE ABSENCE OF LUNG METASTASIS IN BONE AND SOFT TISSUE SARCOMA? A NESTED CASE CONTROL STUDY FROM A REFERRAL SARCOMA CENTER

Obada Hasan¹, Momin Nasir², Mustafa Hashimi², Qiang An¹, Benjamin J. Miller¹

¹Orthopaedics and Rehabilitation, University of Iowa Hospitals & Clinics, Iowa City, Iowa, UNITED STATES;

²University of Iowa, Iowa, Iowa, UNITED STATES

Poster #265 3465904

SURGICAL MANAGEMENT REMAINS THE BEST PREDICTOR OF SURVIVAL: LESSONS FROM THE NATIONAL CANCER DATABASE (NCDB) IN DESCRIBING CHARACTERISTICS, MANAGEMENT, AND OUTCOMES FOR PATIENTS WITH CHONDROSARCOMA

Taylor D. Ottesen¹, Blake S. Shultz¹, Alana M. Munger¹, Michael Amick¹, Jonathan N. Grauer¹

¹Orthopaedics and Rehabilitation, Yale School of Medicine, Orem, Utah, UNITED STATES

Poster #266 3465916

WHAT ARE THE PREDICTORS OF READMISSION AND SHORT TERM MORTALITY IN CHONDROSARCOMA?

Daniel Evans¹, **Alexander L. Lazarides**¹, Mark M. Cullen¹, Julia D. Visgauss¹, Brian E. Brigman¹, William C. Eward¹

¹Department of Orthopaedic Surgery, Duke University Medical Center, Durham, North Carolina, UNITED STATES

Poster #267 3465927

PROBING THE THERAPEUTIC LANDSCAPE OF CHONDROSARCOMA WITH INTEGRATED CHEMICAL SCREENING

Trudy Zou², John Martin², Zeyu Huang², Puviindran Nadesan², Miriam Barrios-Rediles³, Lauren Caldwell³, Adrian Pasculescu³, Alessandro Datti³, Jason A. Somarelli², Julia D. Visgauss¹

¹Orthopedic Surgery, Duke University Medical Center, Durham, North Carolina, UNITED STATES; ²Duke University, Durham, North Carolina, UNITED STATES; ³University of Toronto, Toronto, Ontario, CANADA

Poster #268 3465928

RACIAL DISPARITIES BY HISTOLOGY FOR SARCOMAS OF SOFT-TISSUE AND BONE

David L. Kerr¹, Alexander L. Lazarides¹, Preet Patel², Mark M. Cullen², Sneha Rao¹, Marcelo Cerullo³, Dan G (Trey) Blazer³, Brian E. Brigman¹, Julia D. Visgauss¹, William C. Eward¹

¹Orthopedic Surgery, Duke University Hospital, Durham, North Carolina, UNITED STATES; ²Duke University School of Medicine, Durham, North Carolina, UNITED STATES; ³General Surgery, Duke University Hospital, Durham, North Carolina, UNITED STATES

Poster #269 3465948

CHARACTERISTICS AND LONG-TERM OUTCOMES OF SURGICALLY MANAGED HIGH-GRADE EXTREMITY CHONDROSARCOMA

Mary K. Skalitzky¹, Ryan Wendt¹, Qiang An¹, **Trevor R. Gulbrandsen**¹, Obada Hasan¹, Benjamin J. Miller¹

¹Orthopedic Surgery, University of Iowa Hospitals and Clinics, Iowa City, Iowa, UNITED STATES

Poster #270 3465964

IMPACT OF CHEMOTHERAPY TREATMENT ON OVERALL SURVIVAL IN DEDIFFERENTIATED CHONDROSARCOMA: AN ANALYSIS OF THE SEER DATABASE

Lee D. Cranmer², Bonny Chau², Michael J. Wagner², Elizabeth T. Loggers¹, Seth Pollack¹, Teresa Kim³, Edward Kim⁴, Gabrielle Kane⁴, Matthew J. Thompson⁵, Jared Harwood⁵, Jose Mantilla⁶

¹Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, UNITED STATES;

²Division of Oncology, University of Washington, Seattle, Washington, UNITED STATES; ³Department of Surgery, University of Washington, Seattle, Washington, UNITED STATES; ⁴Department of Radiation Oncology, University of Washington, Seattle, Washington, UNITED STATES; ⁵Department of Orthopedic Surgery, University of Washington, Seattle, Washington, UNITED STATES; ⁶Department of Pathology, University of Washington, Seattle, Washington, UNITED STATES

Poster #271 3466167

A RARE CASE SERIES OF COMPOSITE HEMANGIOENDOTHELIOMA PRESENTING AS BONE TUMOR

Hariharasudan Mani¹, Varun Monga¹, Mohammed Milhem¹

¹University of Iowa, Iowa City, Iowa, UNITED STATES

Poster #272 3467206

COMPREHENSIVE COMPLICATION INDEX BETTER ESTIMATES THE IMPACT OF COMPLICATIONS IN RETROPERITONEAL SARCOMA SURGERY COMPARED TO CLAVIEN-DINDO CLASSIFICATION

Fulvia Aymerito¹, Ferdinando Carlo Maria Cananzi¹, Laura Samà¹, Laura Ruspi², Federico Sicoli², Edoardo A. Baccalini³, Federica Barzaghi¹, Vittorio L. Quagliuolo²

¹Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, ITALY; ²Humanitas Clinical and Research Center – IRCCS, Rozzano, Milan, ITALY; ³Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, ITALY

Poster #273 3467207

FOCUSED ULTRASOUND FOR APPENDICULAR SOFT-TISSUE SARCOMAS: TARGETABILITY ASSESSMENT FOR TISSUE-SELECTIVE TREATMENTS

Lauren Mancina¹, Neffisah D'odoo², Jess Gannon², Nathaniel Meyer¹, Eli Vlasisavljevich², Geoffrey W. Siegel¹

¹University of Michigan, Ann Arbor, Michigan, UNITED STATES; ²Virginia Polytechnic Institute and State University, Blacksburg, Virginia, UNITED STATES

Poster #274 3467256

FOSB-ACTB FUSION IN PSEUDOMYOGENIC HEMANGIOENDOTHELIOMA: CASE STUDY OF THE YOUNGEST PEDIATRIC PATIENT.

Francis Osei¹, Janay McKnight¹, Paul Kent¹

¹Pediatric Oncology, Rush University Medical Center, Chicago, Illinois, UNITED STATES

Poster #275 3467312

THE AMERICAN COLLEGE OF SURGEONS (ACS) SURGICAL RISK CALCULATOR UNDERESTIMATES THE ACTUAL RISKS OF SURGERY FOR RETROPERITONEAL SARCOMA: RESULTS FROM A REFERRAL CENTER

Laura Samà¹, Laura Ruspi², Ferdinando Carlo Maria Cananzi¹, Federico Sicoli², Fulvia Aymerito³, Edoardo A. Baccalini³, Vittorio L. Quagliuolo²

¹Department of Biomedical Sciences, Humanitas Clinical and Research Center – IRCCS / Humanitas University, Rozzano, Milan, ITALY; ²Humanitas Clinical and Research Center – IRCCS, Rozzano, Milan, ITALY; ³Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, ITALY

Poster #276 3467373

WHAT IS THE UTILITY OF CHEST SURVEILLANCE FOR ATYPICAL LIPOMATOUS TUMORS OF THE EXTREMITIES?

Alexander L. Lazarides¹, Harrison R. Ferlauto¹, Zachary D. Burke², Anthony Griffin³, Bruce Leckey¹, Julia D. Visgauss¹, Nicholas Bernthal², Peter Ferguson³, Jay Wunder³, Brian E. Brigman¹, William C. Eward¹

¹Department of Orthopaedic Surgery, Duke University Medical Center, Durham, North Carolina, UNITED STATES;

²Department of Orthopaedic Surgery, UCLA, Los Angeles, California, UNITED STATES; ³Department of Orthopaedic Surgery, Mt Sinai, Toronto, Ontario, CANADA

Poster #277 3467404

PREDICTING THE SURVIVAL PROBABILITY AND ASSESSING PROGNOSTIC FACTORS IN PATIENTS WITH MALIGNANT EPITHELIOD HEMANGIOENDOTHELIOMA OF BONE: A POPULATION-BASED ANALYSIS

Charles Gusho¹, Alan Blank¹

¹Department of Orthopedics, Division of Orthopedic Oncology, Rush University Medical Center, Chicago, Illinois, UNITED STATES

Poster #278 3467407

RETREATMENT WITH FIRST LINE DRUGS IN MULTIPLY RELAPSED OSTEOSARCOMA

Madeline M. Link¹, Paul Kent¹, Janay McKnight¹, Bethany Gutfrucht¹

¹Pediatric Hem/Oncology, Rush University Medical Center, Chicago, Illinois, UNITED STATES

Poster #279 3467486

IS LOCAL RECURRENCE IN EXTREMITY SARCOMA JUST A LOCAL RECURRENCE, OR DOES IT IMPACT THE OVERALL SURVIVAL; NESTED CASE CONTROL STUDY FROM A SARCOMA REFERRAL CENTER.

Obada Hasan¹, Momin Nasir², Mustafa Hashimi², Qiang An¹, Benjamin J. Miller¹

¹Orthopaedics and Rehabilitation, University of Iowa Hospitals & Clinics, Iowa City, Iowa, UNITED STATES;

²University of Iowa, Iowa, Iowa, UNITED STATES

Poster #280 3467593

NOVEL SCORING CRITERIA FOR PREOPERATIVE PREDICTION OF NEOADJUVANT CHEMOTHERAPY RESPONSE IN OSTEOSARCOMA: A RETROSPECTIVE COHORT STUDY FROM A SARCOMA CENTER

Mustafa Hashimi², Obada Hasan¹, Qiang An¹, Benjamin J. Miller¹

¹Orthopaedics and Rehabilitation, University of Iowa Hospitals & Clinics, Iowa City, Iowa, UNITED STATES;

²University of Iowa, Iowa, Iowa, UNITED STATES